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ABSTRACT 
 
Stress is increasingly identified as a risk factor for brain disease, but the underlying 
processes are unkown. This thesis examines the influence of raised levels of the 
glucocorticoid (GC) stress hormone at different stages of life (during late gestation 
and/or in adulthood) on pathways known to be altered in parkinson’s disease (PD), and 
compares this with the effects of repeated adult stress. Adult stress or GC treatment 
produced complex, differential sex and region specific changes in these pathways. 
Notably, adult stress or GC treatment increased markers of nirosative stress in the male 
but not female rat substantia nigra (SN). Prenatal GC treatment produced long term 
effects on both dopamineric (DA) and noradrenergic (NA) nuclei, increasing the 
number of DA neurons in the SN and ventral tegmental area, and reducing the number 
of NA neurons in the locus coeruleus of adult rats. Furthermore microglial and astrocyte 
populations were increased and decreased respectively in these nuclei. Interestingly 
prenatal GC treatment rendered the male midbrain susceptible to a down regulation of 
DA measures in response to adult challenge, whereby the number of SN DA neurons 
and striatal and accumbal DA levels were attenuated. Fascinatingly adult stress or GC 
treatment, but not prenatal GC treatment exacerbated 6-hydroxydopamine-induced 
neurotoxicity, that was associated with increased microglial activation and protein 
nitration in the SN, in males, but afforded neuroprotection in females, neither of which 
were substantially altered by prenatal treatment. This is the first study to demonstrate 
that prenatal GC treatment can permanentlty alter the response of the midbrain DA 
pathways to adult challenge. Furthermore this is one of very few studies looking at male 
and female responses in parallel and thus highlights some striking sex differences in the 
response to stress and GCs. Together these novel data strongly support the premise that 
stress and GCs influence the functional integrity of pathways involved in PD, thereby 
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potentially contributing to PD pathogenesis. The data also highlight the complex 
sexually dimorphic nature of their actions. Although further work is required to 
determine the functional consequences of these stress/GC related changes, these 
findings may have considerable implications for the use of GCs in clinical practice. 
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1.1 Parkinson’s Disease 
Parkinson’s disease (PD) is named after James Parkinson who first described the 
disease in 1817 in his work ‘An essay on the shaking palsy’. The disease is principally 
characterised by a loss of dopaminergic neurons in the substantia nigra pars compacta 
(SNpc) that innervate the striatum and form the nigrostriatal dopaminergic (NSDA) 
pathway. This loss of neurons and the subsequent loss of dopamine (DA) within the 
striatum produce the classic symptoms of tremor, rigidity and bradykinesia. 
 
1.1.1. Prevalence 
PD is the second most prevalent neurodegenerative disorder after alzheimers disease 
(Bower et al., 1999) with 1-2% of the population over 65 years suffering from the 
disease. This increases to 3-5% of people over the age of 85 (Alves et al., 2008) and is 
more common in developed countries where there is a greater life expectancy. Early 
onset of sporadic PD is rare with approximately 4% of patients developing symptoms 
before the age of 50 (Van de beden 2003). Furthermore the incidence of PD is 1.5 times 
higher in men than women (Wooten et al., 2004). 
 
1.1.2. Clinical Symptoms 
Motor Symptoms 
The main motor symptoms of PD are a resting tremor, muscle rigidity and bradykinesia 
which occur early in the disease course. Latter symptoms include a freezing gait, a loss 
of postural reflexes and a flexed posture of neck, trunk and limbs (Maetzler et al., 
2009). When PD patients first present with motor systems they have already suffered 
considerable NSDA degeneration (Schapira et al., 2006). Indeed it has been suggested 
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that ~50-60% of SNpc neurons and 60-70% of striatal nerve terminals are lost before 
the onset of motor symptoms (Foley and Riederer, 1999). 
 
Non-motor symptoms 
Most PD patients also exhibit non motor symptoms which are summarised in Table 1.1. 
These include neuropsychiatric complications such as depression, anxiety and dementia 
and have been shown to have a significant impact on the quality of life of PD patients 
(Cubo et al., 2002). As many of these symptoms do not respond to dopaminergic 
treatment it is thought that they may be a result of degeneration in regions of the brain 
other than the NSDA (See section 1.1.3). Although some of these symptoms appear late 
on in the disease course (e.g. dementia and psychosis), some appear early on in the 
disease course (e.g. depression, anxiety and olfactory disturbances) and have even been 
shown to precede motor symptoms in some cases (Lim et al., 2009). 
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Table 1.1. Non-motor symptoms of PD 
Neuropsychiatric  
 
Depression, apathy, anxiety. 
Anhedonia 
Attention defecit 
Hallucinations, illusions, delusions 
Dementia 
Obsessional behaviour (drug induced), repetitive behaviour 
Confusion 
Delirium 
Panic attacks 
Sleep Disorders Restless leg movement 
REM disorders 
Vivid dreams 
Insomnia 
Breathing disturbance 
Autonomic  Bladder disturbance 
Sweating 
Orthostatic hypotension 
Sexual dysfunction 
Dry eyes 
GI Dribbling 
Ageusia 
Dysphagia 
Reflux/Vomiting 
Nausea 
Constipation 
Faecal incontinence 
Sensory Pain 
Paraethesia 
Olfactory disturbance 
Other Fatigue 
Diplopia 
Blurred vision 
Seborrhoea 
Weight loss/gain 
 
Taken from (Muzerengi et al., 2007) 
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1.1.3 Neuropathology 
Dopaminergic Pathology 
The brains of PD patients show reduced neuromelanin pigmentation in the SN which is 
correlated with neuronal loss and disease severity (Zecca et al., 2003). Neurons that are 
prone to degenerate accumulate cytoplasmic inclusions known as Lewy bodies (Mori et 
al., 2006). Lewy bodies are composed of several proteins including neurofilament, 
ubiquitin and α-synuclein. They are found in the perikarya of neurons, within neurites, 
in axons and have also been found in glial cells (Mochizuki et al., 2002)) within the 
SNpc. It is currently thought that the loss of neurons within the SNpc and the 
subsequent denervation of dorsal areas of the striatum precipitate many of the motor 
symptoms of PD. 
 
Non-Dopaminergic Pathology 
There is now substantial evidence to suggest that the pathology of PD is not restricted to 
the NSDA and that there is extensive non-dopaminergic pathology. Neuronal loss and 
the presence of Lewy bodies in PD patients is evident albeit to a lesser extent in many 
other brain areas and involves many neuronal types including the ventral tegmental area 
(dopaminergic; VTA), locus coeruleus (noradrenergic; LC), nucleus basilis of meynert 
(NBM; cholinergic), dorsal motor nucleus of the vagus (serotonergic) and the 
pedunculopontine nucleus (PPN; cholinergic) suggesting that many neurotransmitter 
systems are effected by the pathogenic disease process (Lim et al., 2009). Furthermore, 
there is increasing evidence to suggest that DA neurons are not the first to degenerate in 
PD. The work of Braak and colleagues suggests that PD begins in the anterior olfactory 
nucleus and medulla (Braak stage 1) and ascends through the brain eventually involving 
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the whole neocortex (Braak stage 5). SNpc degeneration is observed at an intermediate 
stage in the disease process (Braak stage 3)  (Braak et al., 2003). 
1.1.4 Dopaminergic neurotransmission 
Synthesis 
DA is synthesised from tyrosine. The rate limiting step in DA synthesis is the 
conversion of L-tyrosine to L-Dopa by the enzyme tyrosine hydroxylase. Dopa is then 
rapidly converted to DA by L-aromatic amino acid decarboxylase. 
 
Uptake 
The dopamine transporter (DAT) is present in DA nerve terminal membranes 
transporting DA in and out of the terminal according to the concentration gradient. DAT 
is a member of the Na+/Cl- dependent plasma membrane transporters and is responsible 
for the fast uptake of DA into the terminal, thereby regulating DA concentration at the 
synapse and therefore its interaction with pre and post synaptic receptors. 
 
Metabolism 
After reuptake into the nerve terminal DA is converted to dihyroxyphenylacetic acid 
(DOPAC) by monoamineoxidase (MAO). It is also converted to homovanillic acid 
(HVA) by the subsequent action of catechol-O-methytransferase (COMT) and MAO. 
  
Receptors 
DA receptors are G protein coupled receptors (GPCRs) and post synaptic DA receptors 
can be classified as either D1-like (D1,D5) or D2-like (D2,D3,D4). Within the striatum 
post synaptic DA neurons regulate feedback pathways to the SNpc. D2 receptors are 
also present as autoreceptors. Autoreceptors present on the soma or dendrites act to 
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slow firing rate whereas autorecerptors present on the nerve terminal inhibit DA 
synthesis and release. D2 autoreceptors are present within the SNpc and both D1 and 
D2 receptors can be found within the striatum. 
 
Signal transduction 
Activation of D1 receptors results in an increase of adenylate cyclase activity resulting 
in increased cAMP and the activation of protein kinase A, which in turn phosphorylates 
DARPP-32 (dopamine and cyclic AMP-regulated phosphoprotein). Phosphorylation of 
DARPP-32 results in potent inhibition of protein phosphatase-1 activity. Conversely D2 
receptor activation inhibits adenylate cyclase activity resulting in decreased DARPP-32 
phosphorylation. D2 activation also increases calcium influx which in turn also 
inactivates DARPP-32. 
 
1.1.5 The nigrostriatal pathway and the Basal Ganglia Motor Loop 
The NSDA is one of four major dopaminergic pathways within the brain and connects 
the SNpc to the striatum. The NSDA forms part of a complicated set of connections 
known as the basal ganglia motor loop. This loop consists of a group of subcortical 
nuclei that together regulate the initiation and execution of movement.  Basal ganglia 
circuitry is thought to consist of two major projection systems between input structures 
and output structures; a direct pathway between the striatum and the internal segment of 
the globus palidus (GPi) and the substantia nigra reticulata (SNr) (GABAergic; 
inhibitory), and an indirect pathway involving the globus palidus (external segment; 
GPe) and the subthalamic nucleus (STN). Connections between the GPe and STN are 
GABAergic (inhibitory), whereas projections from the STN to the GPi/SNr are 
glutamatergic (excitatory). Activation of the direct pathway results in inhibition of the 
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GPi/SNr  resulting in disinhibition of thalamocortical neurons. Activation of the indirect 
pathway however, causes net excitation of the GPi/SNr thus causing inhibition of the 
thalamocortical neurons. The balance between these pathways is important in regulating 
the output of the basal ganglia and therefore in the control of motor function (Miyachi, 
2009); Figure 1.1). These two pathways are differentially affected by dopaminergic 
projections from the SNpc to the striatum. Most striatal neurons are medium spiny 
GABAergic neurons that differentially express D1 or D2 dopamine receptors: direct 
pathway neurons predominately express D1 receptors whilst indirect pathway neurons 
express D2 receptors. Activation of D1 receptors would activate direct pathway neurons 
whilst activation of D2 receptors would inhibit activation of the indirect pathway. Thus 
the effect of dopamine signalling on both pathways would result in a reduction of basal 
ganglia output to the thalamus. Reduced DA signalling as seen in PD therefore results in 
increased basal ganglia output producing disinhibition of the thalamus. This classical 
model of basal ganglia circuitry has greatly improved our understanding of PD 
pathophysiology and aided the development of treatments for PD. However, more 
recent evidence suggests that the connections within the basal ganglia are actually much 
more complex (Obeso et al., 2002).   
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Figure 1.1.  Schematic diagram of basal ganglia motor loop 
Simplified illustration of basal ganglia anatomy. The direct and indirect pathways from 
the striatum have net effects of disinhibition and inhibition on the cortex, respectively. 
STN, subthalamic nucleus; GPe, external globus pallidus; GPi, internal globus pallidus; 
SNr, substantia nigra pars reticulta; SNc, substantia nigra pars compacta; PPN, 
pedunculopontine nucleus. Adapted from (Yin and Knowlton, 2006) 
1.1.6. Mesolimbic and mesocortical DA system 
Although cell loss in PD is most severe in the SNpc there is also significant 
degeneration of DA neurons, albeit to a lesser extent, within the VTA (German et al., 
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1989). These neurons form two major DA projections forming the mesolimbic (MLDA) 
and mesocortical (MCDA) pathways (Figure 1.2). The MLDA consists of dopaminergic 
neurons within the VTA that primarily project through the medial forebrain bundle to 
the nucleus accumbens (NAcc) which is found in the ventral striatum, as well as 
innervating the amygdala and hippocampus. NAcc DA input from the VTA modulates 
the activity of GABAergic medium spiny neurons within the NAcc that form part of the 
cortico-striato-thalamo-cortico-loop. The MLDA forms the brains major reward 
pathway (Schultz, 2000) and as such has been implicated in depression and addiction. 
On the other hand the MCDA is composed of DA neurons that primarily innervate the 
PFC. This pathway is involved in motivational and emotional responses and has been 
associated with the negative symptoms of schizophrenia. 
 
 
 27
 
Figure 1.2. Dopaminergic pathways within the rat brain 
The nigrostriatal system consists of projections from the SNpc to the striatum. 
Projections from the VTA primarily innervate the nucleus accumbens and the frontal 
cortex forming the mesolimbic and mesocortical pathways respectively. 
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1.1.7 Locus coeruleus 
The locus coeruleus (LC) is a nucleus in the rostral pons and is the main source of 
noradrenergic neurons within the brain. The LC has a mainly excitatory effect on the 
brain and mediates attention and arousal, playing a major role in the physiological 
response to stress. The LC innervates many areas of the brain including the spinal cord, 
brain stem, cerebellum, hypothalamus, thalamus, amygdala and cortex. It receives major 
inputs from the hypothalamus, cingulated gyrus, amygdala and medial prefrontal cortex.  
 
Noradrenaline (NA) utilises the same biosynthetic pathway as DA. DA is subsequently 
converted to NA by dopamine-β-hydroxylase (DβH). NA is taken up into synaptic 
vesicles by VMAT and on its release acts on adrenergic receptors which are broadly 
classified into α (α1, α2) and β(β1, β2, β3) adrenoceptors. Uptake of NA occurs either 
presynaptically by uptake 1 or by non neuronal cells in the vicinity (uptake 2). NA is 
metabolised by COMT and MAO. 
 
1.1.8 Nucleus Basalis Meynert 
The nucleus basalis of meynert (NBM) is located in the basal forebrain and is the 
principal source of cholinergic projections to the cerebral cortex. Central cholinergic 
activity is thought to be involved in the modulation of behaviour.  
 
Acetylcholine (ACh) is synthesised within cholinergic neurons by choline 
acetyltransferase from choline and acetyl-co-A. Acetylcholinesterase which is abundant 
within the synapse converts ACh back to choline and acetyl-co-A and rapidly clears the 
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synapse of ACh. There are two types of Ach receptors – muscarinic metabotrophic 
receptors and nicotinic ionotrophic receptors, both of which are found within the CNS. 
 
1.1.9 Current Treatments for Parkinson’s disease 
Dopaminergic treatments 
Dopamine replacement therapy is the mainstay of PD treatment. This works by either 
replacing the lost DA in the striatum or by mimicking DA action. Three decades after 
its first use, the DA precursor levodopa (L-Dopa) is still the gold standard for the 
treatment of Parkinson’s disease, primarily due to its high efficacy. However, chronic 
treatment with L-Dopa results in disabling motor complications due to the pulsatile 
stimulation of DA receptors such as ‘wearing off’ effects and dyskinesias (Marsden and 
Parkes, 1976). Combination therapy with COMT inhibitors such as entacopone reduces 
L-Dopa metabolism in the periphery, extending the half life of L-dopa thereby 
prolonging its action. It also results in a more continuous stimulation (rather than 
pulsatile) of DA receptors which significantly improves motor fluctuations. Alternately, 
the use of DA agonists provides a more sustained activation of DA receptors due to 
their longer half life but fail to match the efficacy of L-Dopa. However, they do not 
produce motor complications to the same degree as with L-Dopa and are therefore often 
used in younger patients to delay the need for L-Dopa therapy. Side effects of DA 
agonists include hallucinations, confusion and psychosis. The MAO-B inhibitors 
selegiline and rasagiline are effective either alone or in combination with L-Dopa, 
however patients will eventually require L-Dopa treatment. When given in combination 
MAO-B inhibitors prevent the breakdown of dopamine and hence preserve what 
dopamine is formed in the brain allowing a marked reduction in the dose of L-Dopa 
needed to control the motor symptoms. 
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Non-dopaminergic treatments 
A major breakthrough occurred with the development of deep brain stimulation, 
whereby electrodes are stereotactically implanted to achieve thalamic stimulation. This 
reduced drug resistant motor fluctuations and dyskinesias and preserves L-dopa 
responsiveness (Houeto et al., 2002). However, such surgical procedures are not without 
risks and side effects e.g. depression. Promising potential non-dopaminergic treatments 
for PD also include α2 receptor agonists (Rascol et al., 2001) and adenosine A2 
antagonists (LeWitt et al., 2008), both of which act on GABAergic striatal neurons, as 
well as 5-HT agonists (Bara-Jimenez et al., 2005) and glutamate antagonists (Samadi et 
al., 2008), all with the view of normalising the output pathways from the striatum. 
(Olanow et al., 1996). The possibility of the future use of stem cells would make this 
approach more viable. Treatments for the non-dopaminergic symptoms of PD have also 
been developed. Cholinesterase inhibitors and atypical antipsychotics have been 
successful in treating the dementia and psychosis associated with PD (Fox et al., 2008). 
There are currently no reliable biomarkers for preclinical PD. The development of a 
biomarker for the disease would aid the development of neuroprotective strategies to 
prevent the degeneration of SNpc neurons.  
 
1.1.10 Epidemiology 
The etiology of PD is unknown but both genetic and environmental factors have been 
implicated in the disease. 
1.1.10.1 Environmental risk factors 
Several environmental factors such as rural living, drinking well water, pesticide 
exposure and occupation have been associated with an increased risk of developing PD 
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(Tanner and Goldman, 1996). Excess weight in midlife has been associated with a 
greater PD risk whereas a low calorie intake is protective (Love, 2005; Ragonese et al., 
2007). This is particularly interesting as DA is involved in the regulation of food intake. 
Conversely cigarette smoking and coffee/tea consumption have been linked with a 
decreased risk of PD (Ross and Petrovitch, 2001; Kalda et al., 2006; Quik et al., 2008). 
Infectious agents such as influenza, nocardia (tuberculosis like germ) and helicobacter 
have also been connected to PD (Jang et al., 2009).  Furthermore, parental PD increases 
the risk of PD in offspring. This could suggest either a genetic or an environmental 
influence. However, the fact that the risk increases the younger the child is when the 
parent develops PD symptoms suggests that this is due to the environment (Chade et al., 
2006). Moreover, immigrants from Asia and Africa in the US have an increased risk of 
PD than they would in their native countries, again supporting a role of the environment 
(Schoenberg et al., 1988). More recently an interest in the impact of early life events in 
the development of PD has developed. Indeed, a shorter adult height, that may be 
associated with early life events affecting growth, is associated with an increased risk of 
PD in males (Ragonese et al., 2007). Furthermore people born in the year of an 
influenza pandemic have a higher risk of developing PD (Singer and Weiner, 1989). 
 
1.1.10.2 Familial PD 
The causes of almost all cases are unknown but occasionally PD can be inherited as a 
simple mendelian trait. Although sporadic and familial PD are very similar, inherited 
forms tend to have an earlier onset and have atypical clinical features. Five genes have 
been clearly linked to PD and there are a number of other genes or genetic linkages that 
have been associated with PD (Shown in Table 1.2). 
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α-synuclein 
Mutations in α-synuclein were the first genetic mutations to be linked to PD 
(Polymeropoulos et al., 1996). As α-synuclein is a major structural  component of Lewy 
bodies found in both sporadic and familial PD it is likely that it plays a role in both 
forms of PD with high levels or mutated forms of α-synuclein being detrimental 
(Winkler et al., 2007). 
 
Leucine Rich Repeat Kinase-2 (LRRK2) 
LRRK2 is a large protein with multiple functional domains including kinase and 
GTPase domains (West et al., 2005). There is evidence to suggest that LRRK2 may be 
involved in vesicular transport within the SNpc (Biskup et al., 2006). 
 
Parkin 
Kitada et al., 1998 (Kitada et al., 1998) identified the first autosomal recessive gene to 
be linked to PD. Parkin is an ubiquitin E3 ligase and mutations in parkin lead to a loss 
of function resulting in the accumulation of toxic substrates (Zhang et al., 2000). 
Sporadic PD is also characterised by reduced parkin activity thus accumulation of these 
substrates may contribute to the pathogenesis of PD. 
 
DJ-1 
DJ-1 was identified by Bonifati in 2003 and is thought to function as an antioxidant 
protein as well as a redox sensitive chaperone (Bonifati et al., 2003). Knockout of DJ-1 
led to a deficit in mitochondrial scavenging of hydrogen peroxide (Andres-Mateos et 
al., 2007). 
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PINK1 
PINK1 was identified in 2004 by Valente et al., (Valente et al., 2004) and is a 
mitochondrial associated kinase. 
 
These gene defects appear to be linked by a common pathway: the degradation of 
proteins. Figure 1.3 depicts how these genetic mutations could result in cell death due to 
impairments in protein handling. 
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Table 1.2. Genes implicated in familial PD  
 
Locus Gene Inheritence Reference 
PARK 1 (+4) 
PARK 2 
PARK 3 
PARK 5 
PARK 6 
PARK 7 
PARK 8 
PARK 9 
PARK 10 
PARK 11 
PARK 12 
PARK 13 
α-synuclein 
Parkin 
Unknown 
UCH-L1 
PINK1 
DJ-1 
LRRK2 
ATP13A2 
Unknown 
Unknown 
Unknown 
Omi/HHA2 
 
AD 
AR 
AD 
unclear 
AR 
AR 
AD 
AR 
unclear 
unclear 
unclear 
AD 
 
(Polymeropoulos et al., 1997) 
(Kitada et al., 1998) 
(Gasser et al., 1998) 
(Leroy et al., 1998) 
(Valente et al., 2004) 
(Bonifati et al., 2004) 
(Funayama et al., 2002) 
(Ramirez et al., 2006) 
(Hicks et al., 2002) 
(Pankratz et al., 2003) 
(Pankratz et al., 2003) 
(Strauss et al., 2003) 
 
Table adapted from (Vila and Przedborski, 2004). 
 
 
 35
 
 
Figure 1.3. Genetic mutations and the pathogenesis of PD.  
Genetic mutations that lead to PD suggest that misfolded proteins may contribute to PD 
neurodegeneration. Mitochondrial dysfunction, oxidative stress and protein mishandling 
are all tightly interconnected in this hypothesized pathogenic cascade. Adapted from 
(Vila and Przedborski, 2004). 
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1.1.11 Pathogenesis of PD 
Current thinking suggests that PD is not caused by one single factor but from the 
convergence of a number of deleterious factors occurring both within DA neurons as 
well as in the surrounding neurons and glia. Evidence for the involvement of these 
factors has been obtained mainly through the use of toxin-based models but the recent 
identification of genes involved in familial PD have increased our understanding of 
some of these processes. The following sections describe these processes in more detail. 
These detrimental pathways may interact with each other producing a self perpetuating 
cascade of detrimental events ultimately resulting in progressive neurodegeneration.  
 
Oxidative stress 
Most cellular reactions utilise oxygen for catalysis and energy production. This results 
in the production of reactive oxygen species (ROS) such as superoxide anions, 
hydrogen peroxide, hydroxyl radicals, peroxy radicals and reactive nitrogen species 
(RNS) such as peroxynitrite and nitro-tyrosyl radicals. Excessive production of ROS 
and RNS is detrimental to cell membranes and can ultimately result in cell death. To 
balance this there are antioxidants such as glutathione and vitamin E and antioxidant 
enzymes superoxide dismutase, catalase and glutathione peroxidase. Disruption of this 
balance leads to damage of proteins, lipids, DNA and can activate apoptotic pathways. 
Brain cells are particularly susceptible to oxidative damage due to high levels of 
polyunsaturated fatty acids in their membranes and the relatively low activity of 
antioxidant enzymes within the brain (Mariani et al., 2005). Aging is associated with 
elevated oxidative stress due to the accumulation of oxidative damage and decline in 
antioxidant status over time (Mariani et al., 2005). This is considered important as aging 
is a major risk factor for the development of neurodegenerative disease. There is now 
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extensive evidence for a role of oxidative and nitrosative stress in the pathogenesis of 
PD. In the SNpc of  the PD brain there are reduced levels of glutathione (Pearce et al., 
1997); increased lipid peroxidation (Dexter et al., 1989b); increased oxidative protein 
damage (Good et al., 1998) (Duda et al., 2000) and increased levels of DNA damage in 
affected neurons (Alam et al., 1997). ROS and RNS are generated by a number of 
biological processes, for example nitric oxide (NO) can be formed by the enzyme nitric 
oxide synthase (NOS) and iron can drive the formation of hydroxyl radicals by fenton 
reactions (Dexter et al., 1989a). DA is highly reactive and is more predisposed to 
oxidation than other catecholamine (LaVoie et al., 2005). Indeed, the metabolism of DA 
by MAO-B produces hydrogen peroxide as a by product (Adams et al., 1972) as well as 
dopamine quinone which directly modifies proteins (Stokes et al., 1999). In addition, 
several downstream products of DA oxidation result in complex I inhibition (Spencer et 
al., 1998); (Li et al., 1998). Furthermore, nitration of tyrosine on TH by peroxynitrite 
has been shown to inhibit TH activity which may contribute to disease progression 
(Blanchard-Fillion et al., 2001).    
 
Inflammation 
In acute conditions the inflammatory response protects tissues against invading agents 
and promotes healing but when chronically sustained it can cause serious damage to the 
host’s own tissue. The brain was originally thought to be an immune privileged organ 
but recent evidence demonstrates that it has its own unique defence system. Microglia 
are the only cells within the CNS capable of producing an immune response (Aloisi, 
2001). They are immunocompetent and phagocytic cells that mediate the innate defence 
system and are therefore critical for normal CNS function (Kim and de Vellis, 2005). 
They can also act as scavenger cells in the event of a pathologic insult (Beyer et al., 
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2000). Microglia actively monitor the CNS parenchymal environment by continual 
movement of their fine processes (Nimmerjahn et al., 2005). Under normal conditions 
neurons and astrocytes suppress microglial activation. Microglial activation is inhibited 
by the engagement of CD200 glycoprotein expressed on the surface of neurons and its 
receptor on microglia (Hoek et al., 2000). Furthermore electrical activity and soluble 
factors released from neurons suppress microglial MHC II (major histocompatability 
complex II) antigen presentation (Wei and Jonakait, 1999; Neuman 2001) and 
astrocytes suppress microglial activation by releasing TGF-β or IL-10 (Aloisi, 2001). 
Resting microglia are highly sensitive to changes in their immediate environment and 
can quickly activate in response to a pathologic event (Wojtera et al., 2005). In their 
resting state microglia exhibit a ramified morphology and low expression of membrane 
receptors. On their activation there is an increase in IgG reactivity and up-regulation of 
cell adhesion molecules (Orr et al., 2002). Microglia then attach to neurons under the 
direction of chemokines expressed by neurons (Aloisi, 2001). Once activated the 
microglial cell body becomes enlarged and the number of microglia increases (Raivich 
et al., 1996). If the pathogenic stimulus is maintained microglia then cluster around the 
neurons and become phagocytic (McGeer and McGeer, 1998). Activated microglia at 
the site of injury change their morphology, express increased levels of MHC antigens 
and become phagocytic (Hayes et al., 1987, 1988). They release inflammatory cytokines 
that amplify the inflammatory response by activating and recruiting other cells to the 
lesion. Cytokines are key regulators of innate and adaptive immune responses and 
microglia are the principal source of cytokines within the brain. Il-1 and TNF-α are the 
two main proinflammatory cytokines produced by microglia during CNS inflammation 
but microglia are also capable of producing antinflammatory cytokines such as TGF-β 
and IL-10. Moreover, microglia can release ROS that mediate neuron damage. 
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Inflammation was first proposed to be involved in PD by McGeer et al, in 1988 
(McGeer and McGeer, 1998). Their studies found that there was upregulation of MHC 
molecules and an increased number of activated microglia in the brains of PD patients. 
Further evidence for an inflammatory component for PD was provided by studies 
showing that there were increased levels of antibodies to proteins modified by DA 
oxidation (Rowe et al., 1998) and that there was increased levels of the proinflammatory 
cytokines TNF-α, IL-1β and IL-6 in the CSF (cerebro spinal fluid) and striatum of PD 
brains (Mogi et al., 1994b; Mogi et al., 1994a; Blum-Degen et al., 1995; Muller et al., 
1998). Activated microglia expressing TNF-α, IL-1β, IFN-γ and iNOS have been 
identified within the SNpc of PD patients (Hunot et al., 1996; Hirsch et al., 1998). 
Additionally IL-1, IL-6 and TNF-α has been found within the CSF and basal ganglia of 
PD patients (Nagatsu, 2002). Interestingly post-mortem brains of humans exposed to 
MPTP (1-methyl--4-phenyl-1,2,3,6-tetrahydropyridine; commonly used to model PD) 
show activated microglia 16 years after exposure to the toxin suggesting that there is a 
prolonged inflammatory response. 
 
Kim and Joh (2006) proposed a pathway by which inflammation could result in DA 
degeneration. They suggested that activated matrix metalloproteinase 3 (MMP-3) 
released from stressed neurons was responsible for microglial activation and the 
generation of superoxide as well as NFκB mediated cytokine release. Furthermore, 
neuromelanin that is found in DA neurons can elicit pro-inflammatory cytokine and 
nitric oxide release and α-synuclein that is found in Lewy bodies can cause superoxide 
release from microglia. Activated microglial could then cause DA neuron degeneration 
either by superoxide, nitric oxide and pro-inflammatory cytokines or by direct 
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phagocytosis of neurons. This would result in a self propagating cycle that sustains 
chronic inflammation and induces progressive degeneration.  
 
Mitochondrial dysfunction 
The first evidence that mitochondrial dysfunction might be involved in PD came from 
the observation that MPTP inhibition of complex 1 of the electron transport chain 
resulted in a PD like syndrome (Langston and Ballard, 1983). Later, decreased activity 
of complex 1 was found in post-mortem PD brains (Parker et al., 1989). The detrimental 
effects of complex 1 inhibition are: increased production of reactive oxygen species 
leading to oxidative damage of lipids proteins and DNA; energy depletion and the 
activation of apoptotic pathways (Vila et al., 2008). More recently the discovery that 
mutations in several genes that encode mitochondrial proteins result in PD provides 
further evidence for a role of mitochondria in the disease process (section 1.1.10.2).  
 
Mitochondria contain molecules that when released can activate caspase dependent or 
independent cell death. This is regulated by pro (Bax) and anti-apoptotic proteins (Bcl-2 
family) that control permeability of mitochondria. Perrier et al., 2007 proposed a 
pathogenic mechanism by which neuronal death due to complex-1 inhibition results 
from a self perpetuating cascade of detrimental events. The blockade of complex-1 
blocks the electron transport chain resulting in increased ROS production. This in turn 
increases the availability of cytochrome c within the mitochondria which can be 
released by the activation and translocation of Bax due to the activation of the 
transcription factors p53 and JNK resulting from DNA oxidative damage. Several 
elements of this cascade have now been shown to be present in post-mortem PD brains 
(Vila et al., 2008). 
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PD linked genes have the capabilities to either directly or indirectly affect mitochondria. 
Mitochondrial PINK1 can attenuate cytochrome c release and apoptotic cell death 
(Plun-Favreau et al., 2007; Pridgeon et al., 2007). This protective effect of PINK1 is 
mediated by its kinase domain and is abolished in PD mutants (Haque et al., 2008). 
PINK1 can also interact with parkin (Yang et al., 2006) which is localised in 
mitochondria and also prevents cytochrome c release and apoptotic cell death (Kuroda 
et al., 2006). α-synuclein can interact directly with mitochondria to either induce the 
release of ctochrome c (Parihar et al., 2008) or through the inhibition of complex 1 
(Devi et al., 2008). DJ-1 has been identified as an atypical peroxidase able to scavenge 
mitochondrial hydrogen peroxide (Andres-Mateos et al., 2007). Oxidative stress 
promotes its localisation to mitochondria (Zhang et al., 2005a). Additionally LRRK2 is 
partly localised to mitochondria and can induce the release of cytochrome c and 
therefore apoptotic cell death via caspase cascade (West et al., 2005; Iaccarino et al., 
2007). 
 
Mitochondria also have a role in aging and as aging is the biggest risk factor for PD this 
is of significant importance. Mitochondria are a major source of ROS as they are a by 
product of respiratory chain function. Wallace (2005) postulated that due to their close 
proximity to mitochondria, ROS could damage mitochondrial components during aging 
resulting in mitochondrial dysfunction and further ROS production. 
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Ubiquitin-proteasome-system (UPS) dysfunction 
The UPS is an intracellular protein degradation system responsible for protein turnover 
within the cell (Hershko and Ciechanover, 1998). Proteins for degradation are 
covalently tagged with ubiquitin protein. This involves an elaborate ligation reaction 
requiring the sequential activation of ubiquitin activating enzyme (E1), ubiquitin 
conjugating enzyme (E2) and ubiquitin ligating enzyme (E3). This ubiquitination 
process is repeated several times and the polyubiquinated protein is then targeted for 
degeneration by the 20S proteasome. 
 
Direct evidence for a role of the UPS in the pathogenesis of PD came from the 
identification of mutations in the parkin gene that resulted in PD (Kitada et al., 1998). 
Parkin encodes a ubiquitin ligase (Zhang et al., 2000) thus loss of function of this gene 
impaired UPS functioning. In addition, missense mutations in UCHL1 that are linked to 
PD result in decreased ubiquitin hydroxylase activity (Leroy et al., 1998). Although α-
synuclein does not form part of the UPS machinery its over expression can inhibit 
proteasome function (Tanaka et al., 2001; Chen et al., 2006). Further evidence for an 
involvement of the UPS in PD came from studies showing that there was reduced 
expression of subunits of the proteasome in sporadic PD patients and that in SN extracts 
isolated from PD brains there was decreased activity of the 20S proteasome (McNaught 
et al., 2003; Tofaris et al., 2003). Rotenone and MPTP treated mice have also been 
shown to exhibit reduced proteasome function (Betarbet et al., 2006) (Fornai et al., 
2005). Aberrant protein homeostasis in PD patients could result in toxic accumulation 
of intracellular proteins. Indeed, misfolded and aggregated α-synuclein is thought to be 
a primary event in PD caused by mutations in α-synuclein. Additionally, aggregated α-
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synuclein can inhibit proteasome function (Snyder et al., 2003) resulting in a vicious 
cycle of UPS impairment.   
 
Glutamate excitotoxicity 
 Glutamate is the primary excitatory neurotransmitter within the mammalian CNS. 
When neurons are injured they release higher concentrations of glutamate than usual 
that leads to a prolonged post synaptic response. This can ultimately result in cellular 
dysfunction and the initiation of apoptosis, known as excitotoxicity (Olney and de 
Gubareff, 1978). Increased levels of extracellular glutamate result in prolonged 
postsynaptic activation of NMDA receptors causing a greater influx of Ca2+ into 
neurons (Meldrum, 1990). Fast excitotoxicity is mediated by NMDA activation and the 
activation of downstream signalling pathways where as slow excitotoxicity is caused by 
mitochondrial dysfunction. Mitochondria act to sequester excess intracellular Ca2+ 
(Peng and Greenamyre, 1998). If sustained this excess Ca2+ leads to uncoupling of the 
electron transport chain resulting in decreased ATP synthesis producing an energy crisis 
as well as increasing the generation of ROS (Dykens, 1994). Furthermore Ca2+ overload 
results in mitochondrial depolarisation thereby increasing mitochondrial permeability 
and inducing the release of apoptosis initiating factor (AIF) and cytochrome c leading to 
the activation of apoptotic pathways. 
 
There are excitatory glutamate connections between the STN, PPN and SN. These 
pathways have been found to be hyperactive in both PD patients (Benazzouz et al., 
2002) and in animal models of PD (Orieux et al., 2000; Oueslati et al., 2005)). 
Moreover DA neurons express NMDA receptors (Mereu et al., 1991) and 
pharmacological blockade of these receptors is neuroprotective (Turski et al., 1991). 
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Further evidence for a role of glutamate in PD comes from studies in which the 
pathways from the STN and PPN are lesioned, reducing excitatory drive to the SN and 
resulting in neuroprotection. 
 
1.1.12 Animal models of PD 
Toxin based models aim to reproduce the pathological and behavioural features of the 
human disease in rodents and primates. Although genetic models of PD are now 
available, mimicking familial gene defects, such models have been disappointing failing 
to mimic the pathological features of PD. Consequently, toxin based models are still 
widely used due to their ability to induce the loss of SNpc neurons. The advantages and 
disadvantages of the most commonly used models are displayed in table 1.3 and are 
discussed further below. 
 
6-OHDA 
6-hydroxydopamine (6-OHDA) is a noradrenaline analogue that was introduced as a 
catecholaminergic neurotoxin over 40 years ago and was used to produce the first 
animal model of PD (Ungerstedt, 1968) and is still widely used today. Due to its 
structural similarities to DA and noradrenaline, 6-OHDA is selectively taken up by DA 
and noradrenaline transporters (Luthman et al., 1989). The subsequent accumulation of 
6-OHDA within the cytosol promotes a high rate of free radical and quinone formation 
(Figure 1.5) due to the rapid autoxidation of 6-OHDA. Additionally, 6-OHDA can 
accumulate in mitochondria where it inhibits the activity of the electron transport chain 
by inhibiting complex I. 6-OHDA does not cross the blood brain barrier so has to be 
administered stereotactically. 6-OHDA is injected into either the SNpc, the medial 
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forebrain bundle (MFB; contains ascending DA and 5-HT projections to the forebrain) 
or the striatum. Administration to the SNpc results in DA neuron degeneration 24 hours 
after injection that occurs without apoptotic morphology (Jeon et al., 1995) whereas 
injections to the MFB result in apoptotic DA neuron degeneration (He et al., 2000; Zuch 
et al., 2000). On the other hand intrastriatal injections of 6-OHDA result in a prompt 
degeneration of striatal DA terminals but a delayed, retrograde loss of SNpc neurons 
occurring over several weeks. None of these models result in the formation of Lewy 
bodies. Generally unilateral models have been used where the contralateral hemisphere 
can serve as an internal control. In addition, unilaterally lesioned rats exhibit 
characteristic circling behaviour in response to DA releasing drugs that is correlated 
with the degree of neuronal loss. However, this is only observed in animals that have an 
extensive nigrostriatal lesion. Bilateral injections are rare due to high mortality rates due 
to aphagia and adipsia (Ungerstedt, 1971). There is also a marked inflammatory 
response to 6-OHDA characterised by the activation of microglia – the brain’s 
macrophages. This correlates well with the human disease in which inflammation has 
been identified as a key mechanism involved in the degenerative process. The 6-OHDA 
model is also associated with an increase in iron and oxidative stress in the SNc. The 6-
OHDA model is still the most widely used PD model today, mainly due to its 
versatility; the fact that lesions are highly reproducible and the relatively low cost of the 
procedure.  
 
MPTP 
The neurotoxic properties of MPTP were accidently discovered when drug users who 
had injected MPTP developed symptoms remarkably similar to that of PD. MPTP is 
able to cross the blood brain barrier where it is metabolised by MAO-B in astrocytes to 
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the active metabolite MPP+ (1-methyl-4-phenylpyridinium). MPP+ is selectively taken 
up into the cytosol by catecholaminergic transporters (Javitch et al., 1985) (Bezard et 
al., 1999). Within neurons MPP+ can be taken up by the vesicular monoamine 
transporter-2 (VMAT2) into synaptic vesicles which appears to prevent toxicity 
(Takahashi et al., 1997) or it can react with cytosolic enzymes (Klaidman et al., 1993). 
The toxic effects of MPP+  however are due to it’s accumulation in mitochondria where 
it inhibits complex I of the electron transport chain (Nicklas et al., 1985; Mizuno et al., 
1987) resulting in reduced levels of ATP in the striatum and ventral midbrain as well as 
increased ROS formation (Hasegawa et al., 1997; Figure 1.4). Lewy bodies are not 
formed in the MPTP model (Forno et al., 1993). Susceptibility to MPTP neurotoxicity is 
species dependent: rats are relatively resistant to the toxin whereas mice and non human 
primates are more susceptible to its neurotoxic effects. Mice treated with MPTP do not 
develop motor symptoms (Przedborski et al., 2001) so have been used to study 
molecular mechanisms underling degeneration, whereas MPTP non-human primates 
have largely been used to study behavioural and physiological consequences of DA 
neuron degeneration. In the acute model of MPTP administration there is 
neurodegeneration without apoptosis (Jackson-Lewis et al., 1995), as well as an 
inflammatory response (Kurkowska-Jastrzebska et al., 1999). In the chronic model of 
PD however, MPTP administration results in cell death by apoptosis (Tatton and Kish, 
1997). As in PD DA neurons of the SNpc are more susceptible to MPTP neurotoxicity 
than VTA neurons. Additionally neurons that contain neuromelanin are more 
susceptible to MPTP induced degeneration (Herrero et al., 1993). 
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Figure 1.4. Schematic overview of molecular and intracellular pathways of 
dopaminergic neurotoxins applied in  animal models of Parkinson’s 
disease.  
 
MPTP (black vesicles) enters the brain by crossing the blood–brain barrier after 
systemic injection. Thereafter, MPTP (black vesicles) is taken up by astrocytes and 
converted in its active form: MPP+ (blue vesicles, catalyzed by MAO-B). Then, MPP+ 
(blue vesicles) is released from astrocytes into the extracellular space and can be 
specifically transported into dopaminergic neurons via DAT. Inside the dopaminergic 
neuron MPP+ (blue vesicle) can be (i) concentrated in mitochondria or can (ii) be 
sequestrated into synaptic vesicles (yellow-blue vesicle) via VMAT. 6-OHDA (red 
vesicles) has to be stereotactically targeted into the substantia nigra, MFB or the 
striatum. 6-OHDA (red vesicles) is selectively taken up via DAT by dopaminergic 
neurons. 6-OHDA (red vesicle) can also be accumulated by mitochondria. Agricultural 
toxins (green vesicles), penetrate into the dopaminergic neuron unspecifically and 
accumulate inside the mitochondria. MPP+ (blue vesicle), rotenone (red vesicle) and 
paraquat (green vesicle) affect complex 1 (C1) directly, leading to C-1 inhibition and 
the generation of reactive oxygen species.  
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Rotenone 
Rotenone is widely used as an insecticide and fish poison and has only relatively 
recently been developed as a rodent model of PD (Betarbet et al., 2000). It is highly 
lipophillic and can therefore easily cross biological membranes. It binds to the same site 
as MPP+ on complex 1 thus impairing oxidative phosphorylation within mitochrondria 
(Schuler and Casida, 2001). It has been reported that systemic administration of 
rotenone results in selective degeneration of DA SNpc neurons however other studies 
suggest that this degeneration is more widespread (Hoglinger et al., 2003); (Lapointe et 
al., 2004). In the rotenone model α-synuclein positive inclusions have been identified 
within DA neurons of the SNpc (Betarbet et al., 2000). However, in this model the 
extent of the lesion is highly variable and the mortality rate is high. 
 
Paraquat 
Paraquat (N,N’-dimethyl-4-4’-bipiridinium) is a herbicide that has a similar structure to 
MPP+. Epidemiologic studies suggest that environmental exposure to paraquat 
increases the risk of developing PD (Liou et al., 1997). Its toxicity is likely to be due to 
the formation of superoxide free radicals (Day et al., 1999) (Przedborski and 
Ischiropoulos, 2005). Systemic administration of paraquat results in degeneration of 
SNpc neurons and their projections, which is accompanied by the presence of α-
synuclein inclusions (McCormack et al., 2002). There are also increases in levels of α-
synuclein in the frontal cortex and ventral midbrain (Manning-Bog et al., 2002). 
However, in this model the extent of the lesion is highly variable and the mortality rate 
is high. 
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Proteosome Inhibitors 
In 2004, McNaught (McNaught et al., 2004) described a new model of PD. This model 
was based on findings that there were defects in the ubiquitin-proteasome-system in PD 
patients (Furukawa et al., 2002; McNaught et al., 2003) and that mutations in Parkin, an 
ubiquitin E3 ligase causes early onset PD (Kitada et al., 1998). In the McNaught study, 
animals were treated with either a natural (epoxomicin) or synthetic proteasome 
inhibitor (PSI). These rats developed Parkinson like symptoms within 1-2 weeks that 
were alleviated by L-Dopa or apomorphine administration. These animals also had 
reduced levels of DAT, reduced striatal DA levels and DA neuron death with apoptosis. 
In addition, neuronal degeneration was present within the locus coeruleus, dorsal motor 
nucleus of the vagus and the nucleus basalis of meynert. Furthermore degenerating 
neurons contained cytoplasmic inclusions that resembled Lewy bodies. Unfortunately 
several groups, including this group, have failed to reproduce the findings of this study 
and thus the model is surrounded by considerable controversy (Bove et al., 2006; 
Kordower et al., 2006; Manning-Bog et al., 2006). Although highly attractive due to its 
potential to recapitulate many aspects of the disease, the proteasome inhibitor model 
will be unable to provide a suitable for PD until these discrepancies are resolved. 
 
Gene based models 
Although inherited PD accounts for less than 5% of all cases it is likely that they share 
similar pathogenic mechanisms with sporadic PD cases, thus gene based models of PD 
have been generated. For instance a variety of transgenic mice models have been 
developed that over express α-synuclein. Although they are a useful tool to investigate 
the pathogenesis of PD they often exhibit very little SNpc pathology. 
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  Table 1.3. Advantages and disadvantages of animal models of PD 
 
 
 ADVANTAGES DISADVANTAGES 
 
6-OHDA 
 
-Specific loss of DA 
neurons 
-Uniform lesions 
-Low inter-animal 
variability 
-Quantifiable motor deficits
-Unilateral lesions possible 
 
 
-No Lewy body formation 
-Only one type of cell loss 
-Rapid cell death 
-Possible non specific 
damage 
 
MPTP 
 
-Known to produce PD like 
symptoms in humans 
 
-No Lewy body formation 
-No stable motor defecit 
-Inter-species variability 
 
ROTENONE 
 
-Selective NSDA 
degeneration 
-Lewy body formation 
-Complex-1 Inhibition 
-Microglial activation 
-Oxidative stress 
-Proteosomal dysfunction 
-Extra nigral pathology 
 
 
-Considerable variability 
-High mortality 
 
PARAQUAT 
 
-Lewy body formation 
-Only modest 
neurochemical 
modifications 
 
 
-Poor reproducibility 
-High mortality 
 
PROTEOSOME 
INHIBITORS 
 
-Extra-nigral pathology 
-Lewy bodies 
 
 
-Lack of reproducibility 
 
GENE BASED MODELS 
 
-Recapitulate many disease 
aspects 
-Extra nigral pathology 
 
 
-Absence of NSDA 
degeneration 
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1.2 Stress 
Biological stress was defined by Hans Seyle as ‘the non specific response of the body to 
a demand placed upon it’. Later in 1988 Sterling and Eyer coined the termed ‘allostasis’ 
to encompass the physiological response of the body to daily events that enables the 
maintenance of homeostasis, literally meaning ‘achieving stability through change’. 
Modern convention thus defines stress as anything that can disrupt homeostasis, with 
the resultant stress response acting to restore the delicate homeostatic balance via an 
adaptive process enabling the organism to cope both physiologically and behaviourally. 
The physiological response to stress is characterised by activation of the autonomic 
nervous system (ANS) and the hypothalamic-pituitary-adrenal (HPA) axis. 
 
1.2.1 Autonomic response to stress 
In response to stress there is immediate activation of the sympathetic nervous system 
with the consequent release of NA from nerve terminals and adrenaline from the adrenal 
medulla. This mediates the ‘flight or fight response’ whereby mental and physical 
activity is enhanced. There is also a concomitant decrease in parasympathetic drive. 
 
1.2.2 HPA axis response to stress 
The HPA axis (Figure 1.6) mediates the release of glucocorticoids (GCs) in response to 
diurnal cues and stress. In response to stress catecholaminergic, serotonergic and 
cholinergic inputs from limbic and brain stem centres that encode a stress stimulus 
converge on the hypothalamus. Stimulation of the parvocellular neurons of the 
paraventricular nucleus (PVN) results in secretion of corticotrophin releasing hormone 
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(CRH) and arginine vasopressin (AVP) into the hypophyseal portal circulation. CRH 
and AVP act via GPCRs at the anterior pituitary to synergistically stimulate the 
synthesis and cleavage of propiomelanocortin (POMC) into corticotrophin (ACTH). 
ACTH is released into the systemic circulation and transported to the zona fasiculata of 
the adrenal cortex where through action on membrane bound receptors it influences the 
activity of the rate limiting enzyme in the conversion of cholesterol to pregnalone to 
cortisol (humans and primates) and corticosterone (rodents), the endogenous GC 
hormones. GCs are steroid hormones that when released into the systemic circulation, 
exert diverse actions on the body including effects on glucose/lipid metabolism, 
immune function, inflammatory processes, host defence, fluid/electrolyte balance, 
vascular tone and bone metabolism. Within the CNS GCs can act on both neurons and 
glia where they exert organisational effects during development and influence neuronal 
plasticity in adults. GCs are implicated in the regulation of mood, behaviour, food 
intake and body temperature. GCs also regulate the circadian rhythm with GC secretion 
peaking during the morning in man (diurnal) and in the evening in rodents (nocturnal). 
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Figure 1.5 Schematic diagram of the HPA axis 
CRH is synthesized in neurons of the paraventricular nucleus of the hypothalamus and 
released into the hypophysial portal circulation. CRH stimulates ACTH synthesis and 
release from corticotrophs in the anterior pituitary gland. ACTH is released into the 
systemic circulation where it then stimulates production of glucocorticoids from the 
adrenal cortex. GCs exert numerous functions on physiological processes and exert 
negative feedback on several levels of the HPA axis by inhibiting CRH and ACTH. The 
HPA axis is also modulated by higher centres, notably the hippocampus and amygdala. 
Adapted from (Drake et al., 2007). 
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1.2.3 Mechanisms of GC action 
Receptors 
The effects of GCs are mediated by the high affinity (Kd 0.5-2nM) mineralcorticoid 
receptor (MR) and the low affinity (Kd 10-20nM) glucocorticoid receptor (GR), both 
are members of the nuclear hormone receptor family. Within the CNS, GCs act on both 
neurons and glia. Basal levels of CORT occupy MR receptors, the highest CNS levels 
of which are found within limbic regions. They exert tonic inhibition on the HPA axis 
and regulate the normal circadian release of ACTH and CORT. GR receptors are more 
ubiquitously expressed throughout the brain and are progressively activated during 
stress. The density of these receptors varies in relation to circadian rhythm, age and 
stressful life experiences (Meyer et al., 2001). 
 
Regulation of GC signalling 
I) Corticosteroid binding globulin (CBG): Only ~ 4% of circulating GCs are 
unbound, the rest is bound to CBG which determines the availability of free 
GC to its receptors (Siiteri and Stites, 1982). 
II) Multidrug resistance (MDR) P glycoprotein: The presence of MDRP on 
endothelial cells of the blood brain barrier (BBB)(de kloet 1998) prevents 
the penetration of synthetic GCs and cortisol but not corticosterone into the 
rodent brain (Meijer et al., 1998). 
III) 11-β-hydroxysteroid-dehydrogenase (11βHSD): The pre-receptor 
metabolism of GCs by 11βHSD allows for tissue specific delivery of GCs to 
target cells. There are two isoforms of this enzyme: 11βHSD-1 works as a 
reductase converting the inactive cortisone into cortisol and 11βHSD-2 
works as a dehydrogenase converting CORT into inert cortisone. 
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Genomic action of GCs 
Transactivation: GCs are lipophillic, thus easily pass through plasma membranes 
where they can bind to the ligand binding domain of cytosolic GRs. Association of GCs 
with their receptor results in the activation of GR and its dissociation from its 
multiprotein complex. The receptor can then translocate to the nucleus where GR 
homodimers bind to DNA binding sites (GC response element; GRE) in the promoter 
region of target genes, thus activating gene transcription of GC sensitive genes (Almawi 
and Tamim, 2001). This is known as transactivation. 
 
Transrepression: The GC-GR complex can also repress transcription of genes by 
binding to negative GRE’s (Sakai et al., 1988) known as transrepression. Moreover, the 
GC-GR complex can inhibit the transactivation function of transcription factors such as 
AP-1 and NFκB through direct or indirect interactions. The GC-GR complex can either 
bind to transcription factor subunits to prevent their association with DNA or can 
compete with transcription factors for nuclear co-activators (Almawi and Tamim, 2001). 
 
GCs regulate growth, development, metabolism, behaviour and apoptosis. It is thought 
that this diversity in function arises from isoforms of the GR that are a result of 
alternative RNA splicing and post-translational modifications of GR mRNA that may 
modulate the function and stability of the receptor. This would allow for cell type 
specific regulation of gene expression by a single transcription factor (Zhou and 
Cidlowski, 2005).  
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Non-genomic action of GCs 
Some effects of GCs occur too fast for them to be genomic actions. GCs can interact 
with cellular membranes influencing membrane associated proteins, thus membrane 
permeability and lipid peroxidation (Buttergeit 2002). GCs can also diminish ATP 
production by inhibiting oxidative phosphorylation. Furthermore the dissociation of 
proteins (e.g. heat shock proteins) from the GR-multiprotein complex on ligand binding, 
provides an indirect action of GCs (Croxtall et al., 2000). Membrane bound GR’s have 
also been reported (Orchinik et al., 1991). Although their function is currently unknown 
they have been implicated in rheumatoid arthritis. (Bartholome et al., 2004). 
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Figure 1.6 Genomic actions of GCs 
 
Genomic effects of glucocorticoids include transactivation and transrepression. Binding 
of the GC-GR complex to GREs leads to expression of GC sensitive genes 
(transactivation). Transrepression is caused by competition for nuclear coactivators, or 
direct or indirect interaction with transcription factors. 
Taken from (Stahn and Buttgereit, 2008). 
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1.2.4 Negative feedback within the HPA axis 
GC’s exert negative feedback actions on the brain via MR and GR receptors. MRs are 
localised in the hippocampus and other regions of the limbic brain and maintain basal 
HPA activity. GRs are more abundant throughout the brain with the highest expression 
found in the hypothalamus and pituitary corticotrophs and are involved with the 
feedback of both basal and stress induced levels of GCs, enabling termination of the 
stress response. Alterations in the effectiveness of GC negative feedback has profound 
effects on HPA activity and the regulation of the stress response and can increase 
vulnerability to disease (De Kloet et al., 1998; Gomez et al., 1998). 
 
1.2.5 Animal models of stress 
Animal models of stress have been widely used to aid our understanding of the basic 
mechanisms of stress on physiology.  These include a wide variety of escapable and 
unescapable stressors which can be physical, phsychological, acute or chronic. Table 1 
shows the most commonly used models of stress in rodents. The most extensively 
studied is an unavoidable physical stress such as immobilisation, extreme temperature, 
fasting, immersion, or electric shocks. Emotional stressors such as crowding or social 
isolation are useful for the study of psychiatric disorders but it has been suggested that 
immobilisation/restraint stress is most useful in the study of stress on degeneration, post 
traumatic stress disorder (PTSD) and the effects of stress on the immune system 
(Southwick et al., 1994; Garcia-Bueno et al., 2008). The most commonly used stressors 
in human studies are stressful interviews, free speech, mental arithmetic tasks and 
exercise, however these can only be used to study the effects of acute stress. 
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Table 1.4 Rodent models of stress 
 
Immobilisation/Restraint 
Unpredictable Stress 
 
Physical/Psychological Acute / Chronic 
Sleep deprivation 
Intruder 
Predator 
Maternal separation 
Crowding 
Social isolation 
Noise 
Psychological Acute/ Chronic 
Swim stress 
Exercise 
Electric shocks 
Thermal Injury 
Extreme temperatures 
Physical Acute/Chronic 
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1.2.6 Habituation / adaptation to stress 
There is a decrement in HPA response with repeated exposure to the same (homotypic) 
stressor (Jaferi and Bhatnagar, 2006) known as habituation. However, exposure to a 
repeated homotoypic stressor results in an exaggerated response to a novel stressor. This 
is known as facilitation (Bhatnagar and Dallman, 1998).  This is thought to be regulated 
by GC mediated negative feedback 
 
1.2.7 Clinical uses of GCs 
GCs were first used clinically for the treatment of rheumatoid arthritis. Manipulations of 
cortisol structure in the 1950’s led to the development of synthetic GCs that vary in 
their potencies, duration of effect and receptor affinities (Table 1.5; Figure 1.8). GCs 
have a wide range of therapeutic applications. They are used in the treatment of adrenal 
insufficiency (addisons disease), hypoglycaemia, hypercalcaemia, and can be used in 
the treatment of tumours (due to their effects on cell maturation, cell differentiation and 
apoptosis). However their major clinical use is in the treatment of inflammatory and 
immune diseases (Longui, 2007) such as asthma, allergy, inflammatory bowel disease 
and rheumatoid arthritis.  
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Table 1.5 Comparison of the main corticosteroid agents  
 
Compound GR affinity Relative potency 
(anti-
inflammatory) 
Duration of action 
Hydrocortisone 
(cortisol) 
1 1 Short 
Cortisone 0.01 0.8 Short 
Corticosterone 0.85 0.3 Short 
Prednisolone 2.2 4 Intermediate 
Prednisone 0.05 4 Intermediate 
Methylprednisolone 11.9 5 Intermediate 
Triamcinolone 1.9 5 Intermediate 
Dexamethsone 7.1 30 Long 
Betamethasone 5.4 30 Long 
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Figure 1.7 Structure of cortisol, corticosterone and the synthetic GC 
dexamethasone 
 
 
 
 
 
Cortisol Corticosterone 
Dexamethasone
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1.2.8 Detrimental effects of stress and GCs. 
Although activation of the HPA axis enables adaptive changes that enable physiological 
and behavioural coping, prolonged activation of the HPA axis presents a health risk. As 
GCs antagonise the effects of insulin, persistent elevation of GCs can increase blood 
pressure and the risk of diabetes. GCs also suppress the immune system thus may lead 
to an increased risk of infection. Furthermore elevated GC levels pose an increased risk 
for obesity, osteoporosis and cardiovascular disease (McEwen, 2000). 
 
Detrimental effects of GCs in the CNS 
Increased HPA activity has been implicated in major depression; anorexia nervosa, 
obsessive compulsive disorder/ panic disorder and decreased HPA activity implicated in 
PTSD and seasonal affective disorder (Schuppenies et al., 2006; Handwerger, 2009). 
Depression is often precipitated by stressful life events. HPA dysfunction has been 
established in depression and elevated cortisol levels often precede the onset of 
depression (Posener et al., 2000). Depressed patients exhibit greater cortisol levels, an 
increased response to ACTH and elevated CRH levels along with failure of GC negative 
feedback (Pariante, 2004). A decreased hippocampal volume has been reported in both 
depressed and Cushing’s patients that correlates with disease progression (Sheline et al., 
1999) (Starkman et al., 1992; Lupien et al., 2007b). Moreover, the depressive symptoms 
of Cushing’s disease can be relieved by the correction of hypercortisolaemia (Murphy 
1991). Salivary and cerebral spinal fluid (CSF) cortisol levels have been shown to 
correlate with the severity of Alzheimer’s disease (AD) (Giubilei et al., 2001; 
Hoogendijk et al., 2006). There is a high prevalence of depression in AD  (Greenwood 
et al., 2003) suggesting that they may share a common pathogenesis (Meynen et al., 
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2007). Furthermore, GCs increased pathology in a mouse model of AD (Green et al., 
2006).  
 
Hippocampus 
Much of the work on the detrimental effects of stress and GCs has focused on the 
hippoacampus as it has a high density of GC receptors and is involved in the regulation 
of HPA activity. The studies of Landfield at al., 1981 (Landfield et al., 1981) 
demonstrated that chronic exposure to GCs could influence hippocampal neuronal 
viability and function, typified by the degenerative loss of pyramidal neurons and 
subsequent deficits in memory (Sapolsky, 1986). It is now known that within the 
hippocampus chronic GC exposure produces glial cell proliferation, reduced dendritic 
branching, decreased volume, a reduction in CA1 and CA3 cell number  and impaired 
long term potentiation (LTP) (Joels et al., 2004; Swaab et al., 2005). Chronic stress 
studies using daily immobilisation for several weeks; a selection of random stressors 
twice daily or repetitive social stressors have been shown to produce similar effects to 
that of chronic GCs with deficits in hippocampus-related learning, decreased branching 
and length of CA3 dendrites, decreased synaptic contacts, reduced proliferation and 
increased apoptosis (Woolley et al., 1990; Magarinos et al., 1996; Kim and Diamond, 
2002) (Heine et al., 2004b). There is evidence to suggest that these effects are mediated 
by elevations in glutamate and subsequent NMDA receptor activation (McEwen and 
Magarinos, 1997). Chronic CORT treatment in humans results in smaller hippocampal 
volumes and declarative memory deficits when compared to controls (Brown et al., 
2004). 
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Amygdala 
Opposite effects of stress are seen on the amygdala where repeated stress produces 
hypertrophy, dendritic growth in neurons (Vyas et al., 2002) and enhances amygdala 
dependent unlearned fear and fear conditioning (Conrad et al., 1999). 
 
Medial prefrontal cortex 
Within the mPFC repeated stress leads to dendritic shortening (Sousa et al., 2000) 
(Wellman, 2001; Vyas et al., 2002) and attention impairment (Liston et al., 2006) that 
may reflect structural remodelling in the mPFC.  
 
Pro-inflammatory effects of GCs 
GCs are considered anti-inflammatory, immunosuppressive and immunomodulatory. 
However in recent years this view has been challenged in light of findings that suggest 
GCs can also exert pro-inflammatory effects within the CNS (Sorrells and Sapolsky, 
2007). This is exemplified by studies showing that chronic stress in rats fails to suppress 
increases in inflammatory cytokines following LPS infusion (de Pablos et al., 2006). 
Moreover stress through GR activation increases TNF-α, IL-1β and iNOS within the 
hippocampus and cortex when LPS is administered peripherally (Munhoz et al., 2006). 
Stress and GCs can also increase microglial proliferation through a glutamate/NMDA 
mechanism (Nair and Bonneau, 2006). 
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Table 1.6 Evidence for proinflammatory actions of stress in the rodent CNS 
 
Pro-inflammatory 
mediator 
Stressor Effect in CNS Reference 
Glucocorticoids Immobilisation Increased IL-1β, 
TNF-α, IL-6, NFκB 
Minami 1991, 
yamasu 1992, 
nukina 1998 
Catecholamines Inescapable tail 
shock 
Immobilisation 
Footshock 
 
Increased IL-1β, 
IL-6 
Increased NFκB 
Increased NFκB 
Johnson 2005 
 
Madrigal 2001 
Black 2006 
Glutamate Immobilisation Increased COX-2, 
iNOS 
Madrigal 2003 
Cytokines Immobilisation, 
tailshock, footshock 
swim stress 
 
Immbobilisation 
 
Immobilisation, 
footshock 
Increased IL-1β 
 
Decreased IL-1β, 
TNF-α 
Increased TNF-α, 
NFκB, iNOS 
Increased IL-6 
Deak 2005 
 
Connor 2005 
 
Madrigal 2001, 
2002 
Kronfol 2000 
Pro-inflammatory 
enzymes 
Swim stress, heat 
exposure, 
immobilisation 
Increased COX-2, 
iNOS 
Katafuchi 2003, 
Madrigal 2003 
 
Abbreviations COX-2, cyclooxygenase-2; iNOS, inducible nitric oxide synthase; IL, 
interleukin; NFκB, nuclear factor kappa B; TNF-α, tumor necrosis factor-alpha. 
Adapted from (Garcia-Bueno et al., 2008) 
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1.2.9 Effect of sex and age on the HPA axis 
There is generally a greater stress response in adult (pre-menopausal) females than 
males (Kajantie and Phillips, 2006). During aging the concentration of cortisol in CSF 
(cerebrospinal fluid) increases progressively (Laughlin and Barrett-Connor, 2000) and 
there is an age related decline in hippocampal volume in men but not women (Pruessner 
et al., 2001). There is also an age related increase in CRH neurons in men but not 
women (Bao and Swaab, 2007).  In addition men have greater AVP levels than females 
(van Londen et al., 1997). Basal CORT levels in rodents are not altered in aging. 
However, stress responses are greater and recovery takes longer in older animals 
(Lucassen et al., 2001; Heine et al., 2004a). Hippocampal damage resulting from age 
related degeneration results in the disinhibition of GC negative feedback promoting 
further activation of the HPA axis, increasing GC levels thus causing accumulating 
damage. This is known as the GC cascade hypothesis (Sapolsky et al., 1986). Further 
evidence for dissociative effects of stress and GCs in males in females is provided by 
experiments showing that chronic foot shock stress decreases proliferation in the dentate 
gyrus of males but increases proliferation in females (Westenbroek et al., 2004). 
Chronic restraint stress induces the retraction of dendrites in the CA3 hippocampal 
neurons in males but not females (unless they are ovariectomised) (Galea et al., 1997) 
and enhances or has no effect on spatial learning in females but is detrimental in males 
(Bowman et al., 2003; Conrad et al., 2003). 
 
1.2.10 HPA axis interaction with the hypothalamic-pituitary-gonadal 
(HPG) axis 
Both CRH and GCs can prevent GnRH (gonadotrophin releasing hormone) release. 
Moreover GCs can directly influence the testes and ovaries to reduce the production of 
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sex hormones (Swaab et al., 2003; Bao and Swaab, 2007). CRH fibres from the PVN 
also innervate GnRH neurons in the infundibular nucleus (Dudas and Merchenthaler, 
2003). Conversely sex hormones control CRH gene expression and estrogen and 
androgen receptors are co-localised with CRH neurons (Bao et al., 2005; Bao et al., 
2006). Furthermore, ovarian steroids increase HPA activity and enhance the HPA 
response to psychological stress (Kirschbaum et al., 1996). 
 
1.2.11 Early life stress 
Early life manipulations have been carried out in primates, guinea pigs, sheep, cattle, 
pigs, rats and mice. Manipulations can be split into prenatal manipulations and postnatal 
manipulations that impact upon different stages of development. Table 1.7 shows the 
main manipulations used in rodents. 
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Table 1.7 Early life manipulations in rodents 
 
Manipulation Nature of 
treatment 
Timing of 
treatment 
Effect later in life Reference 
Prenatal stress 
 
 
 
Postnatal handling 
 
 
 
Maternal care 
 
 
 
 
Maternal 
separation 
 
 
Novelty exposure 
 
 
 
 
Aversive 
conditioning 
Noise / Restraint 
 
 
 
Brief separation 
from mother 
 
 
Licking and 
grooming of pups 
 
 
 
Prolonged 
separation from 
mother 
 
Exposure to novelty 
 
 
 
 
Odor-shock 
conditioning 
Last week of 
gestation 
 
 
PND 1-14 
 
 
 
PND 1-14 
 
 
 
 
PND1-14 
 
 
 
PND1-21 
 
 
 
 
PND8 
PND23 
PND12-15 * 
PND12-15 # 
Increased HPA reactivity, 
emotionality and 
exploratory behaviour  
 
Decreased HPA reactivity, 
emotionality and 
exploaratory behaviour 
 
Decreased HPA reactivity, 
emotionality and 
exploaratory behaviour 
 
 
Increased HPA reactivity, 
emotionality and 
exploratory behaviour 
 
Enhanced spatial memory, 
social competion and larger 
HPA response to 
unexpected stressor  
 
Odor preference 
Odor avoidance 
Odor preference 
Odor avoidance 
Macari 
2001 
 
 
Levine 
1967 
 
 
Meaney 
1994/ 
francis 
2002 
 
Plotsky 
2005 
 
 
Tang 2007 
 
 
 
 
Moriceau 
2006 
 
PND: post natal day. *With mother present. #without mother present. Table adapted 
from (McEwen, 2007) 
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It is now widely accepted that early life events impact upon adult physiology and 
behaviour. The idea of ‘programming’ or ‘imprinting’ can be described as the 
association between an environmental factor and its action during a critical window on 
the development and organisation of tissues that persist throughout life. Different 
cells/tissues can be sensitive at different times and to different challenges. The purpose 
of this programming that occurs early in life is thought to be to allow adaptation for its 
future environment. Two hypotheses have formed that are thought to underpin this 
programming effect. The first is maternal malnutrition, the second being exposure to 
glucocorticoids or stress. Interestingly, these are interrelated whereby GCs can modulate 
food intake and malnutrition can alter GC exposure. 
 
1.2.11.1 Prenatal Stress 
The offspring of prenatally stressed rats exhibit increased basal corticosterone and 
ACTH levels and an increased HPA response to stress (Review (Matthews, 2002)), 
sensitises to postnatal stressors such as handling (Smythe et al., 1996) and decreased 
habituation to stress (Fride et al., 1986). Prenatally stressed rats also have decreased 
expression of GR and MR (Henry et al., 1994; Koehl et al., 1997; Szuran et al., 2000). 
In humans prenatal stress can cause pre-term birth or full term low birth weight (Barker, 
1996; Wadhwa et al., 2004). Low birth weight is associated with an increased risk of 
cardiovascular and metabolic disease later in life (Barker, 1996). Children that grow up 
in emotionally cold families are at a greater risk of poor mental and physical health in 
adulthood (Repetti et al., 2002). Furthermore abuse during childhood is a known risk 
factor for depression, PTSD, substance abuse, obesity, diabetes and cardiovascular 
disease (Heim and Nemeroff, 2001; Anda et al., 2006) (Felitti et al., 1998). 
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1.2.11.2 Prenatal GCs 
Within the brain GCs are important for the normal maturation of the CNS where they 
are involved in initiating terminal maturation, remodelling axons and dendrites, and 
influencing cell survival (Meyer 1983). Prenatal GCs decrease brain weight at birth 
(Huang et al., 1999), delay the maturation of neurons and glia (Huang et al., 2001b, 
2001a) and influence synapse formation (Antonow-Schlorke et al., 2003) permanently 
altering brain structure. GR and MR are highly expressed within the developing brain 
(Kitraki et al., 1997). However until mid-gestation the developing CNS is protected 
from GCs by 11βHSD2. It is then that 11βHSD2 expression is switched off in the rat 
brain, coinciding with the terminal stage of neurogenesis, allowing GC access to the 
fetal brain (Diaz et al., 1998). A similar phenomenon occurs in humans where 
11βHSD2 is reduced at weeks 19-26 (Stewart et al., 1994). 
 
Glucocorticoids are the primary candidate for early life programming. A large number 
of pregnant women are treated with synthetic GCs to prevent respiratory distress 
syndrome in newborns. GCs are administered to mothers at risk of preterm labour and 
in antenatal treatment of foetuses at risk of congenital adrenal hyperplasia. The most 
commonly used GCs are dexamethasone (DEX) and betamethasone due to the fact they 
are weak MR agonists and have weak immunosuppressant effects (Aghajafari et al., 
2001). Dexamethasone and betamethasone are also poor substrates for 11βHSD2 
(Albiston et al., 1994) therefore readily cross the placenta and have access to the fetus. 
No adverse effects of a single dose have been reported but multiple courses may have 
detrimental effects later in life (Aghajafari et al., 2001). In the rodent brain GR and MR 
are low throughout gestation but rapidly increase after birth, however there are distinct 
patterns of GR and MR expression in the foetal rat brain (Diaz et al., 1998). GR’s are 
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present in the hippocampus, hypothalamus and pituitary by GD13 whereas MR are not 
present in the hippocampus until GD16/17. 
 
The HPA axis is particularly sensitive to programming where it produces an increase in 
basal CORT levels in adult rats and decreases GR and MR expression within the 
hippocampus, thus attenuating feedback sensitivity (Levitt et al., 1996; Welberg et al., 
2001). Primates also exhibit elevated basal and stress levels of cortisol (Uno et al., 
1994). GCs also program behaviour where they seem to impair coping mechanisms later 
in life (Welberg et al., 2001), program anxiety related behaviours (Dunn and Berridge, 
1990; Welberg et al., 2000) and affect the development of dopamine systems with 
implications for the development of schizophrenia, addiction and extrapyramidal 
disorders (Diaz et al., 1997). 
 
In humans antenatal GC treatment results in lower birth weights (French et al., 1999; 
Bloom et al., 2001). However there is a lack of long term follow up studies to ascertain 
their long term implications on adult physiology, pathology and behaviour. Currently 
there is evidence that adolescents that were exposed to synthetic GCs in utero have 
higher blood pressure (Doyle et al., 2000) and that multiple antenatal doses of DEX 
result in a reduced head circumference, a lower IQ and behavioural problems (French et 
al., 1998). Furthermore treatment with DEX of foetuses at risk of cogenital adrenal 
hyperplasia has been associated with increased emotionality and behavioural problems 
(Trautman et al., 1995). Children of low birth weight have higher plasma GC levels, 
have exaggerated adult responses to ACTH, elevated blood pressure, insulin resistance, 
glucose intolerance and hyperlipidemia (Phillips et al., 2000). 
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11βHSD2 is also thought to play a role in low birth weight. Indeed, lower 11βHSD2 
activity correlates with smaller fetus size in rats (Benediktsson et al., 1993) and low 
birth weight in humans (Murphy et al., 2002). Babies homozygous for deleterious 
mutations in 11βHSD2 have low birth weights (Dave-Sharma et al., 1998). 
Interestingly, dietary protein restriction during pregnancy reduces 11βHSD2 (Bertram et 
al., 2001). 
 
1.2.12 Potential involvement of stress and GCs in PD 
One of the earliest proposed causes of PD was stress (Charcot 1878, Gowers 1888). 
This idea has started to regain attention and a hypothesis for the involvement of stress 
and GCs in the pathophysiology of PD is emerging (Kibel and Drenjancevic-Peric, 
2008). In PD patients it has been suggested that acute or chronic stress may result in an 
earlier onset or worsen the symptoms of PD (Macht et al., 2005). Indeed cortisol levels 
are higher in PD patients and have been associated with gait deficits (Hartmann et al., 
1997; Charlett et al., 1998). The presence of GC receptors within the NSDA (Cintra et 
al., 1994) provides a means by which GCs could exert an effect on the NSDA rendering 
it vulnerable to excess levels of GCs. Consequently stress and GCs have been shown to 
negatively affect motor function in both humans (Maki and McIlroy, 1996) and rats 
(Metz et al., 2001; Metz et al., 2005). Of significant interest is the finding that stress can 
elevate oxidative damage in the mouse NSDA (Kim et al., 2005) a mechanism that has 
been heavily implicated in the pathogenesis of PD. Further evidence supporting an 
effect of stress and GCs on the NSDA is provided by studies demonstrating that chronic 
corticosterone treatment elevates D1 receptor mRNA in the striatum of mice (Biron et 
al., 1992); immobilisation stress increases striatal DA levels (Kim et al., 2005) and that 
repeated restraint stress increases DAT mRNA within the rat striatum (Copeland et al., 
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2005). It has also been proposed that the early life environment has a significant impact 
on disease susceptibility in adulthood and that GCs are an important programming 
factor (see section 1.2.11). Thus, stress and excess GCs during development may impact 
upon the developing NSDA. Indeed, prenatal GC treatment permanently alters rat DA 
system (McArthur et al., 2005; McArthur et al., 2007a) 
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1.3 Aims 
The following chapters aim to determine the effect of GC treatment early in life and the 
effects of adult GC treatment or stress exposure on pathways implicated in PD. The 
pathways examined are the dopaminergic NSDA, MLDA and MCDA as well as the 
noradrenergic LC, cholinergic NBM and serotonergic system which are known to 
degenerate in PD. The specific aims of the project are outlined below. 
 
 
1. To determine the effects of prenatal dexamethasone treatment on pathways 
known to degenerate in PD. 
 
2. To determine the effects of repeated adult stress or adult treatment with GCs on 
pathways known to degenerate in PD. 
 
3. To determine how prenatal DEX treatment combined with adult stress or GC 
treatment affects pathways known to degenerate in PD. 
 
4. To examine the influence of prenatal dexamethasone treatment and/or adult 
repeated stress or chronic adult GC treatment on susceptibility to 6-OHDA 
neurotoxin. 
 
5. To establish any sex differences in the effects of 1,2,3 and 4. 
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In order to achieve these aims rats will be bred in-house and treated prenatally with 
dexamethasone (GD16-19) via the maternal drinking water. Pups will be allowed to 
mature and adult rats (3.5 months) will receive repeated restraint stress or chronic GC 
treatment (via drinking water) for a period of 6 weeks. Integrity of the SN, VTA, LC 
and NBM will be assessed by the use of immunohistochemistry and the stereological 
quantification of cell numbers within these regions. Levels of microglia, astrocytes, and 
oxidative damage will also be assessed by immunohistochemistry in these regions. 
Functionality of neuronal systems will be determined using high performance liquid 
chromatography whereby the levels of dopamine and its metabolites, serotonin and its 
metabolite and noradrenaline will be quantified in the striatum, nucleus accumbens and 
frontal cortex. To determine the effects of stress and GCs on susceptibility to a toxic 
insult, 6-OHDA will be administered to the MFB, producing a partial lesion of the 
NSDA. The severity of the lesion and the subsequent DA loss will then be assessed as 
described above using immunohistochemical markers and HPLC. 
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CHAPTER TWO - MATERIALS AND METHODS 
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2.1 – IN VIVO METHODS 
 
2.1.1 - Animals 
All animal procedures were carried out in accordance with the UK Animals (Scientific 
Procedures) Act 1986, under project license number PIL 70/6486 with local ethical 
approval (Ethical Committee of Imperial College, London). Sprague-Dawley rats were 
purchased from Harlan for timed mating and housed in the Comparative Biology Unit at 
Charing Cross Hospital. Animals were allowed to acclimatise for one week before 
undergoing any procedure. Animals were given free access to food and water in a 
temperature controlled (21 ±2C°) 12 h light-dark cycle room (lights on 07:00am, lights 
off 19:00pm). All animals were handled regularly and weighed weekly. Male and 
female animals were housed in separate rooms. Experiments were carried out between 
08:30 and 12:00 to prevent complications associated with circadian rhythm. 
 
2.1.2 - Breeding 
Two females and one male were housed together overnight. Mating was confirmed by 
the presence of vaginal plugs the next morning and recorded as gestational day 1 (GD1). 
Pregnancy was later confirmed by palpation on GD10. Pregnant females were then 
housed individually for littering and monitored regularly. Offspring were weaned at 3 
weeks, when they were randomly assigned to treatment groups with animals from at 
least three different litters in each group. Males and females were then housed in 
separate rooms in cages containing two animals. 
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2.1.3 - Prenatal Dexamethasone Treatment 
Rat pups were indirectly exposed to the synthetic glucocorticoid dexamethasone (DEX). 
0.5μg/ml dexamethasone sodium phosphate (Rosemont Pharmaceuticals, Leeds, UK) 
was administered via the maternal drinking water on GD 16 to 19. In this paradigm the 
developing rats are exposed to DEX via the placenta, a method established by 
(Theogaraj et al., 2005). Control animals received normal drinking water throughout 
gestation. Maternal weights and fluid intake were monitored over the period of DEX 
treatment (see section 2.6.1) Mothers were also closely monitored for any changes in 
behaviour. 
 
2.1.4 - Adult Restraint Stress 
At 3.5 months animals were subjected to physical restraint stress. This was achieved by 
immobilisation in a plastic restraint tube (Harvard Apparatus, UK) for 1 hour every 
other day for 6 weeks. Two different sized tubes were used depending on the size of the 
animal that could be adjusted to achieve a tight fit. The procedure was carried out at the 
same time each day (8.30-11.30am). This produced a model of repeated, intermittent, 
psychological stress that replicates the paradigm used by Fontella et al (2005) that 
reported increased oxidative stress within the hippocampus.  
 
2.1.5 - Adult Hydrocortisone Treatment 
3.5 month old rats were treated with the synthetic glucocorticoid hydrocortisone (the 
synthetic form of cortisol). 400 μg/ml hydrocortisone sodium succinate (Pharmacia Ltd, 
UK) was added to the drinking water for a period of 6 weeks. This non-invasive 
glucocorticoid treatment is based on a method used by (Magarinos et al., 1998), which 
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produced alterations in hippocampal morphology that were comparable to those induced 
by restraint stress. The paradigm produced stress levels of GCs and gave a circadian 
profile due to increased feeding/drinking behaviour in the evening (Conrad et al., 2004). 
Control animals received normal drinking water. Weights and fluid intake were 
recorded throughout the treatment period (see sections 2.6.2-3).  
 
2.1.6 - Assessment of Estrous Cycle  
A subset of female animals from each treatment group were assessed for estrous cycling 
(see section 2.6.4). At ~5 months of age vaginal lavages were collected on 10 
consecutive days and allowed to dry on microscope slides. Slides were then stained with 
haematoxylin and eosin and examined under a light microscope. Evaluation of estrous 
stage was achieved by the identification of the cell types present according to published 
methods (Goldman et al., 2007); (Hubscher et al., 2005); see figure 2.1). 
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Figure 2.1 – Estrus cycle staging.  Haematoxylin and eosin staining of vaginal 
smears at different stages of the estrous cycle. The proestrus stage lasts 12-14 hours and 
is characterised by round nucleated cells of uniform size. Estrus lasts 25-27 hours and is 
distinguished by the appearance of irregularly shaped un-nucleated cornified cells.  
Metestrus lasts 6-8 hours and is characterised by the appearance of leukocytes. During 
diestrus, which lasts 55-57 hours, both leukocytes and nucleated cells are present. For 
the majority of animals the estrus cycle lasts 4-5 days. 
 
 
 
 
Proestrus Estrus 
Metestrus Diestrus 
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2.1.7 - 6-Hydroxydopamine Lesioning of the Nigrostriatal Pathway 
To examine the effects of stress or glucococorticoids on the ability of the nigrostriatal 
system to cope with a toxic insult we employed the neurotoxin 6-OHDA that is used to 
model PD. 6-OHDA is a hydroxylated analogue of dopamine that is taken up by DAT 
where its subsequent accumulation in the cytosol produces prolonged oxidative stress, 
ultimately resulting in neuron death. For more information on the use of 6-OHDA to 
model PD see section 1.1 12. The magnitude of the lesion produced is dependent on site 
of injection and the concentration of the 6-OHDA used. For a review of 6-OHDA 
nigrostriatal lesions see (Deumens et al., 2002).  The medial forebrain bundle was 
chosen as the site of injection as it had previously been used to successfully produce 
partial lesions of the NSDA (Datla et al., 2004). In the work presented here where older 
larger animals were used, 5μg of 6-OHDA was injected into the medial forebrain 
bundle. Preliminary work (see figure 2.3) suggested that this dose produced a 60% 
striatal dopamine loss in males and 40% loss in females. This unilateral, partial lesion 
allowed the determination of any positive or negative effects of preceding stress and 
glucocorticoid treatments on lesion size with the unlesioned hemisphere of the brain 
serving as an internal control.  
 
Before surgery commenced pre-operative weights were recorded. Anaesthesia was 
induced using 5% Isoflurane (Abbott, UK) and 2.5% oxygen (BOC, UK) in an 
induction chamber. Once animals were sufficiently anaesthetised and had lost their 
righting reflex animals were transferred to a stereotaxic frame (Kopf Instruments, USA) 
with ear bars 5 mm below the incisor bar to secure the head and placed on a heated mat. 
Anaesthesia was maintained at 1.5-3% isoflurane and 1 % oxygen and was continually 
monitored throughout the surgical procedure by monitoring the rate and depth of the 
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animals breathing and its reflexes. Once the animal was fixed in the stereotaxic frame 
the scalp was shaved and sterilised with iodine. Animals then received 0.1 ml 
bupivicaine hydrochloride (Marcain, AstraZeneca, UK), a long acting local anaesthetic 
injected sub cutaneously at 4 different sites on the scalp close to the incision site. 5ml of 
glucosaline (Baxter, UK) was given by intraperitoneal injection to prevent dehydration. 
A single incision was made along the scalp from midway between the eyes to midway 
between the ears to expose the skull. The skull was cleaned by scraping away any 
membranous tissue to reveal bregma, an anatomical landmark on the skull from which 
coordinates could be measured. A small hole was  made using a dental drill above the 
proposed site of the medial forebrain bundle, 2.2mm posterior and 1.5mm lateral to 
bregma (based on coordinates from the standard rat brain atlas of Paxinos and Watson, 
1986; see figure 2.2). The meninges were cleared from the surface of the brain and 5μg 
of 6-OHDA hydrobromide free base (dissolved in 0.1% ascorbic acid in 0.9% sodium 
chloride solution) was injected at 7.9mm ventral to the dura over a period of 4 minutes 
(1μl/min) using a 10μl syringe (Hamilton, UK). The needle was then left in place for 
another 4 minutes to allow the toxin to diffuse and to prevent reflux of the toxin before 
being removed. Antibiotic powder was applied to the wound to prevent infection and 
the wound closed with 3 sutures. The animal was then placed in a heated recovery 
chamber to recover from the anaesthetic were it was closely monitored. Post surgery 
animals received mashed food, were housed individually and were culled 14 days post-
op. 
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Figure 2.2 Coronal section showing location of the stereotaxic injection of 
6-OHDA to the left medial forebrain bundle. 6-OHDA was injected 2.2mm 
posterior, 1.5mm lateral and 7.9 mm ventral to bregma. Figure adapted from atlas by 
Paxinos and Watson 1986. 
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Figure 2.3. Percentage striatal DA loss in response to different doses of 6-
OHDA in male (open bars) and female rats (filled bars). 3, 5, 10 and 12μg 6-OHDA 
were stereotaxically injected into the left medial forebrain bundle. Striatal DA levels 
were measured 2 weeks post surgery and expressed as a % of the DA concentration in 
the contralateral striatum. 2 animals of each sex were exposed to each dose. 
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2.1.8 - Post-Mortem Procedure and Tissue Collection 
Animals were culled by decapitation. Trunk blood was collected, allowed to clot on ice 
and was subsequently centrifuged for 15 minutes at 3000 rpm at 4°C. Serum was 
collected and stored at -80°C until further analysis. Brains were rapidly removed, the 
nucleus accumbens, striatum and frontal cortex were dissected out and snap frozen on 
dry ice. They were then stored at -80°C until further processing. The remaining hind 
brain blocks were fixed in 4% paraformaldehyde in PBS (phosphate buffered saline) for 
7 days and then cryoprotected in 30% sucrose in PBS with 0.1 % sodium azide. Once 
brains had sunk they were removed from sucrose solution and stored at -80°C. 
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2.2 - EX VIVO METHODS 
2.2.1 - Corticosterone Enzyme Linked Immuno Assay 
Analysis of circulating corticosterone levels were assessed using a Corticosterone 
ELISA kit (IDS, USA). The assay was performed in accordance with kit instructions 
and all calibrators, controls and solutions were provided within the kit. Each serum 
sample was diluted 1 in 10 with sample diluent (PBS and horse serum). 100μl of each 
calibrator, control or sample was then added to the appropriate well of an antibody 
coated plate (polyclonal rabbit anti-corticosterone) in triplicates. 100μl of enzyme 
conjugate solution (horseradish peroxidise) was added to all wells and the plates were 
left to incubate for 18 hours at 2-8°C. After incubation wells were washed 3 times with 
wash solution followed by the addition of 200μl of the chromagen tetramethylbenzadine 
(TMB substrate) to each well, to visualise the reaction. Plates were left to incubate for 
30 minutes at room temperature after which the reaction was stopped with 100μl of 
0.5M hydrochloric acid. The absorbance of each well was read using a microplate 
reader (Tecan, UK) at 450nm. Calibrator absorbance were used to produce a standard 
curve (see figure 2.4) from which the concentration of corticosterone in each serum 
sample could be established. 
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Figure 2.4 Example of a corticosterone standard curve . Corticosterone 
concentration was plotted against percent binding (B/Bo%).  
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2.2.2 - Cryostat Sectioning 
From fixed and cryoprotected hind brains, 30µm sections were cut using a cryostat 
(Bright Instruments, UK) maintained at -22ºC. Sections were thaw mounted onto slides 
coated in poly-l-lysine (0.1%) in series of 6 slides with two sections per slide. This 
allowed the subsequent staining of adjacent sections.  Sections were collected 
throughout the nucleus basilis of meynert (NBM), substantia nigra (SN) and locus 
coeruleus (LC). These regions were identified using the standard rat brain atlas (Paxinos 
and Watson, 1986; see figure 2.5). Slides were stored at -80ºC until further use. 
 
2.2.3 - Immunohistochemistry 
All immunohistochemical analysis was performed using an avidin-biotin 
immunoperoxidase (ABC) method. Optimisation of all antibodies was performed to 
identify appropriate working dilutions and positive and negative controls were used to 
ensure the specificity of staining. Positive controls consisted of tissue where the epitope 
of interest was known to be expressed and negative controls involved the omission of 
the primary antibody. Working dilutions of all antibodies used can be found in table 2.1. 
 
Sections were circled with a wax blocker and rehydrated with PBS for 15 mins. 
Sections were covered with 0.3% hydrogen peroxide / methanol solution for 45 minutes 
to block endogenous peroxidase activity. Sections were then washed 3 x 5 minutes in 
PBS with 0.1% Triton-X (PBS-T) to enable antibody penetration. Non specific binding 
was blocked by incubation in normal serum (appropriate to the secondary antibody) in 
PBS-T for 1 hour. Sections were left to incubate at room temperature overnight in 
primary antibody made up in normal serum in PBS-T. The following day sections were 
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washed in PBS-T (3 x 5 mins), then incubated in the appropriate secondary antibody for 
1.5 hours. Sections were again washed in PBS-T (3 x 5 mins) and incubated in avidin-
biotin complex using the vector elite kit (1:200) (Vector, UK) for 1 hour.  Following 
washing (3 x 5 mins in Tris buffer) the reaction was visualised with 0.05% 
diaminobenzidene (DAB) dissolved in Tris buffer with 0.01% hydrogen peroxide until 
desired staining intensity was reached. The reaction was stopped by placing slides in 3 
changes of distilled water. Sections were dehydrated in increasing concentrations of 
alcohol, cleared in xylene and cover slips were attached using DPX mountant. Sections 
were then stored for analysis by light microscopy.  
 
2.2.4 - Neuronal Immunohistochemistry 
To determine the effect of treatments on dopaminergic neurons within the SNpc and 
VTA, an antibody against tyrosine hydroxylase (TH) was used. TH is the rate limiting 
enzyme in DA synthesis and can therefore be used as a marker of DA neurons. TH 
would also be found in noradrenergic neurons but these are not present at the level of 
the SNpc and VTA. An antibody against dopamine-β-hydroxylase (DβH), the enzyme 
that converts dopamine to noradrenaline was used as a marker of noradrenergic neurons 
within the LC. To identify and quantify cholinergic neurons in the NBM, an antibody 
against choline-acetyltransferase (ChAT) was used. ChAT is an enzyme that combines 
acetyl coA to choline forming acetylcholine and thus is used as a marker for cholinergic 
neurons. A general neuronal marker neuronal N (NeuN) was additionally used on 
adjacent sections in all regions to indicate whether there were changes in neuronal 
numbers or enzyme expression. When quantifying neurons only cells that displayed 
robust immunoreactivity with a nucleus, a clear cytoplasm and axonal processes were 
counted. Cells that appeared severely damaged or deformed were not included. 
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2.2.5 - Glial Immunohistochemistry 
As inflammation is closely linked to HPA axis function and is thought to be involved in 
the pathogenesis of PD, microglial and astrocyte populations were studied in all brain 
regions. To study microglial populations an OX-42 antibody was used. This antibody 
recognises the cell surface antigen CD11b of the type 3 complement receptor found in 
mononuclear phagocytes. To specifically identify activated microglia an antibody 
against major histocompatability complex class II antigens, OX6 was used. To study 
changes in astrocytic morphology and proliferation an antibody against glial fibrillary 
acidic protein (GFAP), an intermediate filament protein found in astrocytes was used. 
As well as obtaining total numbers of microglia and astrocytes, their morphology was 
also assessed. Reactive astrocytes display intense GFAP staining and have enlarged cell 
bodies with one or two thickened processed whereas resting astrocytes show moderate 
GFAP staining and have small cell bodies and several processes. Resting microglia 
display moderate OX-42 reactivity and have small cell bodies with numerous processes 
with extensive ramifications. Activated microglia however, show intense OX-42 and 
OX-6 staining, have larger cell bodies and have shorter processes and fewer 
ramifications (Raivich et al., 1996). 
 
2.2.6 - Oxidative stress Immunohistochemistry 
As oxidative stress is heavily implicated in the pathogenesis of PD and stress and GCs 
have been shown to elevate levels of oxidative stress within the brain, the consequences 
of oxidative damage within the SNpc, VTA, LC and NBM was determined. An 
antibody against 3-nitrotyrosine, a marker of protein nitration which is indicative of 
nitrosative stress (the formation of peroxynitrite and reactive nitrogen species) and 
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therefore oxidative stress was used. Sections were counterstained with haematoxylin to 
allow cells positive for protein nitration to be counted. 
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Table 2.1 Details of all prima ry and se condary a ntibodies used in ABC 
immunohistochemistry.  
 
 Primary antibody Source Secondary 
antibody 
Normal serum 
Dopaminergic 
neurons 
Rabbit anti-
Tyrosine 
Hydroxylase 
(1:1000) 
Pel-freez Biotinylated 
goat anti-
rabbit (1:200) 
20% NGS,  
Neurons Mouse anti- 
Neu-N (1:1000) 
Chemicon Biotinylated 
horse anti-
mouse (1:100) 
5%NHS 
Activated 
Microglia 
Mouse anti- OX6 
(1:750) 
Serotech Biotinylated 
horse anti-
mouse (1:100) 
5% NHS 
Microglia 
 
Mouse anti- OX-
42 (1:500) 
Serotech Biotinylated 
horse anti-
mouse (1:100) 
5% NHS 
Astrocytes Mouse anti- 
GFAP (1:1000) 
Sigma Biotinylated 
horse anti-
mouse (1:100) 
5% NHS 
Nitrosative 
stress 
Rabbit anti 3-
nitrotyrosine 
(1:1000) 
Chemicon Biotinylated 
goat anti-
rabbit (1:200) 
20%NGS 
Noradrenergic 
neurons 
Rabbit anti-
Dopamine-β-
hydroxylase 
(1:1000) 
Chemicon Biotinylated 
goat anti-
rabbit (1:200) 
20% NGS 
Cholinergic 
neurons 
Rabbit anti- 
Choline 
Acetyltransferase
(1:750) 
Chemicon Biotinylated 
goat anti-
rabbit (1:200) 
20% NGS 
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Figure 2.5. Coronal rat brain sections depicting regions of interest.  Nucleus 
basilis of meynert (A), substantia nigra (B in red), ventral tegmental area (B in blue) and 
locus coeruleus (C). Pictures adapted from atlas by Paxinos and Watson, 1986.
A 
B 
C 
 95
 
 
Figure 2.6. Photomicrographs of immunohistochemical staining depiciting 
tyrosine hydroxylase  in SNpc (A), neuronal n in SNpc (B), ChAT in  NBM (C), DβH 
in LC (D),GFAP in SNpc (E), OX-42 in SNpc (F), OX-6 in SNpc (G) and 3-
nitrotyrosine positive cells in SNpc (H). Images were taken at 200x magnification. 
A B
C
E F
D
G H
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2.2.7 - Image analysis and stereological quantification 
Stereological estimates were made using computer based stereology software (MAG, 
UK) attached to a Nikon Eclispe E800 microscope and JVC analogue camera. Cells 
were counted using the optical fractionator method (Schmitz et al., 2005). The area of 
interest (AOI) was first defined by the user (see Fig 2. A. The software was then used to 
create counting frames within the AOI using uniform random sampling. The total area 
of the counting frames relative to the area of the AOI gives the area sampling fraction 
(asf). The height of the optical dissector which was measured using a heidenhain 
microcator (Heidenhain, Germany), relative to the actual section thickness gives the 
height sampling fraction (hsf). The section sampling fraction (ssf) was 1/6 as every 6 
section throughout the AOI was analysed. Only cells falling within or touching the 
counting frame were counted and forbidden lines were used to avoid edge effects (see 
fig 2.7 B). Total cell estimates (N) were made using the following formula N = 
n(1/ssf)(1/asf)(1/hsf) where n equals the number of positive cells counted.           
 
Figure 2.7. A) Selection of AOI. B) Positive cells w ithin a counting frame.  
Cells falling within the counting frame or touching green lines were counted. If cell was 
touching a red line it was not counted. 
A 
B
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2.2.8 - Monoamine Analysis by HPLC-ECD 
High performance liquid chromatography was used to detect the concentrations of 
monoamines within the striatum, nucleus accumbens and the frontal cortex. The levels 
of DA and its metabolites dihydroxyphenylaceitic acid (DOPAC) and homovanillic acid 
(HVA), 5-hydroxytryptamine (5HT), its metabolite 5-hyroxyindoleacetic acid (5HIAA) 
and noradrenaline (NA) were determined. Individual samples were weighed and then 
homogenised in 0.5ml of ice cold homogenising medium (50mM trichloroacetic acid, 
0.5mM disodium ethylenediaminetetraacetic acid (EDTA) along with 0.5pmol/μl 3,4-
dihydroxybenxylamine as an internal standard, using an ultrasonicator (Soniprep, Sanyp 
UK). Samples were kept on ice for 10 minutes to allow extraction of monoamines and 
then centrifuged for 10 mins at 13000g at 4ºC. The resulting supernatant was filtered 
through a 0.45µm pore syringe filter (Whatman, UK) and placed into glass vials 
(Chromacol UK) on an autosampler (Gina 50 Dionex, UK) maintained at 5ºC. Using 
Chromeleon software  30µl from each sample was injected and then 
chromatographically separated on an Altex Ultrasphere 5µm column (Beckman Coulter, 
High Wycombe, UK) at room temperature using a mobile phase consisting of 0.1 mM 
KH2PO4, 0.1 mM EDTA, 1 mM octyl sodium sulfonate, 12% methanol, adjusted to pH 
2.75 with orthophosphoric acid, at a flow rate of 1.2 ml/min. Samples were quantified 
by an analytical cell (model 5011, ESA Biosciences, UK) attached to a Coulochem II 
electrochemical detector (ESA Biosciences, UK) with electrode one at -0.20 V and 
electrode two at +0.34 V with respect to the palladium reference electrode. Data was 
collected and analysed using chromeleon software (Dionex, UK) which compares 
sample data to data from external standards for each molecule. External standards of 
each monoamine (50pmol/ml) were prepared from a stock solution of each monoamine 
dissolved in 0.1M hydrochloric acid (5μmol/ml) and analysed prior to samples to 
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determine retention times for each monoamine and to allow the subsequent calculation 
of the concentration of each monoamine in each sample. Additionally, DA turnover and 
5-HT turnover was calculated by measuring the ratio of DA and 5-HT to their respective 
metabolites (pmol/ml). Control and treated groups were run on the same day with the 
same external standards. Due to the known variability in baseline across HPLC runs, 
care should be taken when comparing data from different experiments. Due to the large 
number of samples it was not possible to run male and female samples together 
therefore data should not be directly compared. Figure 2.9 shows an example of a trace 
produced for external standards (A) and a striatal sample (B). 
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A  
 
B 
 
Figure 2.8. Example of an HPLC trace for external standards (A) and a striatal 
sample (B). 
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2.3 - STATISTICS 
 
Statistical analysis was carried out using SPSS 16.0 software. Where multiple 
comparisons were made, a two or three way ANOVA with post hoc multiple 
comparison tests were performed. Further details of these analyses can be found in 
appendix 1. Individual comparisons were made using an unpaired, two-tailed student’s 
t-test. All data are expressed as means ± SEM. In all cases differences were considered 
to be significant if p<0.05.  
 
2.4 - MATERIALS AND SOURCES 
All materials are from VWR or Sigma unless otherwise stated in the text. 
 
2.5 - EXPERIMENTAL DESIGN 
This thesis combines results from 3 large, long term studies on the effects of stress and 
GC treatments on brain regions affected by PD. The first study examined the effects of 
prenatal DEX and / or adult repeated restraint stress on brain regions implicated in PD. 
The second experiment replicated the first set of experiments but also exposed animals 
to 6-OHDA. This provided information on how stress and GCs affect the response to a 
toxic insult in the brain regions examined. The third study was identical to study 2 
except for a change in the treatment in adulthood where adult repeated restraint was 
replaced with chronic GC treatment. This allows a comparison of the effects of stress 
and elevated GCs and may help determine whether effects induced by repeated stress 
are caused by elevated GC levels. From this point on experiments where the adult 
treatment was stress is referred to as study 1 and experiments including GC treatment 
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study 2. A time line for the treatments is shown in figure 2.10 and figure 2.11 shows 
how animals were split into different treatment groups. 
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Figure 2.10 Flow chart showing the order and timing of treatment regimes . 
Time mated pregnant females were treated with DEX on GD 16-19. Offspring were 
weaned at 3 weeks of age. At 3.5 months of age animals were subjected to repeated 
restraint or chronic hydrocortisone treatment for a period of 6 weeks. At 5.5 months of 
age (two weeks after last stress session or termination of GC treatment) animals were 
either culled for analysis or subjected to a sterotaxic injection of 6-OHDA. 6-OHDA 
animals were culled 2 weeks after surgery.  
 
 
 
 
 
 
Timed Mating 
Litter 
Weaning 
Week 1 
Week 28 
Week 4 
Week 7 
Week 18 
Week 26 
Restraint 
Tissue collection 
6-OHDA  Tissue collection 
Control 
Hydrocortisone Control 
DEX 
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Study 1 
 
 
 
 
 
 
 
 
 
 
 
Study 2 
 
 
 
 
 
 
 
 
 
 
Figure 2.11.  Flow  chart depiciting the way in which animals were divided 
into treatment groups.  Numbers represent the number of animals per treatment 
group.  
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2.6 PHYSIOLOGICAL IMPACT OF TREATMENT REGIMES 
 
2.6.1 Effect of DEX treatment on maternal physiology 
 
Prenatal DEX treatment increased fluid intake (p<0.05; Figure 2.12A) and prevented 
maternal weight gain (p<0.001; Figure 2.12B) over GD16-19. DEX exerted no effect on 
litter size (Figure 2.12C) and had no observable effects on maternal behaviour. Using 
existing pharmokinetic data (McArthur et al., 2006), average fluid intake and average 
litter size the concentration of DEX received by the pups was estimated to be ~30ng/ml.   
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Figure 2.12. Effect of DEX tr eatment (0.5µg/ml via drinking w ater) on 
GD16-19 o n  maternal fluid intake (A) and w eight gain (B) over GD16-19  
and litter size (C). *p<0.05, **p<0.01, ***p<0.001 versus controls. N= 11 (control), 
13 (DEX). 
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2.6.2 Effect of treatment regimes on growth 
Prenatal DEX treatment or adult repeated restraint stress had no effect on normal 
growth in either male or female offspring (Figure 2.13A,B). By contrast chronic 
hydrocortisone treatment prevented weight gain in both male and females over the 
period of treatment (p<0.001; Figures 2.13C,D, 2.14A,B). This was unaffected by 
prenatal DEX treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A B 
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Figure 2.13. Effect of treatment regimes on growth. Weights were recorded weekly 
following weaning (3 weeks). Effect of DEX (GD16-19) and repeated adult (3.5 months) stress 
on growth in males and females is shown in A and B respectively. Effect of DEX (GD 16-19) 
and adult (3.5 month) GC treatment is shown in C (males) and D (females). Data are expressed 
as means. Initiation of adult treatment shown by arrow. A: n= 16 (control), 17 (DEX), 16 
(stress), 16 (stress and DEX). B: n=18 (Control), 16 (DEX), 18 (stress), 18 (DEX and stress). C: 
n= 14 (control), 13 (DEX), 14 (CORT), 12 (DEX + CORT). D: n= 14 (Control), 16 (DEX), 14 
(CORT), 14 (DEX + CORT). 
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Figure 2.14. Weight g ain (g) ove r adult GC treatment period (14-20 w eeks) in 
males (A) and females (B).  Data are expressed as mean ± sem. *** p<0.001 versus 
control. A: n= 14 (control), 13 (DEX), 14 (CORT), 12 (DEX + CORT). B:n= 14 (Control), 16 
(DEX), 14 (CORT), 14 (DEX + CORT). 
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2.6.3 Fluid intake over hydrocortisone treatment period 
Males showed no preference for hydrocortisone supplemented water (Figure 2.15A). 
Females that were prenatally treated with DEX showed a reduced preference for 
hydrocortisone supplemented water (p<0.01; Figure 2.15B). Average daily fluid intake 
was 30.81 ± 0.91 in males and 30.21 ± 1.39 in females. This equates to a daily dose of 
~35mg/kg in males and ~50mg/kg in females.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15. Average dail y fluid intake (ml) o ver hydrocortisone treatment period 
(14-20 weeks) in mal es (A) and females ( B). Data expressed as mean ± sem. 
**p<0.01 versus control. A: n= 14 (control), 13 (DEX), 14 (CORT), 12 (DEX + CORT). 
B:n= 14 (Control), 16 (DEX), 14 (CORT), 14 (DEX + CORT). 
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2.6.4 Effect of treatment regimes on estrus cycling 
In the subset of animals examined there was no effect of any treatment on estrus 
cycling. Stress and HPA activation exerts an inhibitory action on the female 
reproductive system (Kalantaridou et al., 2004). Repeated stress may not have been a 
severe enough stress to cause disruption to the cycle. CRH is thought to underlie the 
negative effects of stress and HPA activation on the female reproductive system. In our 
GC treatment regime it is likely that CRH release was suppressed due to negative 
feedback and therefore would not impact on the estrus cycle. 
 
2.6.5 Effect of treatment regimes on serum corticosterone levels at 
autopsy 
There were no significant effects of treatment on serum corticosterone levels in males or 
females (Figure 2.16). However this does not mean that our treatment regimes did not 
affect corticosterone levels as serum was collected two weeks after the final session or 
dose of treatment. Nevertheless it does indicate that any affects on corticosterone levels 
were not persistent. Serum was collected during the morning (8.30-10.30am) which 
corresponds with the circadian trough of corticosterone accounting for the low levels of 
corticosterone reported here. It is also known that our method of serum collection 
(decapitation) results in lower morning corticosterone levels than other methods (Dunn 
and Scheving, 1971).   
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Figure 2.16. Effect of treatment regimes on serum corticosterone levels (ng/ml) at 
autopsy. In study 1 (A,B) and study 2 (C,D) Serum was collected at 5.5 months and 
corticosterone levels measured by enzyme immunoassay (females A,C; males B,D).   A: 
n= 8 (control), 9 (DEX), 8 (stress), 8 (stress and DEX). B: n=10 (Control), 8 (DEX), 10 (stress), 
10 (DEX and stress). C: n= 7 (control), 6 (DEX), 7 (CORT), 5 (DEX + CORT). D: n= 7 
(Control), 9 (DEX), 7 (CORT), 7 (DEX + CORT). 
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CHAPTER 3 
The sex-dependent effects of stress and GC treatments 
on the integrity of the adult NSDA. 
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3.1 INTRODUCTION 
 
The main pathological feature of PD is the degeneration of DA neurons within the SNpc 
which results in a loss of DA within the striatum. One of the earliest proposed causes of 
PD was stress and this idea has started to regain attention and a hypothesis for the 
involvement of stress and GCs in the pathophysiology of PD is emerging (Kibel and 
Drenjancevic-Peric, 2008). In PD patients it has been suggested that acute or chronic 
stress may result in an earlier onset or worsen the symptoms of PD (Macht et al., 2005). 
Indeed, cortisol levels are higher in PD patients and have been associated with gait 
deficits (Hartmann et al., 1997; Charlett et al., 1998). The presence of GCs within the 
NSDA provides a means by which GCs could exert an effect on the NSDA rendering it 
vulnerable to excess levels of GCs. Consequently stress and GCs have been shown to 
negatively affect motor function in both humans (Maki and McIlroy, 1996) and rats 
(Metz et al., 2001; Metz et al., 2005). Of significant interest is the finding that stress can 
elevate oxidative damage in the NSDA (Kim et al., 2005) a mechanism that has been 
heavily implicated in the pathogenesis of PD. Further evidence supporting an effect of 
stress and GCs on the NSDA is provided by studies demonstrating that chronic 
corticosterone treatment elevates D1 receptor mRNA in the striatum of mice (Biron et 
al., 1992); immobilisation stress increases striatal DA levels (Kim et al., 2005)  and that 
repeated restraint stress increases DAT mRNA within the striatum (Copeland et al., 
2005). It has also been proposed that the early life environment has a significant impact 
on disease susceptibility in adulthood (see section 1.2.11) and that GCs are an important 
programming factor. Thus, stress and excess GCs during development may impact upon 
the developing NSDA. Indeed, prenatal GC treatment has been shown to permanently 
alter midbrain rat DA systems (McArthur et al., 2005). This chapter aims to address the 
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hypothesis that stress and GCs at different stages in life may affect the integrity of the 
NSDA rendering it vulnerable to toxic insults.  
 
The following experiments therefore sought to determine the effects of prenatal 
treatment with a synthetic glucocorticoid, dexamethasone (DEX), and/or exposure in 
adulthood to repeated intermittent stress or chronic GC treatment on the morphological 
and functional integrity of the rat NSDA. As few studies explore responses in males and 
females in conjunction, the NSDA response to stress and GCs in both male and female 
animals was examined. This is important as the stress response and the effects of early 
life programming differ in males and females (Kudielka and Kirschbaum, 2005; Luine 
et al., 2007; Weinstock, 2007). Moreover, the prevalence of PD is higher in males 
(Schrag et al., 2000) and previous work has demonstrated that females are less 
susceptible to the neurotoxin 6-OHDA which specifically targets the NSDA pathway 
and provides an animal model of PD (Murray et al., 2003).   
 
 
 
 
 
 
 
 
 
 
 
 115
3.2 EXPERIMENTAL DESIGN AND HYPOTHESES 
 
Two highly novel studies were performed in which the integrity of the NSDA system 
and its susceptibility to 6-OHDA were explored:  the first (study 1) examined the effects 
of prenatal DEX treatment and/or repeated restraint stress in adulthood and the second 
(study 2) the effects of prenatal DEX treatment and/or chronic hydrocortisone treatment 
in adulthood. These protocols enable testing of the hypothesis that GCs are the 
important mediators of the effects of adult stress within the NSDA system. As stress and 
GCs have been shown to affect inflammation and oxidative stress within the brain and 
these processes have been heavily implicated in the pathogenesis of PD (see section 
1.1.11) alterations in glial populations and nitrosative protein damage within the SNpc 
were also examined.  
 
To assess the outcome of treatment regimes, nigrostriatal integrity was assessed using 
immunohistochemistry. TH immunohistochemistry was used to determine the number 
of DA neurons within the SNpc and NeuN immunohistochemistry was used to 
deterimine the total number of neurons within the SNpc. HPLC was then used to assess 
NSDA functionality whereby the levels of DA, DOPAC and HVA within the striatum 
were obtained. The effects of these treatment regimes on microglia, astrocytes and 
protein nitration within the SNpc were assessed using immunohistochemical markers 
(see section 2.2.5/6). 
 
The consequences of stress and GCs on the outcome of a 6-OHDA unilateral lesion, 
which is commonly used to model PD (Simola et al., 2007) were also evaluated. Here 
5µg of 6-OHDA was injected into the left MFB, which contains the axons of the 
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neurons within the SNpc, at a dose producing a partial unilateral lesion of the NSDA. 
This method of administration has previously been found to produce a destruction of the 
A9 and A10 cell groups of the SNpc, depletion of DA in the ipsilateral striatum, 
hypersensitivity of postsynaptic receptors in the striatum and characteristic turning 
behaviour in response to amphetamine or apomorhine produced due to the imbalance in 
dopamine activity between the two hemispheres (Duemans, 2002). The effect of stress 
and GC treatment on the lesion was again determined by immunohistochemistry and 
HPLC. For further details of the experimental design and methodology see chapter 2.   
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3.3 RESULTS 
 
3.3.1 The intact nigrostriatal system (NSDA) system 
  
Control values: On combination of data from study 1 and 2 the average number of 
TH-immunoreactive (TH-IR) cells in the normal adult SNpc was estimated to be 8118 ± 
0.276 in males and 7185 ± 0.267 in females. These values are in line with other 
published estimates (Anden et al., 1966; Hedreen and Chalmers, 1972; German and 
Manaye, 1993; Dewing et al., 2006; McArthur et al., 2007a) and accord with findings 
that the number of TH-IR cells in the female SNpc is significantly lower than in the 
male (p<0.05) (Dewing et al., 2006; McArthur et al., 2007a) . Although the number of 
NeuN-IR cells was significantly higher there was also a sex difference in the total 
number of neurons within the SNpc with 9843 ± 0.26 cells in males and 8869 ± 0.45 
cells in adult females (p<0.05). The average striatal DA level was 13.06 ± 1.43 ng/mg 
of tissue in control males and 14.97 ± 0.46 ng/mg of tissue in control females (not 
significant), thereby agreeing with other reports that there are no sex differences in 
control levels of striatal DA (Wagner et al., 1993; Murray et al., 2003). However, it is 
difficult to compare HPLC data across studies as discussed in section 2.2.8. 
 
Adult treatments in male rats: Repeated stress in adulthood had no effect on the 
male NSDA pathway at SNpc or striatal levels (Fig 3.1, 3.2, Table 1). In contrast to 
repeated stress, chronic GC treatment in adulthood increased the number of TH-IR cells 
within the SNpc (p<0.05; Fig 2C) but not NeuN-IR cells and raised striatal DA (p<0.01) 
and DOPAC levels (p<0.001; Table 2). Repeated stress but not GC treatment increased 
the number of OX-42-IR cells within the male SNpc (p<0.05; Figure 3.4A). No changes 
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in microglial morphology were observed with the majority of the counted microglia 
displaying a ramified morphology typical of their resting state. Both adult treatments 
significantly increased 3-NT-IR cells within the SNpc (P<0.005; Figure 3.5A,C) 
indicating a greater degree of oxidative damage. Neither adult treatment altered GFAP-
IR within the SNpc. 
 
Prenatal treatment in male rats: Compared with controls, prenatal DEX treatment 
increased the number of TH-IR (p<0.05) and NeuN-IR (p<0.05) cells within the adult 
male SNpc (Figure 3.1A,C,3.2A,C) without altering DA levels within the striatum 
(Table 1 and 2). There was a trend for a reduced astrocyte population in DEX treated 
males but this did not reach significance (Figure 3.3) and there was an increased 
microglia population within the SNpc of adult rats treated with DEX in study 2 (Figure 
3.4C). 
 
Prenatal treatment in combination with adult treatment in male rats: In rats 
subjected to prenatal DEX, adult stress not only ablated the effects of the prenatal 
treatment on TH-IR (p<001) and NeuN-IR (p<0.001), but reduced TH-IR, and striatal 
DA levels  (p<0.05) to values significantly lower than those of controls (Figures 3.1,3.2; 
Table 3.1). Interestingly, the effects of adult GC treatment were also significantly 
attenuated by prenatal DEX treatment where TH-IR and striatal DA levels in animals 
treated with GCs both prenatally and in adulthood did not differ from those of the 
untreated controls (p<0.001 and 0.01 respectively; Figure 3.1; Table 3.2) . DA 
metabolite levels were however elevated (p<0.05; Table 3.2) in these animals indicating 
an increase in the turnover of DA within the striatum (p<0.05; Table 1, Table 2). 
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Adult treatments in female rats: Unlike males, in females repeated adult stress 
increased the number of TH-IR (but not NeuN-IR) cells in the SNpc (p<0.001; Fig 
3.1B) and elevated striatal DA (p<0.001), DOPAC (p<0.01), but not HVA levels (Table 
3.1). By comparison GC treatment in adulthood did not affect the female NSDA (Figure 
3.1D, Table 3.2), with the exception of elevated HVA levels.  Adult treatments exerted 
no affect on GFAP, OX-42 or 3-NT-IR cell counts in the female SNpc. 
 
Prenatal treatment in female rats: As in males, prenatal DEX treatment increased 
the number of TH-IR (p<0.05) and NeuN-IR (p<0.05) cells in the female SNpc (Fig 
3.1B,D,3.2B,D) without affecting striatal DA levels. An increase in striatal DOPAC 
levels, and therefore DA turnover, reached significance (p<0.05) in the first, but not 
second, study (Table 3.1 and 3.2).  Prenatal DEX treatment had no effect on OX-42-IR 
or 3-NT-IR cell numbers but reduced the number of GFAP-IR astrocytes in study 2 
(p<0.05; Fig 3.3D). 
 
Prenatal treatment in combination with adult treatment in female rats: 
Stress appeared to enhance the effect of prenatal DEX on TH-IR (Fig 3.1B) without 
affecting striatal DA.  By contrast, DOPAC levels and DA turnover in animals treated 
with GCs prenatally and then subjected to stress in adulthood did not differ from those 
of the untreated controls (Table 3.1). Adult GC treatment in DEX treated rats attenuated 
DOPAC levels (p<0.001) but didn’t alter turnover (Table 3.2). TH-IR cell counts in 
animals treated with GCs both prenatally and in adulthood did not differ from those of 
the untreated controls whilst their HVA levels were similar to those of rats given 
prenatal DEX only (Table 3.2).   
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Figure 3.1. Effect of prenatal dexamethasone and/or adult stre ss (study 1) or 
GC treatment (study 2) on TH-IR cells within the SNpc.  Stereological estimates of 
total TH-IR cells within the SNpc in adult (5.5 month) male (A,C,) and female (B,D,) 
animals as assessed by TH immunohistochemistry. A and B indicate the effect of prenatal 
(GD16-19) DEX treatment and/or adult (3.5 month) stress (repeated restraint for 1 hour 
every other day for 6 weeks). C and D depict the effects of prenatal DEX treatment and or 
adult GC treatment (hydrocortisone via the drinking water for 6 weeks) Data are expressed 
as means ± SEM. Statistical significance was assessed by two way ANOVA with tukeys 
post hoc comparison tests. *p<0.05, **p<0.01, ***p<0.001 vs controls, # vs DEX, + vs 
adult treatment. A: n=8 (control), 9 (DEX), 8(stress), 8 (DEX + stress). B: n= 10 (control), 8 
(DEX), 10 (stress), 10 (DEX + stress). C: n = 7 (control), 6 (DEX), 7 (CORT), 5 (DEX + 
CORT). D: n=7 (control), 6 (DEX), 7 (CORT), 7 (DEX + CORT). 
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Figure 3.2. Effect of prenatal dexamethasone and/or adult stre ss (study 1) or 
GC treatment (study 2) on NeuN-IR cells within the SNpc. Stereological estimates 
of total NeuN-IR cells within the SNpc in adult (5.5 month) male (A,C,) and female (B,D,) 
animals as assessed by NeuN immunohistochemistry. A and B indicate the effect of 
prenatal (GD16-19) DEX treatment and/or adult (3.5 month) stress (repeated restraint for 1 
hour every other day for 6 weeks). C and D depict the effects of prenatal DEX treatment 
and or adult GC treatment (hydrocortisone via the drinking water for 6 weeks) Data are 
expressed as means ± SEM. Statistical significance was assessed by two way ANOVA with 
tukeys post hoc comparison tests. *p<0.05, **p<0.01, ***p<0.001 vs controls; # vs DEX, + 
vs adult treatments. A: n=8 (control), 9 (DEX), 8(stress), 8 (DEX + stress). B: n= 10 
(control), 8 (DEX), 10 (stress), 10 (DEX + stress). C: n = 7 (control), 6 (DEX), 7 (CORT), 5 
(DEX + CORT). D: n=7 (control), 6 (DEX), 7 (CORT), 7 (DEX + CORT). 
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   Adult Striatal DA, DOPAC and HVA levels  
 CON DEX STRESS DEX + STRESS 
Male 
DA 20.44 ±  1.29 21.23 ± 1.15 22.41 ±  1.09 17.91 ± 0.92 * ## ++ 
DOPAC 6.71 ± 0.39 8.15 ± 0.57 7.85 ± 0.40 8.04 ± 0.49 
HVA 1.36 ± 0.11 1.66 ± 0.09 1.25 ± 0.09 1.88 ± 0.09 ** ++ 
Turnover 0.44 ± 0.02 0.51 ± 0.03 0.45 ± 0.02 0.62 ± 0.03 *** # 
Female 
DA 15.21 ± 0.49 17.24 ± 0.85 21.35 ± 1.1 *** 19.82 ± 0.66  *** # 
DOPAC 5.68 ± 0.48 9.82 ± 0.37 ** 8.73 ± 1.03 ** 8.01 ± 0.58 * 
HVA 1.55 ± 0.07 2.01 ± 0.07 1.75 ± 0.13 1.91 ± 0.15 
Turnover 0.52 ± 0.03 0.78 ± 0.05 * 0.57 ± 0.09 0.56 ± 0.04 
 
 
Table 3.1. Effect of prenatal DEX and/or adult stress on striatal DA and metabolite 
levels. Striatal DA, DA metabolite and DA turnover were assesed by HPLC at 5.5 
months of age. Male and female rats were treated prenatally with DEX via the maternal 
drinking water and were subjected to adult (3.5month) repeated restraint stress. Data are 
means ± SEM in ng/mg. DA turnover was calculated as the ratio of DA metabolites 
(DOPAC and HVA) to DA in pmol/mg. Statistical significance was assessed by two 
way anova with tukeys post hoc multiple comparison tests. *p<0.05, **p<0.01, 
***p<0.001 vs controls, # vs DEX, + vs adult treatment. Males: n=8 (control), 8 (DEX), 
8(stress), 8 (DEX + stress). Females: n= 9 (control), 8 (DEX), 8 (stress), 8 (DEX + stress).  
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Adult Striatal DA, DOPAC and HVA levels 
 CON DEX CORT DEX + CORT 
Male 
DA 9.13 ± 1.14 12.92 ± 1.23 17.76 ± 2.26 ** 10.57 ± 2.51 + 
DOPAC 2.43 ± 0.32 4.04 ± 0.35 4.88 ± 0.37 *** 5.62 ± 2.49 *** 
HVA 0.63 ± 0.12 0.67 ± 0.07 0.83 ± 0.05 0.98 ± 0.09 * 
Turnover 0.41 ± 0.05 0.38 ± 0.04 0.43 ± 0.06 0.77 ± 0.171 * # + 
Female 
DA 14.81 ± 0.72 15.99 ± 0.80 17.47 ± 0.84 13.19 ± 0.58 + 
DOPAC 2.01 ± 0.17 2.49 ± 0.17 2.73 ± 0.25 1.76 ± 0.25 
HVA 1.03 ± 0.08 1.27 ± 0.06 * 1.49 ± 0.06 *** 1.23 ± 0.03 
Turnover 0.23 ± 0.01 0.25 ± 0.01 *** 0.27 ± 0.01 0.24 ± 0.002 
 
 
Table 3.2. Effect of prenatal DEX and/or adult GC treatment on striatal DA and 
metabolite levels. Striatal DA, DA metabolite and DA turnover were assesed by HPLC 
at 5.5 months of age. Male and female rats were treated prenatally with DEX via the 
maternal drinking water and were subjected to adult (3.5month) GC treatment. Data are 
means ± SEM in ng/mg. DA turnover was calculated as the ratio of DA metabolites 
(DOPAC and HVA) to DA in pmol/mg. Statistical significance was assessed by two 
way anova with tukeys post hoc multiple comparison tests. *p<0.05, **p<0.01, 
***p<0.001 vs controls, # vs DEX, + vs adult treatment. Males: n = 7 (control), 6 (DEX), 
7 (CORT), 5 (DEX + CORT). Females: n=7 (control), 6 (DEX), 7 (CORT), 7 (DEX + CORT). 
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Figure 3.3. Effect of prenat al DEX a nd/or adult stress or GC treatment on 
GFAP-IR cells within the SNpc. Stereological estimates of total GFAP-IR cells within 
the SNpc in adult (5.5 month) male (A,C,) and female (B,D,) animals as assessed by GFAP 
immunohistochemistry. A and B indicate the effect of prenatal (GD16-19) DEX treatment 
and/or adult (3.5 month) stress (repeated restraint for 1 hour every other day for 6 weeks). C 
and D depict the effects of prenatal DEX treatment and or adult GC treatment 
(hydrocortisone via the drinking water for 6 weeks) Data are expressed as means ± SEM. 
Statistical significance was assessed by two way ANOVA with tukeys post hoc comparison 
tests. *p<0.05, **p<0.01, ***p<0.001 vs controls, # vs DEX, + vs adult treatment. A: n=8 
(control), 9 (DEX), 8 (stress), 8 (DEX + stress). B: n= 10 (control), 8 (DEX), 10 (stress), 10 
(DEX + stress). C: n = 7 (control), 6 (DEX), 7 (CORT), 5 (DEX + CORT). D: n=7 
(control), 6 (DEX), 7 (CORT), 7 (DEX + CORT). 
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Figure 3.4. Effect of prenatal DEX and/or adult stress or GC treatment on OX-
42-IR cells within the SNpc. Stereological estimates of total OX-42-IR cells within the 
SNpc in adult (5.5 month) male (A,C,) and female (B,D,) animals as assessed by OX-42 
immunohistochemistry. A and B indicate the effect of prenatal (GD16-19) DEX treatment 
and/or adult (3.5 month) stress (repeated restraint for 1 hour every other day for 6 weeks). C 
and D depict the effects of prenatal DEX treatment and or adult GC treatment 
(hydrocortisone via the drinking water for 6 weeks) Data are expressed as means ± SEM. 
Statistical significance was assessed by two way ANOVA with tukeys post hoc comparison 
tests. *p<0.05, **p<0.01, ***p<0.001 vs controls, # vs DEX, + vs adult treatment. N 
numbers can be found in figure 2.11. A: n=8 (control), 9 (DEX), 8(stress), 8 (DEX + stress). 
B: n= 10 (control), 8 (DEX), 10 (stress), 10 (DEX + stress). C: n = 7 (control), 6 (DEX), 7 
(CORT), 5 (DEX + CORT). D: n=7 (control), 6 (DEX), 7 (CORT), 7 (DEX + CORT). 
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Figure 3.5.  Effect of prenatal DEX and/or adult stress or GC t reatment on 3-
NT-IR cells within the SNpc.  Stereological estimates of total 3-NT-IR cells within the 
SNpc in adult (5.5 month) male (A,C,) and female (B,D,) animals as assessed by 3-NT 
immunohistochemistry. A and B indicate the effect of prenatal (GD16-19) DEX treatment 
and/or adult (3.5 month) stress (repeated restraint for 1 hour every other day for 6 weeks). C 
and D depict the effects of prenatal DEX treatment and or adult GC treatment 
(hydrocortisone via the drinking water for 6 weeks) Data are expressed as means ± SEM. 
Statistical significance was assessed by two way ANOVA with tukeys post hoc comparison 
tests. *p<0.05, **p<0.01, ***p<0.001 vs controls, # vs DEX, + vs adult treatments. N 
numbers can be found in figure 2.11. A: n=8 (control), 9 (DEX), 8(stress), 8 (DEX + stress). 
B: n= 10 (control), 8 (DEX), 10 (stress), 10 (DEX + stress). C: n = 7 (control), 6 (DEX), 7 
(CORT), 5 (DEX + CORT). D: n=7 (control), 6 (DEX), 7 (CORT), 7 (DEX + CORT). 
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Figure 3.6 Representati ve photomicrographs of  immunohistochemistr y 
within the  SNpc.  Shown at x10 (ACEGI) and x200 (BDFHI) magnification. TH 
(AB), NeuN (CD), GFAP (EF), OX-42 (GH), 3-NT (IJ) 
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3.3.2 The injured NSDA system 
 
The number of TH-IR cells in the SNpc and DA levels within the striatum are expressed 
both as actual levels (Figure 3.8; Tables 3.4,3.6) in the lesioned and unlesioned 
hemisphere and as a percentage loss in the lesioned vs unlesioned hemisphere  (Figures 
3.9,3.12) to aid interpretation of the data. 
 
Controls: In order to examine the implications of our treatment regimes for 
susceptibility to pathological change, we employed the 6-OHDA model of PD. Here 
administration of 5µg 6-OHDA to the left medial forebrain bundle consistently 
produced a significant loss of TH-IR cells within the SNpc and depleted DA levels 
within the striatum of the ipsilateral hemisphere. On combination of data from study 1 
and study 2 in male controls there was a 38.75 ± 6.03 % loss of TH-IR cells in the 
lesioned SNpc compared to the contralateral SNpc and a 48.9 ± 5.33 % loss of striatal 
DA. The size of the lesion and subsequent DA loss was not significantly different in 
females where there was a 45.78 ± 6.2 % loss of TH-IR cells and a 54.14 ± 8.13 % loss 
of striatal DA. The number of TH-IR cells in the control hemisphere of lesioned animals 
was greater than in the SNpc of control animals that had not received 6-OHDA (figures 
3.8 and 3.1). This was found to be the case in both males and females (p<0.05) 
however, striatal DA levels within the contralateral striatum were lower than in 
unlesioned controls, although as discussed in section 2.8 it is difficult to compare HPLC 
data from different runs. It is also interesting to note that the effects previously reported 
were lost in the contralateral SNpc of lesioned animals.  
 
To dissect further the effects of GCs and stress on the outcome of a 6-OHDA lesion, 
microglial activation within the lesioned SNpc was assessed using 
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immunohistochemistry for OX-6 (a MHC class II antigen) which selectively identifies 
activated microglia. Negligible microglial activation was detected in the contralateral 
SNpc of lesioned animals but within the ipsilateral SNpc extensive microglial activation 
was observed therefore the number of OX-6-IR cells was expressed as a percentage 
change from the number of positive cells in the lesioned SNpc of control rats (Figure 
3.14). The average number of OX-6-IR cells within the lesioned SNpc was estimated to 
be 2332 ± 288 in male controls and 3536 ± 435 in female controls. Administration of 6-
OHDA also produced proliferation of GFAP-IR cells within the lesioned SNpc where 
the number of GFAP-IR+ cells rose by 34.48 ± 4.27% and 28.70 ±  2.91% in male and 
female controls respectively (Figure 3.13). Additionally there was an increase in the 
number of GFAP-IR cells displaying an activated reactive morphology (Figure 3.10). 
Levels of nitrosative stress within the lesioned SNpc were significantly increased when 
compared to the contralateral SNpc. There were 32.12 ±  2.96% more 3-NT-IR+ cells in 
the lesioned male SNpc and 31.84 ± 4.22% more 3-NT-IR+ cells in the female lesioned 
SNpc (Figure 15).  
 
Adult treatments in male 6-OHDA rats: Repeated restraint stress in adult males 
significantly exacerbated 6-OHDA induced TH-IR cell loss (p<0.01; Figure 3.7A), 
NeuN-IR cell loss (p<0.05; Figure 3.9) and striatal DA depletion (p<0.05; Table 3). In 
addition there was an increase in OX6-IR cells (p<0.001; Figure 3.12A, 3.13) and 3-
NT-IR cells (p<0.05; Figure 3.14A,3.15) in the SNpc of repeatedly stressed males 
above that seen in  6-OHDA control animals. Chronic adult GC treatment also enhanced 
the loss of TH-IR cells (p<0.05; Fig 5E,M), increased the number of OX-6-IR (p<0.01; 
Figure 6C,F) and 3-NT-IR (p<0.05; Figure 7C,G) cells, but did not significantly affect 
DA depletion.  
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Prenatal treatment in male 6-OHDA rats: Prenatal DEX treatment did not alter the 
susceptibility of the NSDA to 6-OHDA neurotoxicity at SNpc or striatal levels (Figures 
3.7, 3.9, tables 3 and 4 ). 
 
Prenatal treatment in combination with adult treatments in male 6-OHDA 
rats: Prenatal DEX treatment did not alter the effect of adult stress on 6-OHDA 
induced TH-IR or striatal DA depletion. However adult GC treatment in DEX treated 
males exacerbated 6-OHDA-induced striatal DA loss (p<0.05), without producing a 
further effect on TH-IR cell loss.  
 
Adult treatments in females: In contrast to its effect in males, repeated stress in 
adult females attenuated 6-OHDA-induced TH-IR cell loss (p<0.05; Figure 3.7B,3.8L), 
NeuN-IR cell loss (p<0.05; Figure 3.8B) and striatal DA loss (p<0.05; Table 3). Chronic 
adult GC treatment similarly reduced TH-IR cell loss (p<0.05; Figures 3.7C 3.8F) but 
did not affect DA depletion (Table 4).  Neither treatment altered GFAP-IR, OX6-IR or 
3-NT-IR above that observed in 6-OHDA control animals.  
 
Prenatal treatment in 6-OHDA females: As for males, prenatal DEX treatment did 
not alter the susceptibility of the NSDA to 6-OHDA neurotoxicity at SNpc or striatal 
levels (Figure 3 B, D, F, H). 
 
Prenatal treatment in combination with adult treatments in 6-OHDA 
females:  In females that received GC treatment striatal DA depletion was unaffected 
by previous prenatal DEX treatment, whereas the SNpc effects caused by adult restraint 
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stress were attenuated, such that TH-IR cell loss was no longer significantly reduced 
after exposure to adult stress. Prenatal DEX treatment didn’t alter the response to 6-
OHDA in GC treated females. 
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Figure 3.8. Effect of prenatal DEX treat ment and/or adult stress or GC treatment 
on TH-IR c ells within the SNpc follo wing 6-OHDA lesioning. Stereological estimates 
of the number of TH-IR cells within the SNpc of male (A,C) and female (B,D) animals exposed 
to a 6-OHDA  were determined by TH immunohistocemistry. Measurements were made in 6 
month old animals, 2 weeks after exposure to 5μg 6-OHDA injected into the MFB. A and B 
indicate the effect of prenatal (GD16-19) DEX treatment and/or adult (3.5 month) stress 
(repeated restraint for 1 hour every other day for 6 weeks). C and D depict the effects of 
prenatal DEX treatment and or adult GC treatment (hydrocortisone via the drinking water for 6 
weeks). Data are expressed as means ± SEM. Statistical significance was assessed by three way 
ANOVA with tukey’s post hoc comparison tests *p<0.05, **p<0.01, ***p<0.001 vs controls, # 
vs unlesioned hemisphere. A: n=8 (control), 8(DEX), 8(stress), 8 (DEX + stress). B: n= 8 
(control), 8 (DEX), 8 (stress), 8  (DEX + stress). C: n = 7 (control), 7  (DEX), 7 (CORT), 6 
(DEX + CORT). D: n=7 (control), 7 (DEX), 7 (CORT), 7 (DEX + CORT). 
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Figure 3.9. Effect of prenatal DEX treat ment and/or adult stress or GC treatment 
on percentage loss of TH-IR cells in the SNpc follo wing 6-OHDA lesioning.  The 
percentage loss of TH-IR cells in the lesioned SNpc versus the unlesioned SNpc in male (A,C) 
and female (B,D) animals exposed to a 6-OHDA. Measurements were made in 6 month old 
animals, 2 weeks after exposure to 5μg 6-OHDA injected into the MFB. A and B indicate the 
effects of prenatal (GD16-19) DEX treatment and/or adult (3.5 month) stress (repeated restraint 
for 1 hour every other day for 6 weeks). C and D depict the effects of prenatal DEX treatment 
and or adult GC treatment (hydrocortisone via the drinking water for 6 weeks). Data are 
expressed as means ± SEM. Statistical significance was assessed by two way ANOVA with 
tukey’s post hoc comparison tests *p<0.05, **p<0.01, ***p<0.001 vs controls, # vs DEX, + vs 
adult treatment. A: n=8 (control), 8(DEX), 8(stress), 8 (DEX + stress). B: n= 8 (control), 8 
(DEX), 8 (stress), 8  (DEX + stress). C: n = 7 (control), 7  (DEX), 7 (CORT), 6 (DEX + CORT). 
D: n=7 (control), 7 (DEX), 7 (CORT), 7 (DEX + CORT). 
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Figure 3.10 Representative photomic rographs of TH-IR staining  within the 
SNpc and VTA of male (A,C,E,G) and female (B,D,F,G) rats. Controls (A,B), DEX 
treated (C,D), stressed (E,F) and GC treated (G,H). Images were taken at 10x 
magnification. 
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Figure 3.11. Effect of prenatal DEX treatment and/or adult stress or GC treatment 
on NeuN-I R cells w ithin the SNpc following 6-OHDA lesioning.  Stereological 
estimates of the number of NeuN-IR cells within the SNpc of male (A,C) and female (B,D) 
animals exposed to a 6-OHDA  were determined by immunohistocemistry. Measurements were 
made in 6 month old animals, 2 weeks after exposure to 5μg 6-OHDA injected into the MFB. A 
and B indicate the effects of prenatal (GD16-19) DEX treatment and/or adult (3.5 month) stress 
(repeated restraint for 1 hour every other day for 6 weeks). C and D depict the effects of 
prenatal DEX treatment and or adult GC treatment (hydrocortisone via the drinking water for 6 
weeks). Data are expressed as means ± SEM. Statistical significance was assessed by three way 
ANOVA with tukey’s post hoc comparison tests *p<0.05, **p<0.01, ***p<0.001 vs controls. 
A: n=8 (control), 8(DEX), 8(stress), 8 (DEX + stress). B: n= 8 (control), 8 (DEX), 8 (stress), 8  
(DEX + stress). C: n = 7 (control), 7  (DEX), 7 (CORT), 6 (DEX + CORT). D: n=7 (control), 7 
(DEX), 7 (CORT), 7 (DEX + CORT). 
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Striatal DA, DOPAC and HVA in 6-OHDA lesioned animals 
  Control DEX STRESS DEX + STRESS 
Right Left Right Left Right Left Right Left 
Males 
DA 15.05 ± 
1.48 
8.17 ± 
1.65 ## 
17.76 
± 1.74
10.74 ± 
2.19 # 
19.80 ± 
1.77 
5.03 ± 
2.30 
###*  
13.71 ± 
1.10 
3.77 ± 
1.26 
###* 
DOPAC 2.94 ± 
0.31 
1.24 ± 
0.39 
4.29 ± 
0.65 
2.1 ± 
0.47 
3.63 ± 
0.55 
1.09 ± 
0.42 
2.91 ± 
0.47 
0.88 ± 
0.31 
HVA 0.77 ± 
0.09 
0.41 ± 
0.11 
1.21 ± 
0.15 
0.63 ± 
0.15 
0.91 ± 
0.14 
0.51 ± 
0.14 
0.93 ± 
0.10 
0.32 ± 
0.12 
Turnover 0.44 ± 
0.02 
0.91 ± 
0.03 
0.50 ± 
0.03 
0.57 ± 
0.04 
0.78 ± 
0.02 
1.52 ± 
0.05 
1.01 ± 
0.08 
1.41 ± 
0.04 
Females 
DA 8.01 ± 
1.17 
4.45 ± 
0.63 # 
10.50 
± 0.61
5.99 ± 
0.98 ## 
16.23 ± 
0.51 
11.78 ± 
1.78 # 
*** 
16.28 ± 
0.65 
12.27 ± 
1.62 # 
*** 
DOPAC 6.49 ± 
0.81 
3.44 ± 
0.28 
5.61 ± 
0.26 
2.67 ± 
0.40 
2.14 ± 
0.23 
1.28 ± 
0.24 
2.67 ± 
0.20 
1.70 ± 
0.27 
HVA 1.59 ± 
0.21 
1.23 ± 
0.11 
1.29 ± 
0.08 
0.85 ± 
0.13 
0.83 ± 
0.04 
0.60 ± 
0.09 
0.84 ± 
0.04 
0.63 ± 
0.09 
Turnover 1.15 ± 
0.21 
1.13 ± 
0.17 
0.74 ± 
0.07 
0.70 ± 
0.08 
0.34 ± 
0.14 
0.20 ± 
0.02 
0.22 ± 
0.02 
0.22 ± 
0.02 
 
 
 
 
Table 3.3. Effect of prenatal DEX treatment and / or adult stress on striatal DA 
and metabolite levels in response to 6-OHDA lesioning. Striatal DA, DA metabolite 
and DA turnover were assesed by HPLC at 6 months of age. Male and female rats were 
treated prenatally with DEX via the maternal drinking water and were subjected to adult 
(3.5month) repeated restraint stress. At 5.5 months rats received an injection of 5µg 6-
OHDA to the left MFB. Data are means ± SEM in ng/mg. DA turnover was calculated 
as the ratio of DA to it’s metabolites (DOPAC and HVA) in pmol/mg. Statistical 
significance was assessed by three way anova with tukeys post hoc multiple comparison 
tests.*p<0.05, **p<0.01, ***p<0.001 vs controls, # vs unlesioned hemisphere. Males: : 
n=8 (control), 8(DEX), 8(stress), 8 (DEX + stress). Females:: n= 8 (control), 8 (DEX), 8 
(stress), 8  (DEX + stress).  
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Striatal DA, DOPAC and HVA in 6-OHDA lesioned animals 
  Control DEX CORT DEX + CORT 
Right Left Right Left Right Left Right Left 
Males 
DA 7.69 ± 
1.04 
4.34 ± 
1.21 
## 
9.58 ± 
1.06 
6.42 ± 
1.61 #
10.04 ± 
0.77 
3.23 ± 
1.05 
###** 
8.20 ± 
1.93 
1.93 ± 
1.58 
### * 
DOPAC 2.36 ± 
0.38 
1.27 ± 
0.41 
3.51 ± 
0.17 
2.33 ± 
0.56 
5.86 ± 
0.59 
3.41 ± 
0.90 
5.51 ± 
0.41 
1.83 ± 
0.97 *
HVA 0.87 ± 
0.13 
0.64 ± 
0.19 
1.11 ± 
0.27 
1.32 ± 
0.10 
1.87 ± 
0.22 
1.41 ± 
0.31 
1.97 ± 
0.15 
0.81 ± 
0.34 
Turnover 0.90 ± 
0.21 
3.48 ± 
1.46 
0.58 ± 
0.21 
2.08 ± 
0.86 
1.01 ± 
0.15 
3.81 ± 
1.16 
1.06 ± 
0.13 
4.49 ± 
1.63 
Females 
DA 9.59 ± 
0.58 
5.57 ± 
0.97 
## 
9.24 ± 
1.78 
6.87 ± 
1.20 
10.77 ± 
0.81 
5.62 ± 
1.39 
## 
7.98 ± 
0.65 
5.19 ± 
1.42 
DOPAC 3.06 ± 
0.14 
1.30 ± 
0.36 
3.08 ± 
0.22 
1.86 ± 
0.45 
3.08 ± 
0.56 
1.34 ± 
0.47 
2.66 ± 
0.22 
1.73 ± 
0.47 
HVA 0.78 ± 
0.06 
0.46 ± 
0.07 
0.92 ± 
0.09 
0.73 ± 
0.13 
0.76 ± 
0.09 
0.44 ± 
0.16 
0.81 ± 
0.03 
0.58 ± 
0.11 
Turnover 0.42 ± 
0.003 
0.52 ± 
0.04 
0.44 ± 
0.009 
0.47 ± 
0.01 
0.41 ± 
0.005 
0.58 ± 
0.09 
0.45 ± 
0.01 
0.49 ± 
0.04 
 
 
 
 
Table 3.4. Effect of prenatal DEX treatment and / or adult GC treatment on striatal 
DA and m etabolite levels in res ponse to 6 -OHDA lesi oning.  Striatal DA, DA 
metabolite and DA turnover were assesed by HPLC at 6 months of age. Male and 
female rats were treated prenatally with DEX via the maternal drinking water and were 
subjected to adult (3.5month) GC treatment. At 5.5 months rats received an injection of 
5µg 6-OHDA to the left MFB. Data are means ± SEM in ng/mg. DA turnover was 
calculated as the ratio of DA to it’s metabolites (DOPAC and HVA) in pmol/mg. 
Statistical significance was assessed by three way anova with tukeys post hoc multiple 
comparison tests.*p<0.05, **p<0.01, ***p<0.001 vs controls, # vs unlesioned 
hemisphere. Males:: n = 7 (control), 7  (DEX), 7 (CORT), 7 (DEX + CORT). Females:: n=7 
(control), 7 (DEX), 7 (CORT), 7 (DEX + CORT). 
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Figure 3.12. Effect of prenatal DEX treatment and/or adult stress or GC treatment 
on percentage striatal DA loss follow ing 6-OHDA lesion ing. Striatal DA loss in the 
ipsilateral striatum versus contralateral striatum in male (A,C) and female (B,D) animals 
exposed to a 6-OHDA. Measurements were made in 6 month old animals, 2 weeks after 
exposure to 5μg 6-OHDA injected into the MFB. A and B indicate the effects of prenatal 
(GD16-19) DEX treatment and / or adult (3.5 month) stress (repeated restraint for 1 hour every 
other day for 6 weeks). C and D depict the effects of prenatal DEX treatment and/or adult GC 
treatment (hydrocortisone via the drinking water for 6 weeks). Data are expressed as means ± 
SEM. Statistical significance was assessed by two way ANOVA with tukey’s post hoc 
comparison tests *p<0.05, **p<0.01, ***p<0.001 vs controls, # vs DEX, + vs adult treatment. . 
A: n=8 (control), 8(DEX), 8(stress), 8 (DEX + stress). B: n= 8 (control), 8 (DEX), 8 (stress), 8  
(DEX + stress). C: n = 7 (control), 7  (DEX), 7 (CORT), 7 (DEX + CORT). D: n=7 (control), 7 
(DEX), 7 (CORT), 7 (DEX + CORT). 
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Figure 3.13. Effect of prenatal DEX treatment and/or adult stress or GC treatment 
on GFAP-I R cells within the S Npc follo wing 6-OHDA lesioning.  Stereological 
estimates of the number of GFAP-IR cells within the SNpc of male (A,C) and female (B,D) 
animals exposed to a 6-OHDA  were determined by immunohistocemistry. Measurements were 
made in 6 month old animals, 2 weeks after exposure to 5μg 6-OHDA injected into the MFB. A 
and B indicate the effects of prenatal (GD16-19) DEX treatment and/or adult (3.5 month) stress 
(repeated restraint for 1 hour every other day for 6 weeks). C and D depict the effects of 
prenatal DEX treatment and or adult GC treatment (hydrocortisone via the drinking water for 6 
weeks). Data are expressed as means ± SEM. Statistical significance was assessed by two way 
ANOVA with tukey’s post hoc comparison tests *p<0.05, **p<0.01, ***p<0.001 vs controls A: 
n=8 (control), 8(DEX), 8(stress), 8 (DEX + stress). B: n= 8 (control), 8 (DEX), 8 (stress), 8  
(DEX + stress). C: n = 7 (control), 7  (DEX), 7 (CORT), 6 (DEX + CORT). D: n=7 (control), 7 
(DEX), 7 (CORT), 7 (DEX + CORT). 
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Figure 3.14. Representative photomicrographs of GFAP-IR staining within 
the unlesioned (A) and lesioned (B) SNpc. Images were taken at x100 
magnification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B
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Figure 3.15. Effect of pr enatal DEX treatment and/ or adult stress or GC 
treatment on OX-6-IR cells  after 6-OHDA lesioning. Stereological estimates of 
the total number of ox-6 positive microglia within the left SNpc of male (A,C) and 
female (B,D) animals were obtained and expressed as a percentage of controls. 
Measurements were made in 6 month old animals, 2 weeks after exposure to 5μg 6-
OHDA injected into the left MFB. A and B indicate the effects of prenatal (GD16-19) 
DEX treatment and/or adult (3.5 month) stress (repeated restraint for 1 hour every other 
day for 6 weeks). C and D depict the effects of prenatal DEX treatment and or adult GC 
treatment (hydrocortisone via the drinking water for 6 weeks).  Data are expressed as 
means ± SEM. Statistical significance was assessed by two way ANOVA with post hoc 
comparison tests *p<0.05, **p<0.01, ***p<0.001, # vs DEX, + vs adult treatment. A: 
n=8 (control), 8(DEX), 8(stress), 8 (DEX + stress). B: n= 8 (control), 8 (DEX), 8 (stress), 8  
(DEX + stress). C: n = 7 (control), 7  (DEX), 7 (CORT), 6 (DEX + CORT). D: n=7 (control), 7 
(DEX), 7 (CORT), 7 (DEX + CORT). 
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Figure 3.16. Representative photomicrographs of OX-6 staining within the 6-
OHDA lesioned SNpc of male (A,C,E,G) and female (B,D,F,H) rats. Controls (A,B), 
stressed (C), DEX + stress (D,E), CORT (F,G), DEX + CORT (H). Images were taken 
at x200 magnification. 
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Figure 3.17. Effect of pr enatal DEX treatment and/ or adult stress or GC 
treatment on 3-NT-IR cells after 6-OHDA lesioning.  Stereological estimates of 
the total number of 3-NT positive positive cells within the left SNpc of male (A,C) and 
female (B,D) animals were obtained and expressed as a percentage of controls. 
Measurements were made in 6 month old animals, 2 weeks after exposure to 5μg 6-
OHDA injected into the left MFB. A and B indicate the effects of prenatal (GD16-19) 
DEX treatment and/or adult (3.5 month) stress (repeated restraint for 1 hour every other 
day for 6 weeks). C and D depict the effects of prenatal DEX treatment and or adult GC 
treatment (hydrocortisone via the drinking water for 6 weeks).  Data are expressed as 
means ± SEM. Statistical significance was assessed by two way ANOVA with post hoc 
comparison tests *p<0.05, **p<0.01, ***p<0.001, # vs DEX, + vs adult treatment. A: 
n=8 (control), 8(DEX), 8(stress), 8 (DEX + stress). B: n= 8 (control), 8 (DEX), 8 (stress), 8  
(DEX + stress). C: n = 7 (control), 7  (DEX), 7 (CORT), 6 (DEX + CORT). D: n=7 (control), 7 
(DEX), 7 (CORT), 7 (DEX + CORT). 
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Figure 3.18. Representative photom icrographs of 3-NT staining  within the 
SNpc of male rats. Unlesioned SNpc (A) and lesioned SNpc (B) of controls and 
lesioned SNpc of stressed (C) and GC treated (D) males. Images were taken at x 100 
magnification.  
 
 
 
 
A B
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3.4 DISCUSSION 
 
The data presented within this chapter demonstrate that chronic GC treatment and 
exposure to repeated stress in adulthood have complex but different effects on NSDA 
integrity that are sexually dimorphic. Specifically, repeated stress in adulthood causes 
up-regulation of NSDA measures (TH-IR and striatal DA) in females but not males. 
Conversely chronic GC treatment in adulthood produces up-regulation of the NSDA in 
males but has no effect on the female NSDA. Furthermore, prenatal GC treatment 
permanently alters both the male and female NSDA by increasing TH-IR within the 
SNpc but renders the male NSDA only susceptible to a negative effect of adult 
challenge (repeated stress or GC treatment), resulting in a significant down-regulation 
of both TH-IR and striatal DA. Finally, adult challenge but not prenatal GC treatment, 
sex-dependently altered the NSDA response to a neurotoxic insult, where both adult 
stress and GC treatment are detrimental to a 6-OHDA induced lesion in males but 
protective in females. Together these findings increase our understanding of the 
sexually dimorphic nature of NSDA responses and provide compelling evidence for a 
potential role of stress and/or GCs in the pathogenesis of PD. 
 
3.4.1 The Intact NSDA 
 
Effect of repeated adult stress alone: Although the male NSDA appeared totally 
unaffected by adult stress, both TH-IR and striatal DA content were increased after 
repeated restraint in females compared with controls. These data indicate marked sex 
differences in the capacity of the pathway to adapt to repeated stress. Other groups have 
reported elevated striatal DA levels in male mice and increased DA uptake by the DA 
transporter (DAT) within the striatum in response to restraint stress (Kim et al., 2005) 
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(Copeland et al., 2005).  Although there are discrepancies between these studies they 
could be attributed to differences in strain and the timing or duration of stress. However, 
together with our data they indicate that repeated stress is capable of manipulating the 
NSDA pathway.  
 
Repeated intermittent restraint provides a model of mild psychogenic stress. Animals 
exposed to repeated homotypic stressors show habituation to that stress which was 
readily observed in the behaviour of our animals. This induces plastic changes in the 
HPA axis that are partly due to GC negative feedback inhibition of the HPA axis (Jaferi 
et al., 2003). Evidence for a detrimental effect of stress and GCs on the brain comes 
mainly from work on the hippocampus where chronic stress causes degeneration of 
pyramidal neurons and subsequent deficits in memory and cognitive function in rats 
(Sapolsky et al., 1986; Lupien et al., 2007a). Hippocampal damage results in a reduction 
in GC negative feedback with the overall effect of further increasing GC levels. This is 
known as the GC cascade hypothesis which is implicated in brain aging (Sapolsky et al., 
1986) and therefore of relevance to diseases associated with aging such as PD. 
 
The data also show that there is an increased number of OX-42-IR microglia within the 
male SNpc in response to repeated stress but these microglia did not show any changes 
in morphology, indicating proliferation but not activation of microglia. Small increases 
in protein nitration within the male SNpc were also reported in response to repeated 
stress. It has previously been hypothesised that elevations in DA levels may lead to 
increased oxidative stress as the autoxoidation and normal metabolism of DA result in 
the production of reactive oxygen and nitrogen species as well as toxic DA quinones 
(Sulzer and Zecca 2000).  
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Effect of chronic GC treatment alone: Unlike our repeated stress paradigm 
animals treated with chronic hydrocortisone would not undergo habituation to treatment 
although they would adapt to treatment. Treatment would raise circulating GC levels 
but presumably suppress endogenous corticosterone release via HPA negative and result 
in a downregulation of GR. Treatment would also elicit a circadian profile of GC levels 
due to the increase in activity and therefore drinking behaviour in the evening. The dose 
of hydrocortisone that we used was based on a study (Magarinos et al., 1998) that 
showed chronic GC administration via the drinking water produced morphological 
changes within the hippocampus similar to that produced by repeated restraint stress. 
The dose reduced adrenal and thymic weights (indicative of a suppressed HPA axis) and 
increased circulating levels of GCs (Magarinos et al., 1998). They also found that 
animals failed to gain weight, a finding that was replicated in the present study (section 
2.6.2). In contrast to the pattern of responsiveness for repeated adult stress, chronic GC 
treatment did not affect measures of the NSDA system, whereas in males this treatment 
significantly increased both TH-IR and striatal DA, without a significant effect on 
turnover. The number of NeuN-IR cells was not altered in the same animals suggesting 
that chronic GC treatment results in increased TH expression/phenotype rather than an 
increase in the number of neurons within the SNpc. However, it is shown here and by 
others (Finklestein 2000) that only ~10% of neurons within the SNpc are not TH-IR 
neurons. Therefore changes in the expression of TH may not fully account for this. 
Although the SNpc is thought to have neurogenic potential throughout adulthood (Lie et 
al., 2002; Zhao et al., 2003; Shan et al., 2006), this remains controversial (Frielingsdorf 
et al., 2004). On the other hand a putative GC response element has been found in the 
regulatory region of the TH gene (Hagerty et al., 2001)  and both TH protein and 
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mRNA expression are increased by GCs (Kumer and Vrana, 1996).  Elevated striatal 
DA levels observed in males could be due to an increased synthesis of DA as a result of 
increased TH expression / activity or could be due to effects on DA metabolism and 
clearance. The main metabolising enzymes of DA, monoamine oxidase and catechol-o-
methyltransferase are unaffected by GC treatment (Lindley et al., 2005). However, 
stress increases DAT expression and binding in the male striatum (Copeland et al., 
2005; Lucas et al., 2007) and recently it has been shown that the organic cation 
transporter 3 (OCT-3, uptake 2) is present within the NSDA (Gasser et al., 2009) and 
that this transporter can be inhibited by GCs (Gasser et al., 2006) thus it may contribute 
to the effects of stress and GCs on the NSDA by reducing the clearance of DA. As with 
repeated stress chronic GC treatment resulted in elevated levels of protein nitration 
within the SNpc which could be a result of elevated DA levels leading to elevated 
oxidative stress as a result of enhanced DA metabolism. 
 
Together, these results show that the effects of repeated stress and GC treatment in 
adulthood on the NSDA pathway are clearly dissociated in both sexes. Responses are 
also sexually dimorphic, with males exhibiting an ability to respond/adapt to GCs 
(increase in NSDA parameters) but failing to respond to repeated restraint, and vice-
versa in females. Our observation that GC treated rats failed to gain weight over the 
treatment period whereas stressed rats gained weight normally further highlights the 
differences between the two treatments.Thus, the effects of repeated stress on the NSDA 
in adulthood are unlikely mediated by GCs. 
 
Effect of prenatal DEX on the ‘resting’ adult NSDA: The observed effects of 
DEX on the NSDA were likely due to the action of DEX on the fetus, as at the time of 
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treatment (GD16-19) it is known that DEX is able to cross the placenta and blood brain 
barrier (Owen et al., 2005). Moreover GR are present within the developing brain from 
E15.5 (Diaz et al., 1998) which supports a direct effect of DEX on the developing 
NSDA. Furthermore, the effects of DEX were not confounded by any observable 
changes in maternal behaviour. Treatment via the maternal drinking water has the 
distinct advantage that it avoids the stress which would be associated with parenteral 
treatments and associated handling, and available pharmacokinetic data allow us to 
estimate that the plasma concentrations achieved with this regime of DEX treatment 
which  exposes the fetus to GC levels approximating those seen in the physiological 
stress range (McArthur et al., 2006). There is a vast literature on the programming 
effects of stress and GCs on the developing fetus and the purpose of this plasticity early 
in life is thought to be to program the fetus for survival in a presumptive detrimental 
environment. Prenatal stress or GC exposure produces a hyperactive HPA axis in 
adulthood (Kapoor et al., 2006) and epidemiologic evidence suggests that this can 
increase susceptibility to disease later in life (Barker, 2002). More recently, adverse 
environments early in life have been linked to disorders of the CNS such as addictive 
behaviour (Meaney et al., 2002) and affective disorders (Seckl, 2008). There is now an 
emerging interest in the role of the early environment in the development of 
neurodegenerative diseases such as PD (Carvey et al., 2003; Barlow et al., 2007; 
Pienaar et al., 2008a).  
 
The data show that prenatal DEX significantly increased TH-IR cell numbers in males 
and females, without affecting striatal DA levels. This corroborates our earlier findings 
(McArthur et al., 2005; McArthur et al., 2007a) and suggests that adaptive mechanisms 
in the NSDA system permit maintenance of striatal DA levels in the face of changing 
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cell numbers. Although the underlying mechanisms are unclear, they appear not to 
involve major changes in neuronal activity because DA turnover is not significantly 
altered by prenatal DEX. Prenatal DEX also increased the number of SNpc cells IR for 
a general neuronal marker (NeuN) suggesting that DEX produces an increase in the 
number of cells rather than an increase in TH enzyme expression/phenotype. The 
processes of neurogenesis and migration of TH-expressing cells into the midbrain nuclei 
are thought to be complete around E16 (Bayer et al., 1995; Lieb et al., 1996) and are 
therefore unlikely to be the major targets of GC influences between E16-19. However, 
this is a period of programmed cell death in the brain via apoptotic mechanisms and it 
has been proposed that GCs play a significant role in this process.   Although often 
thought of as inducers of apopotosis, GCs can also promote cell survival in the 
developing brain (Gould and Cameron, 1996; Abraham et al., 2001) suggesting a 
process which could influence DA cell counts in the adult SNc.  
 
There are limited studies exploring the functional consequences of prenatal GC 
programming on the NSDA, but reports that prenatal GC treatment can increase 
spontaneous motor activity in male and female rats and exerts sexually dimorphic 
effects on apomorphine induced motor behaviour (Diaz et al., 1997) as well as data 
reporting that that postnatal treatment with GCs results in a deficit in motor 
coordination in adulthood (Benesova and Pavlik, 1989), support our findings that this 
has significant impact upon the adult NSDA system. By comparison prenatal exposure 
to lipopolysaccharide (LPS) during pregnancy results in offspring with a reduced 
number of DA neurons within the SNpc that exhibit greater levels of neuroinflammation 
(Ling et al., 2002; Carvey et al., 2003). Low dose GCs have potent anti-inflammatory 
actions (Sorrells and Sapolsky, 2007) therefore it could be hypothesised that decreased 
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neuroinflammation in our prenatally treated animals could account for the increased 
number of DA neurons. However, OX-42 immunohistochemistry demonstrated that 
prenatal DEX treatment resulted in a larger microglial population in adulthood. 
Although GCs are known to suppress microglia it has also been shown that stress via 
elevated corticosterone can induce microglia proliferation (Nair and Bonneau, 2006). 
During development amoeboid microglia are likely responsible for the phagocytosis of 
dying neurons and dendritic debris, however microglia are not always associated with 
dying cells and can display a ramified morphology (typical of resting microglia). These 
microglia are present within the developing brain from E14 (Ashwell, 1991; Jonakait, 
2007) and have been shown to produce neurotrophic factors. This extra neurotrophic 
support provided by proliferating microglia may result in an increased number of DA 
neurons within the SNpc that is seen in DEX treated animals.  Astrocytes are not 
present in the rodent brain until the first postnatal week when they proliferate and play a 
significant role in synaptogenesis (Ullian et al., 2001; Ullian et al., 2004). Our regime 
would therefore not directly impact upon the astrocyte population. However the data 
presented here suggest that DEX treatment results in a reduced astrocyte population 
which presumably is an indirect effect of prenatal DEX treatment. Further study is 
required to determine the mechanism behind this. 
 
 
Effect of prenatal dexamethasone on the challenged adult NSDA 
pathway 
 
Adult stress challenge: In males prenatal DEX had a profound effect on the adult 
response to repeated stress. Thus, although prenatal DEX increased TH-IR numbers in 
the unchallenged male SNpc compared with controls (as discussed above), it inhibited 
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the NSDA response to repeated stress such that TH-IR numbers and striatal DA were 
significantly suppressed in the prenatal DEX + adult restraint group compared with 
controls after exposure to repeated adult restraint. This clearly contrasts with the failure 
of the normal adult male NSDA system to respond to stress and indicates the potential 
of the male NSDA to suffer long term consequences of prenatal stress exposure. In 
striking contrast, the ability of the normal female NSDA pathway to up-regulate both 
TH-IR and striatal DA in response to adult stress was completely unaffected by prenatal 
DEX exposure. This may indicate an ability of normal females to adapt positively, 
whereas males cannot, possibly making them more vulnerable. It also suggests a 
robustness of the female NSDA to early intervention, but a susceptibility in males, 
where the normal failure to adapt may even be worsened, as indicated by suppressed 
TH-IR cell numbers and striatal DA. 
 
Adult GC challenge: As was the case for stress in adulthood, prenatal DEX 
profoundly altered the response of the male, but not female, NSDA to chronic adult CG 
treatment. Thus, in males chronic stress ablated the up-regulation of the NSDA induced 
by prenatal DEX treatment (increased TH-IR in SNpc) or adult GC treatment (increased 
TH-IR and striatal DA) and both TH-IR and striatal DA were reduced to levels below 
those of the untreated control. This was accompanied by an increase in DA turnover, 
which may indicate an increase in activity in an attempt to compensate for the reduction 
in TH-IR and striatal DA. 
 
It appears, therefore, that prenatal DEX treatment may compromise the ability of the 
adult male NSDA system to respond appropriately to either repeated stress or chronic 
GC treatment in adulthood. By contrast, the resistance (upregulation of NSDA 
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measures) of the female NSDA to adult stress or GCs, respectively, were unaffected by 
prenatal DEX. The fact that there were similar effects (suppression of NSDA measures) 
of prenatal DEX on adult stress and GC treatment suggests that this novel programming 
effect in males is HPA mediated. We propose that this down-regulation is the result of 
the failure of prenatally programmed males but not females to adapt to an adult 
challenge (Bhatnagar et al., 2005).  The premise of early life experience influencing 
adult NSDA structure and function is supported by a study demonstrating that prenatal 
LPS exposure followed by adult LPS resulted in progressive DA neuron loss within the 
SNpc where pre-existing neuroinflammation prolonged the inflammatory response to 
the second exposure (Ling et al., 2006).  There are also data supporting the idea that 
prenatal GC treatment can suppress the response to adult challenge in adult rats that had 
been treated prenatally with DEX failed to display a reduction in pituitary ACTH 
release in response to GCs (Theogaraj 2005, 2006). 
 
 
 
3.4.2 The injured NSDA system 
 
It is important to consider that the process of producing a 6-OHDA lesion is in itself a 
stressful procedure. Surgical stress results from a combination of anaesthesia, tissue 
injury and post-operative pain and is characterised by activation of the HPA axis 
(Desborough 2000). It has also been shown that volatile anaesthetics such as isofluorane 
can stimulate the HPA axis (Karuri 1998). As we have shown that chronic GCs can 
increase TH-IR in the SNpc we hypothesise that surgical stress may produce an increase 
in TH-IR via elevated GC levels. 
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Adult repeated stress had marked and opposite effects on susceptibility to 6-
OHDA-induced lesions in males and females, which were harmful and protective, 
respectively, at both DA cell bodies in the SNpc and terminals in the striatum. This is a 
striking sex dimorphism which indicates that stress has a major influence on 
susceptibility to neurodegenerative stimuli. This may correlate with the failure of the 
normal (unlesioned) male NSDA to respond/adapt to chronic stress, whereas a positive 
response was seen in females. A recent study (Smith et al., 2008) examined the effects 
of chronic stress on 6-OHDA neurotoxicity in female rats. The authors did not observe 
any changes in TH-IR loss within the SNpc but did not assess effects in males. Sex 
differences in response to 6-OHDA are discussed further below. 
 
Chronic adult GC treatment also had sexually dimorphic effects at SNpc level on 
susceptibility to 6-OHDA-induced lesions in males (harmful) and females (protective), 
providing further evidence for sex differences in the response of this pathway to 
stressful stimuli. These results therefore identify certain similarities in the effects of 
adult exposure to stress and GCs with respect to survival of the SNpc DA cell 
populations in the injured NSDA, albeit in opposite directions in males and females. 
These data indicate that GCs could be important mediators of this effect of stress. 
However, unlike stress, GCs were without effect on DA depletion at striatal level in 
both sexes, demonstrating that changes in DA cell numbers can occur independently of 
striatal DA content. It is not possible to determine the underlying mechanisms from the 
present study, but we have recently shown that although manipulation of circulating sex 
steroid hormone levels can significantly modify striatal DA depletion in response to 
neurotoxins, there is no concomitant effect on SNpc DA cell survival, further 
illustrating dissociation of effects of steroid hormones at perikarya and terminal level 
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(McArthur et al., 2007a). In order to explain this, we have proposed that sex hormones 
influence the activity of the surviving DA neurons, which would compensate for cell 
loss in the partially injured NSDA pathway, rather than affecting cell survival per se.  
Conversely, it would appear that GCs predominantly influence cell survival without 
affecting the compensatory mechanisms. 
 
Prenatal treatments alone and in combination with adult treatments. 
In male and female rats which received no adult treatments, prenatal DEX was without 
effect on 6-OHDA-induced toxicity at SNpc or striatal level. However other studies 
have found that perinatal manipulations such as maternal separation or prenatal LPS 
exaggerated the toxic effects of 6-OHDA (Ling et al., 2004; Pienaar et al., 2008b) 
highlighting the importance of the nature and timing of the perinatal manipulation on 
the impact they have on the NSDA.  Presentation of the adult animals with stress or GC 
treatment had striking, sexually dimorphic and treatment-specific effects.  
 
Prenatal dexamethasone plus challenge with adult stress: The damaging 
effects of adult stress in males on 6-OHDA-induced SNpc neuron loss and striatal DA 
depletion were unaffected by prenatal DEX exposure. The protective effect of repeated 
adult stress in females, as detected by the attenuation of striatal DA depletion by 
prenatal DEX treatment, was also not affected, but the protective effect at SNpc level 
was lost. It would therefore appear that early exposure to GCs may render the female, 
but not male, SNpc more vulnerable to the effects of stress on neurotoxic injury, 
without affecting the degree of striatal DA depletion. 
 
Prenatal dexamethasone plus challenge with adult GC treatment: In males 
the ability of adult GC treatment to exacerbate 6-OHDA-induced SNpc DA cell loss 
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was not influenced by prenatal dexamethasone treatment, but it did render adult GCs 
capable of enhancing striatal DA depletion, which they were unable to do in the absence 
of early GC exposure. In contrast, in females the effects of adult GCs on 6-OHDA 
toxicity at either SNpc (reduced cell loss) or striatum (no effect) were unaffected by 
prenatal dexamethasone. It would therefore appear that early exposure to GCs renders 
the male, but not female, striatum more vulnerable to the effects of glucocorticoids, 
without affecting the SNpc. The turnover of DA within the striatum was increased in 
both stressed and GC treated males that were prenatally treated with DEX indicating an 
increase in DA activity. Increased DA metabolism would result in an increase in the 
production of reactive oxygen species, elevating levels of oxidative stress and 
potentially further endangering neurons.  
3.4.3 Mechanisms of toxicity 
 
As aforementioned stress can increase DAT expression and binding in the male 
striatum. By increasing the uptake of 6-OHDA into neurons this may underlie increased 
neurodegeneration. The exacerbation of the 6-OHDA lesion by repeated stress and 
chronic GC treatment in male animals was associated with elevated levels of microglial 
activation and increased protein nitration within the lesioned SNpc. Both inflammation 
and oxidative stress are heavily implicated in the pathogenesis of PD (Olanow, 2007) 
and in the 6-OHDA model (Simola et al., 2007). Evidence to suggest that these 
processes might underlie the increased toxicity we see in response to repeated stress and 
GCs is provided by findings that chronic stress elevates oxidative stress and antioxidant 
status within the rodent brain (Fontella et al., 2005; Kim et al., 2005; Zafir and Banu, 
2008). Furthermore, although GCs are traditionally thought of as anti-inflammatory, 
stress and GCs can promote a pro inflammatory environment within the brain (Garcia-
Bueno et al., 2008), an area of research that is currently gaining significant attention. 
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Our finding that both these processes are potentiated by our repeated stress and chronic 
GC treatment paradigms suggest that they may contribute to the associated increased 
toxicity of 6-OHDA. Microglia can produce a number of neurotoxic molecules 
including proinflammatory cytokines and prostaglandins as well as reactive oxygen and 
nitrogen species. Conversely elevated oxidative stress can stimulate microglial 
activation. However, the effects on inflammatory and oxidative markers may merely be 
a result of increased toxicity rather than being a causative factor. Another process 
thought to play a role in PD that may underlie the effects of stress and GCs on the 
NSDA is glutamate excitotoxicity. This was not investigated in the present study but 
stress and GCs have previously been found to elevate extracellular glutamate 
concentration within the male striatum (Moghaddam, 1993; Moghaddam et al., 1994). 
Excessive glutamate signaling may lead to excitotoxicity and subsequent 
neurodegeneration.  
 
3.4.4 Role of the environment on the integrity of the NSDA 
 
Repeated restraint is an example of a psychogenic stress where there is no actual threat 
to the animal’s well-being. The effect of systemic stressors on the NSDA have also been 
evaluated. Systemic administration of bacterial endotoxin (LPS) or TNF-α 
administration results in neuroinflammation and a progressive loss of SNpc 
dopaminergic neurons (Qin et al., 2007) caused by elevations in brain levels of TNF-α 
and the subsequent induction of proinflammatory mediators within the brain. As there 
are relatively high numbers of microglia in the SNpc compared to other brain regions 
(Kim et al., 2000) an increased susceptibility to inflammation has been hypothesised to 
underlie the SNpc’s sensitivity to degeneration. Further studies revealed that a non toxic 
dose of LPS administered directly to the SNpc exacerbated the effects of 6-OHDA and 
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increased degeneration in response to paraquat exposure (Koprich et al., 2008; Mangano 
and Hayley, 2008). Furthermore, systemic IL-1 administration also exaggerates 6-
OHDA neurotoxicity (Godoy et al., 2008). Moreover, LPS has also been found to 
decrease glutathione and increase levels of lipid peroxidation within the brain (Zhu et 
al., 2007) that are indicative of elevated oxidative stress. The fact that the effects of LPS 
and other inflammogens are similar to those of repeated stress and GC treatment 
reported here and may indicate a similar mode of action. This hypothesis is further 
supported by our evidence of elevated microglial activation and oxidative stress in the 
SNpc in response to stress and GCs. In addition viruses have also been linked to an 
enhanced susceptibility to PD. In particular the influenza virus has been indentified as a 
predisposing factor. Although it probably does not directly cause PD, some strains of 
the influenza virus are able to enter the brain where they can produce cytokine induction 
and cell death (Jang et al., 2008) and may therefore contribute to a number of hits, 
precipitating PD.  
 
Further evidence for an effect of the environment on the NSDA is provided by 
experiments that study the impact of environmental enrichment or exercise. 
Environmental enrichment confers resistance to MPTP (Bezard et al., 2003; Faherty et 
al., 2005) by decreasing DAT expression and increasing neurotrophic factors within the 
striatum.  In 6-OHDA rats exercise suppresses NSDA neuron loss (Mabandla et al., 
2004; Yoon et al., 2007) and provides some beneficial effects to PD patients (Goodwin 
et al., 2008). It is currently thought that exercise and environmental enrichment confer 
neuroprotection by decreasing levels of oxidative stress (Radak et al., 2008). 
Interestingly and of significant relevance to the present study, stress reversed the 
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neuroprotective effect of exercise in the 6-OHDA rat (Howells et al., 2005) providing 
further evidence for our hypothesis that stress and GCs can endanger the NSDA. 
 
3.4.5 Sex differences in the susceptibility to 6-OHDA 
 
Unlike other studies we do not report a sex difference in the size of 6-OHDA lesion in 
control animals. However, there are data to suggest that sex differences are lost when 
the lesion size exceeds a certain limit (Gillies et al., 2004). Additionally our animals 
were significantly older than those used in most other studies and thus may also impact 
upon both lesion size and sex differences (Tamas et al., 2005). Furthermore the stage of 
estrous in our female animals may impact on lesion size. There are intrinsic sex 
differences within the NSDA. For example there is greater expression of and uptake by 
the DA transporter (DAT)(Walker et al., 2000; Bhatt and Dluzen, 2005) and recently it 
has been demonstrated that although females have a more highly active DAT (and 
VMAT2) they are less sensitive to the toxic effects of methamphetamine (Dluzen and 
McDermott, 2008). They suggest that although females express a more active DAT, this 
can be downregulated by estrogen (Disshon et al., 1998), allowing for fine control of the 
system and more efficient sequestering of DA or neurotoxin. There are also differences 
in the response to stress where females generally exhibit a greater HPA response to 
stressors than males but are more able to cope with subsequent stressors (Dalla et al., 
2005). Recent studies support our findings that stress produces opposing effects in 
males and females. Chronic stress was shown to produce sexually dimorphic effects on 
DA transmission (Dalla et al., 2008) and skilled movement in response to restraint stress 
was better in females than in males study (Jadavji and Metz, 2008). Furthermore 
females used a different strategy to overcome motor disturbances caused by stress and 
are able to recover faster.  
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It is thought that sex differences arise due to the organisational effects (during 
development) or the activational effects (during adulthood) of sex steroid hormones. 
Interestingly our previous work has shown that systemic estrogen and gonadal factors 
have opposing effects on striatal susceptibility to 6-OHDA where they are protective in 
females but are detrimental in males (Gillies et al., 2004). Thus, stress may be acting 
indirectly through an influence on sex steroids. Stress is known to suppress both the 
male and female reproductive systems and both CRH and GCs can prevent the release 
of GnRH. GCs also decrease the production of sex hormones via a direct action on the 
testes and ovaries (Swaab et al., 2003). Conversely sex steroids also have an impact on 
HPA function. 
 
Resistance to stress induced elevated neurotoxicity could partly account for the sex 
differences observed in the susceptibility to 6-OHDA (Gillies et al., 2004) and to PD 
(Schrag et al., 2000). It has been proposed that estrogen underlies the sex difference in 
the higher prevalence of PD in males (Shulman, 2007) and the lower toxicity of 6-
OHDA, MPTP and LPS in female animals (Dluzen, 2000; Murray et al., 2003; Liu et 
al., 2008).  Estrogen decreases the expression of DAT which is elevated by stress 
(Copeland et al., 2005) and it has been reported that estrogen has antioxidant properties 
(Sawada et al., 1998; Nilsen, 2008), indeed administration of supraphysiologic levels of 
estradiol prior to MPTP treatment in male mice reduced levels of nitrotyrosine  
immunoreactivity and increased levels of antioxidant enzymes (Tripanichkul et al., 
2007) within the SNpc. Estrogen can also exert anti-inflammatory actions for example; 
pre-treatment with estradiol (supraphysiological) was found to down regulate microglial 
activation and attenuate DA neuron loss in MPTP male mice (Tripanichkul et al., 2006). 
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Furthermore, estrogen can attenuate glutamate excitotoxicity (Behl, 2002a). Further 
study is required to determine exactly what is conferring neuroprotection in our female 
animals.  
 
3.4.6 Clinical Implications 
 
In this study plasma concentration of CORT in DEX treated pups was estimated to be ~ 
30ng/ml. This is a lower dose than that used in perinatal medicine (Theogaraj et al., 
2005) therefore our findings are of considerable interest to the use of GCs in cases of 
preterm labour in which GCs are used to promote lung maturation. Human prenatal GC 
treatment has been shown to cause impaired childhood cognition and long term 
behavioural implications (Sloboda et al., 2005) but at present there is a lack of 
information on the long term implications of perinatal GC treatment in humans 
highlighting the need for long term follow up studies. In addition these results have 
implications for the use of inhalational low dose corticosteroids in pregnancy and in 
children where the HPA axis has been shown to be suppressed (Zollner, 2007).  
 
PD is increasingly thought to be a multifactorial disease (Sulzer, 2007) whereby a 
number of genetic and/or environmental insults act in concert to cause disease onset and 
progression. Our data support a role for stress and GCs in accelerating the onset or 
progression of PD and provide  further evidence for the multiple hit hypothesis of PD 
(Carvey et al., 2006). The sexually dimorphic responses of the NSDA to stress may to 
some degree contribute to the higher prevalence of PD in males. As GCs are often used 
to treat autoimmune and inflammatory conditions, it may be of benefit to limit their use 
in PD patients. In patients with elevated GC levels, measures to control GC levels may 
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confer some beneficial effect however there is a need for epidemiological studies to 
assess this.  
 
3.4.7 Conclusions 
 
In summary the data within this chapter show that adult chronic GC treatment or 
repeated stress produce opposing sex-dependent effects on the NSDA. Furthermore 
although prenatal DEX treatment increases the DA neuron population of both the adult 
male and female SNpc we present a novel programming effect of prenatal GCs whereby 
males, but not females, are rendered susceptible to a down-regulation of both TH-IR 
cells and striatal DA in response to an adult challenge (repeated stress or chronic GC 
treatment). Our data also reveal striking sexually dimorphic effects of adult challenge 
on the susceptibility of the NSDA to 6-OHDA where exposure to an adult challenge 
exacerbates the neurotoxic lesion in males but confers neuroprotection in females. The 
data also indicate that oxidative stress may be involved in the detrimental effects of the 
stress/GCs on the NSDA. The study highlights important sexual dimorphisms in the 
effects of stress and GCs on the NSDA and provides novel insights into the possible 
involvement of stress and GCs in PD.  
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CHAPTER 4 
Sex-specific effects of stress and glucocorticoid 
treatments on the integrity of the mesolimbic and 
mesocortical dopaminergic pathways. 
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4.1 INTRODUCTION 
 
PD is primarily considered a disease of motor function but there is a high prevalence of 
disabling non-motor symptoms including psychiatric complications such as depression 
(Allain et al., 2000; Wermuth and Bech, 2006), anxiety (Richard, 2005), apathy 
(Dujardin et al., 2007), anhedonia (Isella et al., 2003) and compulsive behaviour (Torta 
and Castelli, 2008). Although cell loss in PD is most severe in the SNpc there is also 
significant degeneration of DA neurons, albeit to a lesser extent, within the VTA 
(German et al., 1989). These neurons form two major DA projections, the mesolimbic 
(MLDA) and mesocortical (MCDA) pathways. Degeneration of these pathways in PD 
patients is now thought to contribute to the neuropsychiatric symptoms of PD. Growing 
attention for the non motor symptoms of PD mirrors the desire for improved quality of 
life for PD patients. The MLDA system consists of dopaminergic neurons within the 
VTA that primarily project through the medial forebrain bundle to the NAcc which is 
found in the ventral striatum, as well as innervating the amygdala and hippocampus. 
NAcc DA input from the VTA modulates the activity of GABAergic medium spiny 
neurons within the NAcc that form part of the cortico-striato-thalamo-cortico-loop. The 
MLDA forms the brains major reward pathway (Schultz, 2000) and as such has been 
implicated in depression and addiction. On the other hand the MCDA is composed of 
DA neurons that primarily innervate the PFC. This pathway is involved in motivation 
and emotional responses and has been associated with the negative symptoms of 
schizophrenia. 
 
There is considerable evidence supporting a role of midbrain DA in depression (Martin-
Soelch, 2009) and although there are numerous difficulties in diagnosing major 
depression in PD patients, meta analysis of published data suggest that 31% of PD 
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patients suffer from depression compared to 16% of the general population (Kessler et 
al., 2003). Additionally there is greater degeneration of VTA neurons in depressed PD 
patients than non depressed PD patients (Mann and Snowden, 1995) supporting a role 
of the MLDA and MCDA pathways in depression in PD. Stress and GC’s both in early 
life and adulthood have been linked to depression (Heim et al., 2008; Yu et al., 2008). 
Similarly, stressful events both early in life and as an adult have been implicated in the 
pathogenesis of schizophrenia (Cotter and Pariante, 2002; Bennett, 2008). The 
dopamine hypothesis of schizophrenia suggests that excess DA activity in the MLDA 
system contributes to the positive symptoms of the disease that are mediated by D2 
receptors, whilst reduced DA in the MCDA system underlie the negative symptoms of 
schizophrenia via D1 receptors . Futhermore D2 receptors are increased in post mortem 
brains of schizophrenics (Seeman and Kapur, 2000). Most evidence for an effect of 
stress and GCs on DA pathways comes from studies on drugs of abuse. Current data 
suggest that stress induced elevations in GCs, increase vulnerability to drug abuse via 
alterations in the MLDA that mimic the effects of psychostimulant drugs (Marinelli and 
Piazza, 2002).  Moreover GC suppression by adrenalectomy reduces NAcc levels of DA 
(Piazza et al., 1996; Barrot et al., 2001) which can be reversed by corticosterone 
supplementation. These effects are mediated by GR (Marinelli et al., 1998). Together, 
these observations illustrate the prime importance of both stress and glucocorticoids on 
the mesocorticolimbic pathways in the most common psychiatric disorders. However, 
the actual consequence of stress or GC exposure on these pathways is poorly defined. 
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4.2 EXPERIMENTAL DESIGN 
 
The aims of the work presented in chapter 4 were to firstly elucidate the effects of 
prenatal GCs and adult stress or chronic GC treatment on the MLDA and MCDA 
pathways and secondly whether these treatments compounded with the effects of 6-
OHDA induced lesions, affect these pathways. To achieve this, 2 studies were 
performed. The first examined the effects in adulthood of prenatal DEX treatment that 
was administered via the maternal drinking water on GD16-19 and/or repeated 
intermittent restraint stress (immobilisation for 1 hour every other day) at 3.5 months 
for a period of 6 weeks. The second study examined the effects of prenatal DEX 
treatment as well as adult (3.5 month) chronic GC treatment (via the drinking water for 
6 weeks). To determine how stress and GC treatments affected MLDA and MCDA 
responses to insults an injection of 6-OHDA was administered to the MFB of a subset 
of rats from each treatment group.  
 
Integrity of the DA systems was assessed by the analysis of the number of neurons 
within the VTA which was achieved by immunohistochemistry for TH (DA neurons) 
and NeuN (all neurons). The number of astrocytes and microglia within the VTA were 
also evaluated by GFAP and OX-42/OX-6 immunohistochemistry respectively. 3-NT 
immunohistochemistry measured the amount of protein nitration within the VTA that 
would be indicative of levels of oxidative stress. HPLC was used to measure DA and its 
metabolites within the PFC and NAcc as indicators of the dynamics of DA transmision. 
For detailed methodology please refer to chapter 2. 
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4.3. RESULTS 
 
4.3.1. The unchallenged MLDA and MCDA 
 
Controls: On combination of data from study 1 and study 2 the number of TH-IR cells 
within the VTA was estimated to be 16000 ± 837 in adult male rats. Female rats had 
~20% more TH-IR cells than males (19620 ± 688; p<0.01) which agrees with previous 
findings of a sex difference (McArthur et al., 2006). The number of NeuN-IR cells 
within the VTA was significantly higher in both males and females (34120 ± 1775 in 
males and 39710 ± 1583 in females). Thus, TH-IR neurons represented ~50% of the 
total number of VTA neurons. To establish the size of the astrocyte population in our 
control (unchallenged) adult (5.5month old) VTA, immunohistochemistry for GFAP 
was performed. The estimated number of GFAP-IR cells in the male VTA was 4226 ± 
192 and 3885 ± 141 in the female. Similarly OX-42 immunohistochemsitry was used to 
assess the VTA microglial population. In controls there were 2187 ± 200 and 2127 ± 
148 OX-42-IR cells in the male and female VTA respectively. We also established that 
the number of VTA cells positive for protein nitration in adult controls was estimated to 
be 4100 ± 270 in males and 3747 ± 261 in females. The two main dopaminergic efferent 
pathways of the VTA project to the NAcc and PFC. DA levels within the adult NAcc 
were 6.75 ± 0.59 ng/mg in adult males and 12.87 ± 0.51 ng/mg in females (p<0.001; 
Table 4.1) again this supports previous findings of sex differences within the MLDA 
(Becker, 2009). Additionally, DA turnover within the NAcc was higher in males than in 
females (p<0.001; 1.65 ± 0.26 in males and 0.62 ± 0.04 in females; table 1).  The VTA 
also contains DA neurons that project to the PFC, here average adult male DA levels 
were 0.14 ± 0.04 ng/mg . Adult female PFC DA levels in females were increased but 
not significantly different in study 1 but in study two female DA levels were found to be 
significantly higher (p<0.001; Table 2). As in the NAcc DA turnover within the PFC 
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was higher in males (p<0.001). HVA levels within the female PFC were negligible in 
study 1.   
 
Adult treatments in male rats: In adult males repeated stress increased the number 
of TH-IR cells in the VTA by ~20% (p<0.05; Figure 4.1A). DA levels within the NAcc 
were elevated by ~50% (p<0.01) in male rats that had been subjected to repeated 
restraint stress (Table 4.1). Unlike repeated stress, adult GC treatment did not affect TH-
IR in the VTA but did produce comparable changes in the NAcc where DA levels were 
increased by ~60% in (p<0.05; Table 4.1). By comparison PFC DA levels were not 
significantly altered by repeated stress or chronic GC treatment (Table 4.2). The number 
of OX-42-IR cells within the VTA were increased in both stressed (~60%) and GC 
treated (~40%) animals (p<0.05; figure 4.4). An effect on GFAP-IR cells was only seen 
in stressed males where the GFAP population was increased by ~25% (p<0.01; Figure 
4.3). Neither repeated stress nor chronic GC treatment exerted an effect on the number 
of 3-NT-IR cells in the VTA (Figure 4.5).  
 
Prenatal treatment in male rats: Prenatal DEX treatment resulted in an elevation 
of TH-IR cell numbers within the VTA of adult male rats that was only significant in 
study 1 (p<0.05; Figure 4.1A). Interestingly, DA levels within the male NAcc were 
elevated in study 2 (p<0.05; Table 4.1) but not study 1 and within the PFC prenatal 
DEX treatment increased adult DA turnover in study 1 only (p<0.01; Table 4.2). The 
number of GFAP-IR cells in the adult VTA was reduced by ~20% in rats exposed to 
gestational DEX (p<0.05; Figure 4.3A,C). Male rats that had been treated prenatally 
with DEX exhibited a higher number of OX-42-IR cells (p<0.001 in study 1 and p<0.01 
in study 2; Figure 4.4A,C) where the average number of OX-42-IR cells was increased 
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approximately two fold to 4875 ± 358 in males. Prenatal DEX treatment did not affect 
3-NT-IR cell number within the VTA  (Figure 4.5A,C). 
 
Prenatal DEX treatment in combination with adult treatment in male rats: 
Interestingly a history of prenatal DEX treatment attenuated adult NAcc DA levels (p< 
0.05; Table 4.1) in both stressed and GC treated males but did not alter their effect on 
TH-IR cells in the VTA (figure 4.1). The combination of prenatal DEX treatment and 
adult repeated stress or GC treatment did not elicit any interactive effect on GFAP, OX-
42 or 3-NT-IR  cell counts (Figure 4.3-4.5).  
 
 
Adult treatments in female rats: As in males repeated stress in adulthood increased 
the number of TH-IR cells within the female VTA (P<0.01, Figure 4.1B) but in contrast 
to the effect of stress in males DA levels within the NAcc were reduced by ~45% 
(p<0.001; Table 4.1). Additionally in females, DOPAC and DA turnover were increased 
by repeated restraint (p<0.05). The number of OX-42-IR cells within the female VTA 
were also increased by repeated stress (p<0.05). Adult GC treatment didn’t alter the 
number of TH-IR cells within the VTA but did reduce NAcc DA levels by ~20% 
(p<0.05; Table 4.2) and elevate the number of OX-42-IR cells within the VTA. DA 
levels within the female PFC were not altered by either adult treatment (Table 4.3). 
There was no effect of adult treatment on GFAP or 3-NT-IR cell numbers. 
 
Prenatal treatment in female rats: In contrast to its effects in the male prenatal 
DEX did not exert an effect on TH-IR cells within the adult  female VTA but reduced 
female NAcc DA levels (p<0.05 in study 1, p<0.001 in study 2; Table 4.1) and 
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increased DA turnover in study 2 (p<0.05). By contrast, DA levels within the adult 
female PFC were unaffected by DEX treatment (Table 4.2). As for males prenatal DEX 
reduced the number of GFAP-IR cells (p<0.05; Figure 4.3 B,D) and dramatically 
increased the number of OX-42-IR cells (p<0.01; Figure 4.4 B,D) but didn’t affect 3-
NT-IR. 
 
Prenatal treatment in combination with adult treatment in female rats: 
Again in contrast to the effect seen in males NAcc DA levels in stressed and GC treated 
females were not changed by prenatal exposure to DEX. However, there was an 
increase in NAcc DA turnover in stressed females that had also been treated prenatally 
with DEX (p<0.05). In the same group of animals DA and DOPAC levels within the 
PFC were reduced (Table 4.2). 
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Figure 4.1. Effect of prenatal dexam ethasone an d/or adult stress or GC 
treatment on TH-IR cells within the VTA. Stereological estimates of total TH-IR+ 
cells within the VTA in adult (5.5 month) male (A,C,) and female (B,D,) animals as 
assessed by TH immunohistochemistry. A and B indicate the effect of prenatal (GD16-
19) DEX treatment and/or adult (3.5 month) stress (repeated restraint for 1 hour every 
other day for 6 weeks). C and D depict the effects of prenatal DEX treatment and or 
adult GC treatment (hydrocortisone via the drinking water for 6 weeks) Data are 
expressed as means ± SEM. Statistical significance was assessed by two way ANOVA 
with tukeys post hoc comparison tests. *p<0.05, **p<0.01, ***p<0.001 vs controls, # vs 
DEX, + vs adult treatment. A: n=8 (control), 9 (DEX), 8(stress), 8 (DEX + stress). B: n= 
10 (control), 8 (DEX), 10 (stress), 10 (DEX + stress). C: n = 7 (control), 6 (DEX), 7 
(CORT), 5 (DEX + CORT). D: n=7 (control), 6 (DEX), 7 (CORT), 7 (DEX + CORT). 
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Figure 4.2. Effect of prenatal dexam ethasone an d/or adult stress or GC 
treatment on NeuN-IR cells w ithin the VTA.  Stereological estimates of total 
NeuN-IR cells within the VTA in adult (5.5 month) male (A,C,) and female (B,D,) 
animals as assessed by TH immunohistochemistry. A and B indicate the effect of 
prenatal (GD16-19) DEX treatment and/or adult (3.5 month) stress (repeated restraint 
for 1 hour every other day for 6 weeks). C and D depict the effects of prenatal DEX 
treatment and or adult GC treatment (hydrocortisone via the drinking water for 6 weeks) 
Data are expressed as means ± SEM. Statistical significance was assessed by two way 
ANOVA with tukeys post hoc comparison tests. *p<0.05, **p<0.01, ***p<0.001 vs 
controls. N numbers can be found in figure 2.11. A: n=8 (control), 9 (DEX), 8(stress), 8 
(DEX + stress). B: n= 10 (control), 8 (DEX), 10 (stress), 10 (DEX + stress). C: n = 7 
(control), 6 (DEX), 7 (CORT), 5 (DEX + CORT). D: n=7 (control), 6 (DEX), 7 (CORT), 7 
(DEX + CORT). 
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Figure 4.3 . Effec t of  prena tal dexamethasone and/ or adult stress o r GC 
treatment on GFAP-IR cells within the VTA. Stereological estimates of total GFAP-
IR cells within the VTA in adult (5.5 month) male (A,C,) and female (B,D,) animals as 
assessed by GFAP immunohistochemistry. A and B indicate the effect of prenatal (GD16-
19) DEX treatment and/or adult (3.5 month) stress (repeated restraint for 1 hour every other 
day for 6 weeks). C and D depict the effects of prenatal DEX treatment and or adult GC 
treatment (hydrocortisone via the drinking water for 6 weeks) Data are expressed as means 
± SEM. Statistical significance was assessed by two way ANOVA with tukeys post hoc 
comparison tests. *p<0.05, **p<0.01, ***p<0.001 vs controls, # vs DEX, + vs adult 
treatment. A: n=8 (control), 9 (DEX), 8(stress), 8 (DEX + stress). B: n= 10 (control), 8 
(DEX), 10 (stress), 10 (DEX + stress). C: n = 7 (control), 6 (DEX), 7 (CORT), 5 (DEX + 
CORT). D: n=7 (control), 6 (DEX), 7 (CORT), 7 (DEX + CORT). 
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Figure 4.4. Effect of pr enatal dexameth asone and  or adult stress or GC 
treatment on OX-42-IR cells within the VTA. Stereological estimates of total OX-
42-IR cells within the VTA in adult (5.5 month) male (A,C,) and female (B,D,) animals 
as assessed by OX-42 immunohistochemistry. A and B indicate the effect of prenatal 
(GD16-19) DEX treatment and / or adult (3.5 month) stress (repeated restraint for 1 
hour every other day for 6 weeks). C and D depict the effects of prenatal DEX treatment 
and or adult GC treatment (hydrocortisone via the drinking water for 6 weeks) Data are 
expressed as means ± SEM. Statistical significance was assessed by two way ANOVA 
with tukeys post hoc comparison tests. *p<0.05, **p<0.01, ***p<0.001 vs controls, # vs 
DEX, + vs adult treatment. A: n=8 (control), 9 (DEX), 8(stress), 8 (DEX + stress). B: n= 
10 (control), 8 (DEX), 10 (stress), 10 (DEX + stress). C: n = 7 (control), 6 (DEX), 7 
(CORT), 5 (DEX + CORT). D: n=7 (control), 6 (DEX), 7 (CORT), 7 (DEX + CORT 
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Figure 4.5. Effect of pr enatal dexameth asone and  or adult stress or GC 
treatment on 3-NT-IR cells within the VTA. Stereological estimates of total 3-NT-
IR cells within the VTA in adult (5.5 month) male (A,C,) and female (B,D,) animals as 
assessed by 3-NT immunohistochemistry. A and B indicate the effect of prenatal 
(GD16-19) DEX treatment and / or adult (3.5 month) stress (repeated restraint for 1 
hour every other day for 6 weeks). C and D depict the effects of prenatal DEX treatment 
and or adult GC treatment (hydrocortisone via the drinking water for 6 weeks) Data are 
expressed as means ± SEM. Statistical significance was assessed by two way ANOVA 
with tukeys post hoc comparison tests. *p<0.05, **p<0.01, ***p<0.001 vs controls, # vs 
DEX, + vs adult treatment. A: n=8 (control), 9 (DEX), 8(stress), 8 (DEX + stress). B: n= 
10 (control), 8 (DEX), 10 (stress), 10 (DEX + stress). C: n = 7 (control), 6 (DEX), 7 
(CORT), 5 (DEX + CORT). D: n=7 (control), 6 (DEX), 7 (CORT), 7 (DEX + CORT). 
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Figure 4.6. Representative photomicrographs of TH (A), NeuN (B), OX-42 
(C) and G FAP (D) w ithin the VTA of control males.  Pictures taken at 200x 
magnification.  
 
 
 
 
 
 
 
 
 
 
 
A C
DB 
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Table 4.1. Effect of prenatal DEX and or adult stress or GC tre atment on DA 
levels within the NAcc. NAcc DA, DA metabolite and DA turnover were assesed by HPLC 
at 5.5 months of age. Male and female rats were treated prenatally with DEX via the maternal 
drinking water and were subjected to adult (3.5month) repeated restraint stress or GC treatment. 
Data are means ± SEM in ng/mg. DA turnover was calculated as the ratio of DA metabolites 
(DOPAC and HVA) to DA in pmol/mg. Statistical significance was assessed by two way anova 
with tukeys post hoc multiple comparison tests. *p<0.05, **p<0.01, ***p<0.001 vs controls, # 
vs DEX, + vs adult treatment. Study 1: Males: n=8 (control), 8 (DEX), 8(stress), 8 (DEX + 
stress). Females: n= 9 (control), 8 (DEX), 8 (stress), 8 (DEX + stress). Study 2: Males: n = 7 
(control), 6 (DEX), 7 (CORT), 5 (DEX + CORT). Females: n=7 (control), 6 (DEX), 7 (CORT), 
7 (DEX + CORT). 
 
DA, DOPAC and HVA levels (ng/mg) 
STUDY 1 CONTROL DEX STRESS DEX + STRESS 
Male Nucleus Accumbens 
DA 7.70 ± 0.64 8.21 ± 0.56 11.54 ± 1.00 ** 8.86 ± 0.67 
DOPAC 7.72 ± 0.85 7.65 ± 0.48 6.37 ± 0.47 6.59 ±0.42 
HVA 0.54 ± 0.04 0.50 ± 0.05 0.40 ± 0.03 0.44 ± 0.003 
Turnover 1.47 ± 0.18 1.15 ± 0.10 0.71 ± 0.10 *** 0.92 ± 0.08 * 
Female Nucleus Accumbens 
DA 14.41 ± 0.79 10.48 ± 0.95 * 7.72 ± 0.66 *** 8.08 ± 1.32 *** 
DOPAC 8.384 ± 0.23 7.69 ± 0.57 8.13 ± 0.57 8.46 ± 0.48 
HVA 0.62 ± 0.04 0.61 ± 0.05 0.64 ± 0.06 0.85 ± 0.07 * 
Turnover 0.72 ± 0.04 0.95 ± 0.13 1.40 ± 0.19 * 1.70 ± 0.38 * 
 STUDY 2 CONTROL DEX CORT DEX + CORT 
Male Nucleus Accumbens 
DA 5.52 ± 0.86 8.84 ± 0.72 * 8.93 ± 0.84 * 6.29 ± 0.62 
DOPAC 4.52 ± 0.67 4.03 ± 0.13 5.89 ± 0.98 5.98 ± 0.98 
HVA 0.67 ± 0.07 0.76 ± 0.05 0.86 ± 0.05 0.78 ± 0.04 
Turnover 1.79 ± 0.44 0.71 ± 0.09 1.16 ± 0.42 1.31 ± 0.16 
Female Nucleus Accumbens 
DA 11.78 ± 0.49 7.89 ± 0.37 *** 9.54 ± 0.67 * 7.15 ± 0.46 *** 
DOPAC 4.56 ± 0.59 5.10 ± 0.40 7.07 ± 0.69 * 5.20 ± 5.20 
HVA 1.05 ± 0.02 0.98 ± 0.04 1.14 ± 0.06 1.02 ± 0.05 
Turnover 0.54 ± 0.06 0.89 ± 0.07 * 1.03 ± 0.12 ** 1.03 ± 0.09 ** 
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Table 4.2. Effect of prenatal DEX and adult stress or GC treatment on DA levels  
within the PFC. PFC DA, DA metabolite and DA turnover were assesed by HPLC at 5.5 
months of age. Male and female rats were treated prenatally with DEX via the maternal drinking 
water and were subjected to adult (3.5month) repeated restraint stress or GC treatment. Data are 
means ± SEM in ng/mg. DA turnover was calculated as the ratio of DA metabolites (DOPAC 
and HVA) to DA in pmol/mg. Statistical significance was assessed by two way anova with 
tukeys post hoc multiple comparison tests. *p<0.05, **p<0.01, ***p<0.001 vs controls, # vs 
DEX, + vs adult treatment. Study 1: Males: n=8 (control), 8 (DEX), 8(stress), 8 (DEX + stress). 
Females: n= 9 (control), 8 (DEX), 8 (stress), 8 (DEX + stress). Study 2: Males: n = 7 (control), 
6 (DEX), 7 (CORT), 5 (DEX + CORT). Females: n=7 (control), 6 (DEX), 7 (CORT), 7 (DEX + 
CORT).
DA, DOPAC and HVA levels (ng/mg) 
 STUDY 1 CONTROL DEX STRESS DEX + 
STRESS 
Male Frontal Cortex 
DA 0.21 ± 0.03 0.15 ± 0.01 0.16 ± 0.008 0.18 ± 0.02 
DOPAC 0.06 ± 0.01 0.07 ± 0.008 0.06 ± 0.006 0.09 ± 0.02 
HVA 0.14 ± 0.009 0.16 ± 0.01 0.15 ± 0.009 0.17 ± 0.007 
Turnover 1.16 ± 0.09 1.67 ± 0.12 ** 1.46 ± 0.73 1.65 ± 0.11 ** 
Female Frontal Cortex 
DA 0.31 ± 0.05 0.22 ± 0.04 0.20 ± 0.03 0.15 ± 0.007 * 
DOPAC 0.14 ± 0.02 0.17 ± 0.05 0.10 ± 0.02 0.07 ± 0.008 *# 
HVA - - - - 
Turnover 0.54 ± 0.07 0.64 ± 0.05 0.59 ± 0.04 0.65 ± 0.09 
 STUDY 2 CONTROL DEX CORT DEX + CORT 
Male Frontal Cortex 
DA 0.10 ± 0.06 0.09 ± 0.12 0.06 ± 0.05 0.11 ± 0.04 
DOPAC 0.41 ± 0.08 0.47 ± 0.03 0.36 ± 0.02 0.50 ± 0.05 
HVA 0.04 ± 0.02 0.04 ± 0.003 0.03 ± 0.001 0.05 ± 0.009 
Turnover 8.30 ± 1.92 6.69 ± 0.70 7.77 ± 0.70 5.58 ± 1.98 
Female Frontal Cortex 
DA 4.03 ± 0.96 1.73 ± 0.70 2.42 ± 0.95 3.33 ± 1.36 
DOPAC 0.56 ± 0.07 0.56 ± 0.07 0.64 ±  0.10 0.74 ± 0.05 
HVA 0.29 ± 0.06 0.38 ± 0.05 0.43 ± 0.06 0.35 ± 0.04 
Turnover 0.39 ±  0.13 0.84 ± 0.18 0.86 ± 0.20 0.73 ± 0.18 
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4.3.2. 6-OHDA challenged MLDA and MCDA 
 
Controls: On combination of data from study 1 and study 2, administration of 5μg 6-
OHDA to the MFB resulted in a ~15% loss of VTA TH-IR cells in males (p<0.05) and 
~25% loss in females (p<0.01). The size of the lesion was calculated as a % loss in the 
lesioned versus unlesioned hemisphere (figure 4.8, 4.10). The sex difference previously 
reported in VTA TH-IR cell number (section 4.3.1) was lost in response to 6-OHDA 
lesioning. No significant difference in NeuN-IR cells within the VTA in response to 6-
OHDA was found in either sex (figure 4.9) but there was a concomitant fall in DA 
levels within the NAcc (Table 4.3/4.4). In the male, DA levels in the contralateral NAcc 
were 5.29 ± 0.51, which were reduced by ~25% to 3.92 ± 0.95 ng/mg in the ipsilateral 
NAcc (p<0.05; table 4.3). Similarily, in response to 6-OHDA there was a ~55% 
reduction in female NAcc DA (13.84 ± 0.71 versus 7.06 ± 1.29; p<0.01) Please note 
that there was only significant DA loss in the male on combination of the data sets - for 
individual study values see tables 4.3 and 4.4. In the adult male, 6-OHDA had no effect 
on DA metabolite levels or turnover but in the female 6-OHDA caused significant 
depletion of NAcc HVA (p<0.05). Within the PFC, 6-OHDA lesioning resulted in 
depletion of DA levels (p<0.05) in males but not females (Table 4.5).  There was no 
effect on GFAP-IR cells within VTA after 6-OHDA lesioning when compared to the 
contralateral hemisphere. However, there was more intense staining and a higher 
proportion of cells showing a reactive morphology in the VTA of the lesioned 
hemisphere.  In response to 6-OHDA we also observed microglial activation in the 
lateral portion of the VTA of the lesioned but not unlesioned hemisphere of both male 
and female rats. The number of OX-6-IR cells was 594 ± 67 and 586 ± 67 in males and 
females respectively. Minimal OX-6-IR cells were present in the contralateral VTA. 3-
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NT immunoreactivity within the VTA of lesioned rats was not significantly different to 
that of naïve rats.   
 
Repeated stress in 6-OHDA treated males: Previous exposure to repeated stress 
caused the TH-IR but not NeuN-IR 6-OHDA lesion to become significant (p<0.05; 
figure 4.7). In contrast to effects on TH, stressed males do not exhibit  significant NAcc 
DA depletion in response to 6-OHDA. In the adult male NAcc, repeated stress did not 
significantly affect DA or metabolite levels but did increase DA turnover in the 
contralateral NAcc (p<0.05; table 4.3). Stress had no effect on DA levels within the 
PFC of 6-OHDA treated males. Furthermore previous repeated stress did not alter 
GFAP immunoreactivity (Figure 4.11) of lesioned rats but did increase the number of 
OX-6-IR cells (Figure 4.12) in the VTA in response to a 6-OHDA lesion. These were 
primarily located in the area of VTA adjacent to the SNpc. In males the number of OX-
6-IR cells rose from 720 ± 94 to 1494 ± 153 (p<0.01; figure 4.12). There were no 
alterations in 3-NT-IR cells in stressed males subjected to 6-OHDA (Figure 4.13). 
 
Repeated stress in 6-OHDA treated females: In stressed females that were 
subjected to 6-OHDA there was no longer a significant TH lesion (Figure 4.7B). 
Repeated stress resulted in decreased DA levels (p<0.05) and DOPAC levels (p<0.001; 
Table 4.3) in the contralateral NAcc that were inline with the effects seen in naïve 
females but there was no effect on the ipsilateral hemisphere. Similarly within the PFC 
adult stress reduced DA levels in 6-OHDA females (p<0.05; table 4.5). As in males 
repeated stress resulted in an elevated number of OX-6-IR cells within the ipsilateral 
VTA (p<0.05; figure 4.12B) but had no effect on GFAP or 3-NT levels in the ipsilateral 
VTA of 6-OHDA treated females. 
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Chronic GC treatment in 6-OHDA treated males: In male 6-OHDA treated rats, 
a history of chronic GC treatment had no effect on TH-IR cell counts in the VTA of 
either hemisphere. Chronic GC treatment had no effect on  DA levels in either the 
ipsilateral or contralateral NAcc but did increased DOPAC and HVA levels in both 
(p<0.05; table 4.4). Dopamine turnover in the male NAcc was also increased but only 
significantly in the contralateral NAcc (p<0.05). In the male, chronic GC treatment 
resulted in increased DA (p<0.05) and HVA (p<0.01) levels within the PFC of 6-OHDA 
males (table 4.5). Similarly to repeated stress, chronic GC treatment resulted in a greater 
number of OX-6-IR cells in the VTA of 6-OHDA males (p<0.05; figure 4.12C) and 
females (although not significant P=0.0564; figure 4.12D) but didn’t affect the number 
of GFAP-IR cells (figure 4.11) 
 
Chronic GC treatment in 6-OHDA treated females: As with repeated stress 
previous chronic GC treatment eliminates the TH-IR lesion in female 6-OHDA rats 
(Figure 4.7D). In addition although DA levels were reduced in the contralateral 
hemisphere of female rats that had been treated with GCs (p<0.05), there was no longer 
significant DA depletion in the ipsilateral verus contralateral NAcc (table 4.5). DA 
metabolite levels and turnover in lesioned females were unaffected by a history of GC 
treatment. There was also a trend for reduced DA levels in the PFC of lesioned females 
that had received chronic GC treatment. Although this was not significant, there was a 
significant increase in DA turnover (Figure p<0.05; table 4.5). 
 
Prenatal DEX in 6-OHDA treated males: In 6-OHDA males that had received 
prenatal DEX treatment a significant TH-IR lesion within the VTA was seen in study 1 
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only (p<0.05; figure 4.7A,B). Prenatal DEX treatment did not significantly alter the 
number of TH-IR (Figure 4.7A,C) or NeuN-IR (Figure 4.9A,C) cells in the VTA of 
either hemisphere. The level of DA in both the ipsilateral and contralateral NAcc of 
animals treated with prenatal DEX was no different to that of the controls, and there was 
no significant hemispheric difference in NAcc DA levels (tables 4.3,4.4). DA 
metabolite levels and turnover within the adult NAcc of 6-OHDA rats were similarly 
unaffected by DEX. Within the PFC prenatal DEX increased DA turnover in 6-OHDA 
(DA and HVA levels were increased in study 1 only; table 4.5). In study 1 prenatal 
DEX decreased the number of GFAP-IR cells in the VTA of lesioned male rats but this 
wasn’t significant in study 2 (p<0.05, figure 4.11A,C). OX-6 and 3-NT-IR cell number 
were not altered by prenatal DEX in male 6-OHDA rats (Figure 4.12-4.13).  
 
Prenatal DEX in 6-OHDA treated females: In female 6-OHDA rats prenatal DEX 
treatment eliminated the lesion in TH-IR within the VTA (figure 4.7B,D). In study 2, 
prenatally DEX treated females had less DA in the contralateral NAcc compared to 
controls (p<0.05; tables 4.3, 4.4) which is comparable to the effect reported in section 
4.2.2 but did not impact upon DA levels in the ipsilateral NAcc (9.615 ± 1.38; 6.41 ± 
0.69; p<0.05) meaning that there was no longer significant DA loss as a result of 6-
OHDA lesioning . NAcc DOPAC levels of 6-OHDA rats were also decreased in DEX 
treated females in study 2 (p<0.05) but not significantly in study 1. Within the PFC of 
6-OHDA females prenatal DEX treatment increased DA turnover in study 1 only. 
Furthermore, DEX treatment did not alter GFAP-IR, OX-6-IR or 3-NT-IR within the 
VTA of female lesioned rats (Figures 4.11-13) 
. 
 
 185
Prenatal DEX in combination with adult treatment in 6-OHDA males: 
Prenatal DEX treatment in stressed or GC treated rats did not alter the effect of 6-
OHDA on TH-IR cells and NeuN-IR cells within the VTA. Interestingly, male rats that 
received both gestational DEX and repeated stress or chronic GC treatment in adulthood 
exhibit significantly less DA in the lesioned versus unlesioned hemisphere (p<0.05; 
table 4.3,4.4; figure 4.10 AC). In stressed males there was also significantly less DA in 
the NAcc of both hemispheres (p<0.05; tables 4.3,4.4) when compared to control males. 
In GC treated males there was less DA, DOPAC and HVA in the ipsilateral NAcc when 
compared to the contralateral NAcc (p<0.05; table 4.4) and in stressed males that had 
been exposed to gestational DEX there was decreased DA and DA turnover in the 
ipsilateral versus contralateral NAcc (p<0.05; table 4.3). Within the PFC prior DEX 
treatment didn’t alter the effect of stress or GC treatment on lesioned males.  
 
Prenatal DEX in combination with adult treatment in 6-OHDA females: In 
stressed females that had received DEX prenataly there was more significant fall in DA 
levels of the contralateral NAcc (p<0.01; table 4.3) and significant depletion of HVA 
(contralateral versus ipsilateral; p<0.05).   Comparably GC treated females that had a 
history of DEX treatment also showed a more significant reduction in DA levels of the 
unlesioned hemisphere (p<0.01; table 4.4). By contrast to males prenatal DEX treatment 
resulted in a significant fall in DA levels and an increase in HVA levels in 6-OHDA 
females (table 4.5).  There was also an interactive effect of DEX and repeated stress in 
lesioned females on GFAP-IR cells which were reduced in these animals (p<0.05; 
figure 4.11).  
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Figure 4.7. Effect of prenatal DEX treat ment and/or adult stress or GC treatment 
on TH-IR cells within the VTA follow ing 6-OHDA lesioning. Stereological estimates of 
the number of TH-IR cells within the VTA of male (A,C) and female (B,D) animals exposed to 
a 6-OHDA  were determined by TH immunohistocemistry. Measurements were made in 6 
month old animals, 2 weeks after exposure to 5μg 6-OHDA injected into the MFB. A and B 
indicate the effect of prenatal (GD16-19) DEX treatment and/or adult (3.5 month) stress 
(repeated restraint for 1 hour every other day for 6 weeks). C and D depict the effects of 
prenatal DEX treatment and or adult GC treatment (hydrocortisone via the drinking water for 6 
weeks). Data are expressed as means ± SEM. Statistical significance was assessed by two way 
ANOVA with tukey’s post hoc comparison tests *p<0.05, **p<0.01, ***p<0.001 vs controls, # 
vs unlesioned hemisphere. A: n=8 (control), 8(DEX), 8(stress), 7 (DEX + stress). B: n= 8 
(control), 8 (DEX), 8 (stress), 8  (DEX + stress). C: n = 7 (control), 7  (DEX), 7 (CORT), 
7(DEX + CORT). D: n=7 (control), 7 (DEX), 7 (CORT), 7 (DEX + CORT). 
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Figure 4.8. Effect of prenatal DEX treat ment and/or adult stress or GC treatment 
on percentage loss of TH-IR cells in the VTA follow ing 6-OHDA lesioning. The 
percentage loss of TH-IR cells in the lesioned VTA versus the unlesioned VTA in male (A,C) 
and female (B,D) animals exposed to a 6-OHDA. Measurements were made in 6 month old 
animals, 2 weeks after exposure to 5μg 6-OHDA injected into the MFB. A and B indicate the 
effects of prenatal (GD16-19) DEX treatment and/or adult (3.5 month) stress (repeated restraint 
for 1 hour every other day for 6 weeks). C and D depict the effects of prenatal DEX treatment 
and or adult GC treatment (hydrocortisone via the drinking water for 6 weeks). Data are 
expressed as means ± SEM. Statistical significance was assessed by two way ANOVA with 
tukey’s post hoc comparison tests *p<0.05, **p<0.01, ***p<0.001 vs controls, # vs DEX, + vs 
adult treatment. . A: n=8 (control), 8(DEX), 8(stress), 7 (DEX + stress). B: n= 8 (control), 8 
(DEX), 8 (stress), 8  (DEX + stress). C: n = 7 (control), 7  (DEX), 7 (CORT), 7(DEX + CORT). 
D: n=7 (control), 7 (DEX), 7 (CORT), 7 (DEX + CORT). 
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Figure 4.9. Effect of prenatal DEX treat ment and/or adult stress or GC treatment 
on NeuN-IR cells within the VTA following 6-OHDA lesioning. Stereological estimates 
of the number of NeuN-IR cells within the VTA of male (A,C) and female (B,D) animals 
exposed to a 6-OHDA  were determined by NeuN immunohistocemistry. Measurements were 
made in 6 month old animals, 2 weeks after exposure to 5μg 6-OHDA injected into the MFB. A 
and B indicate the effect of prenatal (GD16-19) DEX treatment and/or adult (3.5 month) stress 
(repeated restraint for 1 hour every other day for 6 weeks). C and D depict the effects of 
prenatal DEX treatment and or adult GC treatment (hydrocortisone via the drinking water for 6 
weeks). Data are expressed as means ± SEM. Statistical significance was assessed by two way 
ANOVA with tukey’s post hoc comparison tests *p<0.05, **p<0.01, ***p<0.001 vs controls, # 
vs DEX, + vs adult treatment. . A: n=8 (control), 8(DEX), 8(stress), 7 (DEX + stress). B: n= 8 
(control), 8 (DEX), 8 (stress), 8  (DEX + stress). C: n = 7 (control), 7  (DEX), 7 (CORT), 
7(DEX + CORT). D: n=7 (control), 7 (DEX), 7 (CORT), 7 (DEX + CORT). 
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NAcc DA, DOPAC and HVA in 6-OHDA lesioned animals 
  CONTROL DEX STRESS DEX + STRESS 
Right Left Right Left Right Left Right Left 
Male NAcc 
DA 5.45 ± 
1.06 
4.19 ± 
1.85 
5.20 ± 
1.42 
4.79 ± 
2.02 
3.99 ± 
0.59 
3.35 ± 
0.88 
2.81 ± 
0.54 * 
1.12 ± 
0.38 # 
DOPAC 4.91 ± 
0.75 
3.04 ± 
0.47 
3.30 ± 
0.42 
2.89 ± 
0.65 
6.18 ± 
0.87 
4.61 ± 
0.62 
4.17 ± 
0.47 
5.00 ± 
0.27 
HVA 0.51 ± 
0.20  
0.87 ± 
0.16 
0.75 ± 
0.20 
0.63 ± 
0.24 
0.90 ± 
0.10 
1.12 ± 
0.12 
0.50 ± 
0.17 
0.89 ± 
0.15 
Turnover 1.23 ± 
0.28 
1.03 ± 
0.59 
0.81 ± 
0.19 
0.78 ± 
0.44 
2.18 ± 
0.21 * 
1.99 ± 
0.32 
2.13 ± 
0.27* 
5.35 ± 
0.27 # 
Female NAcc 
DA 14.10 
±  
1.40 
7.25 ±  
2.11 # 
11.01 
±  2.30
6.26 ±  
1.14 
9.05 ±  
1.92 * 
7.11 ±  
2.38  
6.46 ±  
0.76 ** 
4.06 ±  
1.4 
DOPAC 5.11 ±  
0.61 
6.40 ±  
0.35 
4.29 ±  
0.15 
*** 
3.56 ±  
0.23 
3.76 ±  
0.45 
*** 
3.82 ±  
0.28 
3.69 ±  
0.37 *** 
3.68 ±  
0.42 
HVA 1.32 ±  
0.17 
0.73 ±  
0.12 # 
1.22 ±  
0.09 
1.64 ±  
0.29 
1.16 ±  
0.22 
0.99 ±  
0.21 
1.51 ±  
0.14 
0.93 ±  
0.25 
Turnover 0.65 ±  
0.09 
0.93 ±  
0.23 
0.59 ±  
0.09 
0.87 ±  
0.13 
0.82 ±  
0.19 
1.04 ±  
0.32 
0.85 ±  
0.2 
0.97 ±  
0.11 
 
 
Table 4.3. Effect of prenatal DEX and adult stress on NAcc DA levels in 6-OHDA 
unilaterally lesioned rats. NAcc DA, DA metabolite and DA turnover were assesed by HPLC 
at 6 months of age. Male and female rats were treated prenatally with DEX via the maternal 
drinking water and were subjected to adult (3.5month) repeated restraint stress. At 5.5 months 
rats received an injection of 5µg 6-OHDA to the left MFB. Data are means ± SEM in ng/mg. 
DA turnover was calculated as the ratio of DA metabolites to DA in pmol/mg. Statistical 
significance was assessed by three way anova with tukeys post hoc multiple comparison 
tests.*p<0.05, **p<0.01, ***p<0.001 vs controls, # vs unlesioned hemisphere. A: n=8 (control), 
8(DEX), 8(stress), 7 (DEX + stress). B: n= 8 (control), 8 (DEX), 8 (stress), 8  (DEX + stress). 
C: n = 7 (control), 7  (DEX), 7 (CORT), 7(DEX + CORT). D: n=7 (control), 7 (DEX), 7 
(CORT), 7 (DEX + CORT). 
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NAcc DA, DOPAC and HVA in 6-OHDA lesioned animals 
  CONTROL DEX CORT DEX + CORT 
Right Left Right Left Right Left Right Left 
Male NAcc 
DA 5.13 ± 
1.01 
3.65 ± 
1.93 
7.59 ± 
1.06 
6.93 ± 
0.55 
5.15 ± 
0.45 
4.35 ± 
1.09 
4.40 ± 
0.39 
1.39 ± 
0.70 # 
DOPAC 4.72 ± 
0.85 
2.48 ± 
0.57 
3.78 ± 
0.61 
3.60 ± 
0.55 
8.22 ± 
0.87 * 
6.01 ± 
0.45 * 
6.55 ± 
0.40 
3.09 ± 
0.80 # 
HVA 0.81 ± 
0.14 
0.42 ± 
0.17 
0.74 ± 
0.26 
0.81 ± 
0.20 
1.49 ± 
0.11 * 
1.20 ± 
0.09 * 
1.37 ± 
0.11 
0.61 ± 
0.20 # 
Turnover 1.33 ± 
0.19 
1.89 ± 
0.76 
0.80 ± 
0.17 
0.82 ± 
0.17 
2.55 ± 
0.32 * 
2.58 ± 
0.55 
2.02 ± 
0.06 * 
2.71 ± 
0.22 
Female NAcc 
DA 13.59 
± 1.64 
6.86 ± 
1.75 # 
8.22 ± 
1.54 * 
6.56 ± 
0.88 
9.86 ± 
1.14 * 
7.88 ± 
2.80 
6.93 ± 
0.56 ** 
4.11 ± 
1.27 
DOPAC 6.76 ± 
1.12 
5.05 ± 
0.88 
3.48 ± 
0.29 
3.97 ± 
0.52 
4.90 ± 
0.77 
3.84 ± 
0.45 
4.21 ± 
0.62 
3.89 ± 
0.38 
HVA 1.04 ± 
1.50 
0.72 ± 
0.13 # 
0.74 ± 
1.76 
1.06 ± 
1.64 
1.29 ± 
0.16 
1.05 ± 
0.26 
1.65 ± 
0.11 
0.97 ± 
0.24 # 
Turnover 0.66 ± 
0.09 
0.98 ± 
0.31 
0.59 ± 
0.09 
0.84 ± 
0.12 
0.82 ± 
0.19 
1.11 ± 
0.38 
0.98 ± 
0.13 
0.96 ± 
0.13 
 
Table 4.4. Effect of prenatal DEX and GC treatment on NAcc DA levels in 6-
OHDA unilaterally lesioned rats . NAcc DA, DA metabolite and DA turnover were 
assesed by HPLC at 6 months of age. Male and female rats were treated prenatally with 
DEX via the maternal drinking water and were subjected to adult (3.5month) chronic 
GC treatment. At 5.5 months rats received an injection of 5µg 6-OHDA to the left 
MFB. Data are means ± SEM in ng/mg. DA turnover was calculated as the ratio of DA 
metabolites to DA in pmol/mg. Statistical significance was assessed by three way anova 
with tukeys post hoc multiple comparison tests.*p<0.05, **p<0.01, ***p<0.001 vs 
controls, # vs unlesioned hemisphere. A: n=8 (control), 8(DEX), 8(stress), 8 (DEX + stress). 
B: n= 8 (control), 8 (DEX), 7 (stress), 8  (DEX + stress). C: n = 7 (control), 7  (DEX), 7 
(CORT), 67(DEX + CORT). D: n=7 (control), 7 (DEX), 7 (CORT), 7 (DEX + CORT). 
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PFC DA, DOPAC and HVA levels (ng/mg) in 6-OHDA lesioned rats 
  CONTROL DEX STRESS DEX + 
STRESS 
Male PFC 
DA 0.11 ± 0.02 0.08 ± 0.008 0.08 ± 0.007 0.09 ± 0.009 
DOPAC 0.03 ± 0.006 0.03 ± 0.004 0.03 ± 0.004 0.04 ± 0.005 
HVA 0.07 ± 0.003 0.07 ± 0.003 0.07 ± 0.002 0.08 ± 0.002 
Turnover 1.17 ± 0.09 1.67 ± 0.11 ** 1.46 ± 0.07 1.65 ± 0.11 ** 
Female PFC 
DA 0.40 ± 0.08 0.36 ± 0.11 0.20 ± 0.04  * 0.15 ± 0.01 * 
DOPAC 0.15 ± 0.02 0.20 ± 0.07 0.10 ± 0.03 0.07 ± 0.01 * 
HVA 0.01 ± 0.004 0.02 ± 0.008 0.004 ± 0.003 0.01 ± 0.006 
Turnover 0.54 ± 0.07 0.64 ± 0.05 0.59 ± 0.04 0.65 ± 0.09 
 
  CONTROL DEX CORT DEX + CORT 
Male PFC 
DA 0.02 ± 0.002 0.04 ± 0.006 * 0.07 ± 0.02 * 0.04 ±  0.01 * 
DOPAC 0.58 ±  0.07 0.45 ±  0.03 0.50 ± 0.03 0.45 ± 0.02 
HVA 0.02 ± 0.002 0.04 ± 0.004 * 0.05 ± 0.007 ** 0.03 ± 0.006 
Turnover 39.19 ± 8.90 15.58 ± 1.93 * 15.13 ± 2.37 * 14.66 ± 3.04 * 
Female PFC 
DA 4.26 ± 0.99 2.67 ± 1.07 2.68 ± 1.00 1.69 ± 0.30 * 
DOPAC 0.55 ± 0.04 0.64 ± 0.05 0.62 ± 0.06 0.55 ±  0.08 
HVA 0.15 ± 0.02 0.24 ± 0.03 0.23 ± 0.03 0.28 ± 0.03 * 
Turnover 0.25 ± 0.06 0.65 ± 0.16 * 0.52 ± 0.09 * 0.56 ±  0.15 
 
Table 4.5. Effect of prenatal DEX and or adult stress or GC treatment on PFC DA levels 
in 6-OHDA unilaterally lesioned rats. PFC DA, DA metabolite and DA turnover were assesed 
by HPLC at 6 months of age. Male and female rats were treated prenatally with DEX via the 
maternal drinking water and were subjected to adult (3.5month) repeated restraint stress or 
chronic GC treatment. At 5.5 months rats received an injection of 5µg 6-OHDA to the left 
MFB. Data are means ± SEM in ng/mg. DA turnover was calculated as the ratio of DA 
metabolites to DA in pmol/mg. Statistical significance was assessed by three way anova with 
tukeys post hoc multiple comparison tests.*p<0.05, **p<0.01, ***p<0.001 vs controls, # vs 
unlesioned hemisphere. A: n=8 (control), 8(DEX), 8(stress), 8 (DEX + stress). B: n= 8 (control), 
8 (DEX), 7 (stress), 8  (DEX + stress). C: n = 7 (control), 7  (DEX), 7 (CORT), 67(DEX + 
CORT). D: n=7 (control), 7 (DEX), 7 (CORT), 7 (DEX + CORT). 
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Figure 4.10. Effect of prenatal DEX treatment and/or adult stress or GC treatment 
on percentage NAcc  DA loss  fo llowing 6-OHDA lesi oning. NAcc DA loss in the 
lesioned versus unlesioned hemisphere in male (A,C) and female (B,D) animals exposed to a 6-
OHDA. Measurements were made in 6 month old animals, 2 weeks after exposure to 5μg 6-
OHDA injected into the MFB. A and B indicate the effects of prenatal (GD16-19) DEX 
treatment and / or adult (3.5 month) stress (repeated restraint for 1 hour every other day for 6 
weeks). C and D depict the effects of prenatal DEX treatment and/or adult GC treatment 
(hydrocortisone via the drinking water for 6 weeks). Data are expressed as means ± SEM. 
Statistical significance was assessed by two way ANOVA with tukey’s post hoc comparison 
tests *p<0.05, **p<0.01, ***p<0.001 vs controls, # vs DEX, + vs adult treatment. A: n=8 
(control), 8(DEX), 8(stress), 8 (DEX + stress). B: n= 8 (control), 8 (DEX), 7 (stress), 8  (DEX + 
stress). C: n = 7 (control), 7  (DEX), 7 (CORT), 67(DEX + CORT). D: n=7 (control), 7 (DEX), 
7 (CORT), 7 (DEX + CORT). 
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Figure 4.11. Effect of prenatal DEX treatment and/or adult stress or GC treatment 
on GFAP-IR cells within the VTA following 6-OHDA lesioning. Stereological estimates 
of the number of GFAP-IR cells within the ipsilateral VTA of male (A,C) and female (B,D) 
animals exposed to a 6-OHDA lesion  were determined by GFAP immunohistocemistry. 
Measurements were made in 6 month old animals, 2 weeks after exposure to 5μg 6-OHDA 
injected into the MFB. A and B indicate the effect of prenatal (GD16-19) DEX treatment and/or 
adult (3.5 month) stress (repeated restraint for 1 hour every other day for 6 weeks). C and D 
depict the effects of prenatal DEX treatment and or adult GC treatment (hydrocortisone via the 
drinking water for 6 weeks). Data are expressed as means ± SEM. Statistical significance was 
assessed by two way ANOVA with tukey’s post hoc comparison tests *p<0.05, **p<0.01, 
***p<0.001 vs controls, # vs DEX, + vs adult treatment. A: n=8 (control), 8(DEX), 8(stress), 7 
(DEX + stress). B: n= 8 (control), 8 (DEX), 8 (stress), 8  (DEX + stress). C: n = 7 (control), 7  
(DEX), 7 (CORT), 67(DEX + CORT). D: n=7 (control), 7 (DEX), 7 (CORT), 7 (DEX + 
CORT). 
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Figure 4.12. Effect of prenatal DEX treatment and/or adult stress or GC treatment 
on OX-6-IR cells within the VTA follow ing 6-OHDA lesioning. Stereological estimates 
of the number of OX-6-IR cells within the VTA of male (A,C) and female (B,D) animals 
exposed to a 6-OHDA  were determined by OX-6 immunohistocemistry. Measurements were 
made in 6 month old animals, 2 weeks after exposure to 5μg 6-OHDA injected into the MFB. A 
and B indicate the effect of prenatal (GD16-19) DEX treatment and/or adult (3.5 month) stress 
(repeated restraint for 1 hour every other day for 6 weeks). C and D depict the effects of 
prenatal DEX treatment and or adult GC treatment (hydrocortisone via the drinking water for 6 
weeks). Data are expressed as means ± SEM. Statistical significance was assessed by two way 
ANOVA with tukey’s post hoc comparison tests *p<0.05, **p<0.01, ***p<0.001 vs controls, # 
vs DEX, + vs adult treatment. A: n=8 (control), 8(DEX), 8(stress), 7 (DEX + stress). B: n= 8 
(control), 8 (DEX), 8 (stress), 8  (DEX + stress). C: n = 7 (control), 7  (DEX), 7 (CORT), 
67(DEX + CORT). D: n=7 (control), 7 (DEX), 7 (CORT), 7 (DEX + CORT). 
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Figure 4.13. Effect of prenatal DEX treatment and/or adult stress or GC treatment 
on 3-NT-IR cells within the VTA following 6-OHDA lesioning. Stereological estimates 
of the number of TH-IR cells within the VTA of male (A,C) and female (B,D) animals exposed 
to a 6-OHDA  were determined by 3-NT immunohistocemistry. Measurements were made in 6 
month old animals, 2 weeks after exposure to 5μg 6-OHDA injected into the MFB. A and B 
indicate the effect of prenatal (GD16-19) DEX treatment and/or adult (3.5 month) stress 
(repeated restraint for 1 hour every other day for 6 weeks). C and D depict the effects of 
prenatal DEX treatment and or adult GC treatment (hydrocortisone via the drinking water for 6 
weeks). Data are expressed as means ± SEM. Statistical significance was assessed by two way 
ANOVA with tukey’s post hoc comparison tests *p<0.05, **p<0.01, ***p<0.001 vs controls, # 
vs DEX, + vs adult treatment. A: n=8 (control), 8(DEX), 8(stress), 7 (DEX + stress). B: n= 8 
(control), 8 (DEX), 8 (stress), 8  (DEX + stress). C: n = 7 (control), 7  (DEX), 7 (CORT), 
67(DEX + CORT). D: n=7 (control), 7 (DEX), 7 (CORT), 7 (DEX + CORT). 
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4.4. DISCUSSION 
 
The data presented within this chapter demonstrate that stress and GC treatments exert 
persistent sexually dimorphic effects on the MLDA pathway. Significant emerging 
patterns include the ability of adult exposure to either repeated stress or chronic GC 
treatment to suppress DA content in the female NAcc but to enhance it in males. These 
changes appear not to be direct consequences of changes in the total numbers of DA 
neurons in the VTA, and not to be influenced by treatment-induced changes in the 
patterns of glial cell numbers in the VTA, which follow a similar trend in males and 
females. It is likely, therefore, that the MLDA pathway itself, as well as input pathways 
that regulate its activity, are targets for the actions of GCs and stress. Notably, prenatal 
DEX treatment eliminates the effect of adult stress and GCs on NAcc DA content in 
males, but not females. This indicates an important role for the MLDA in GC 
programming and adds to the evidence in the literature that programming is sexually 
dimorphic. The work also provides the first evidence that at the level of the NAcc, the 
MLDA system in females is considerably more susceptible to a neurodegenerative 
stimulus (6-OHDA) than males. Although the degenerative response of the male system 
appears resistant to stress or GC treatment in adulthood, both these factors exacerbate 
the loss of TH-IR cells in the VTA and NAcc DA in adult males previously exposed to 
DEX. In complete contrast, all treatments (DEX, stress, GCs, DEX + stress, DEX + 
GCs) suppress 6-OHDA-induced toxicity in the female NAcc. On balance, the MCDA 
system, as assessed by PFC DA levels, appears relatively unresponsive to treatments. 
Overall, these data add to the body of evidence supporting the premise that stress and 
GCs modify DA pathways and support the view that the effects of adult stress on 
MLDA are due, at least in part, to GCs. They also highlight novel interactive effects of 
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early life and adult treatments that could have implications for the development of 
neuropsychiatric disease. 
 
4.4.1 Adult treatments  
 
The effects of adult stress and GC exposure on the MLDA and MCDA have been 
widely studied and exert similar effects to that of drugs of abuse.  Microdialysis studies 
revealed that like acute exposure to drugs of abuse, acute exposure to stress increases 
extracellular DA within the ventral striatum of humans and that repeated stress or 
repeated drug exposure results in the sensitisation (Sorg and Kalivas, 1993) that 
underlies addiction. In the present study repeated stress in adult male rats increased the 
number of TH-IR, GFAP-IR and OX-42-IR cells in the VTA. Similarly, chronic drug 
exposure has previously been shown to produce increased TH and GFAP levels and 
reduced levels of neurofilament proteins in the VTA (Ortiz et al., 1995). A study by the 
same group later revealed that chronic unpredictable stress produced similar effects 
within the VTA (Ortiz et al., 1996).  In support of these findings the present data show 
that repeated restraint stress also produces a persistent elevation in DA levels and DA 
turnover in the NAcc suggesting that increases in the number of dopaminergic neurons 
results in elevated DA levels and activity in the male NAcc . 
 
Repeated exposure to stress enhances behavioural responses to subsequent stress but 
also to drugs of abuse (Robinson and Becker, 1986; Sorg and Kalivas, 1991; Stewart 
and Badiani, 1993) that are associated with augmented DA release in the NAcc 
(Doherty and Gratton, 1992). Cross sensitisation of stress and drugs of abuse is 
associated with their similar effects that are characterised by enhanced DA release in the 
NAcc, decreased DAT expression and reduced D3 receptor mRNA in the NAcc shell 
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(Kalivas and Stewart, 1991; Doherty and Gratton, 1992; Brake et al., 2004). Although 
acute drug abuse increases MLDA activity, repeated use followed by withdrawal down 
regulates MLDA activity resulting in reduced basal and stimulated DA levels (Di 
Chiara et al., 2004). This may be due to autoregulation whereby increased DA levels 
reduce DA neuron firing by increasing activation of somatodendritic autoreceptors. 
Interestingly these autoreceptors are not present on projections to the PFC.  
 
The study that examined the effects of chronic variable stress within the VTA also 
investigated the effects of chronic GC exposure and although this produced increases in 
TH, neither GFAP or neurofilament levels were altered (Ortiz et al., 1996). The present 
data do not indicate alterations in either GFAP-IR or TH-IR in response to chronic GC 
treatment suggesting that in this instance, mediators other than GCs may be involved in 
the effects of stress on the VTA.  Nevertheless, suppression of GCs by adrenalectomy 
resulted in reduced extracellular DA levels within the NAcc shell both basally and in 
response to psychostimulants (Piazza et al., 1996; Barrot et al., 2000). 
Adrenalectomised animals also show reduced psychomotor stimulant effects of cocaine 
(Marinelli et al., 1997) and amphetamine (Cador et al., 1993) which can be reversed by 
administration of corticosterone. In addition to these effects, the reinforcing effects of 
drugs of abuse, as measured by self administration, are reduced in situations of low GC 
levels (Goeders and Guerin, 1996). 
 
Chronic GC treatment also resulted in greater NAcc DA levels. Human studies have 
also reported that elevations in cortisol are correlated with DA accumulation within the 
ventral striatum (Oswald et al., 2005). Together these data imply that stress induced 
elevations of GCs result in increased DA levels and DA release that may increase the 
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reinforcing effects of drugs of abuse. This increase in NAcc DA content may be a result 
of changes in release, synthesis or metabolism. Drugs of abuse, stress and elevations in 
CRF and GCs have been shown to potentiate glutamate synapses on DA neurons within 
the VTA, enhancing the activity of DA neurons (Overton et al., 1996; Saal et al., 2003; 
Ungless et al., 2003; Wang et al., 2005). This activation of the MLDA by stress may 
represent a coping mechanism by which stress can increase motivation and drive. 
 
GC’s may impact on DA systems via their genomic actions through GR activation. GR 
is a transcriptional regulator that through binding to a GRE or interference with other 
transcription factors such as NF-kB, AP-1 or CREB can influence gene expression (De 
Bosscher et al., 2003). Promoter regions of genes encoding DA-synthesising enzymes, 
DA receptors and the DAT all have motifs for transcription factors such as AP-1 and 
CREB (Van Craenenbroeck et al., 2005). Additionally GCs could exert effects on DA 
systems via epigenetic mechanisms or non genomic actions.  
 
4.4.2 Prenatal DEX treatment  
 
Stressful experiences early in life are thought to predispose individuals to psychiatric 
disorders such as addiction, depression and schizophrenia which have been linked to 
dysfunction in the MLDA and MCDA pathways. Here we report that prenatal DEX 
exposure increased TH-IR and NeuN-IR within the adult male VTA, supporting 
previous findings by (McArthur et al., 2007a) but not (Leao et al., 2007) who report a 
reduced number of TH-IR cells in the adult VTA of prenatally DEX treated animals. 
These discrepancies may be due to the route of administration of DEX, which was via 
the maternal drinking water in the McArthur study and the present study but by sub 
cutaneous injection, which would cause additional stress to the mother in the Leao 
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study. Additionally the dose of DEX received in the Leao study was higher than in the 
McArthur study and the present study. Together however, these studies confirm that 
prenatal GCs are capable of exerting programming effects on the VTA that persist into 
adulthood, although this may depend upon the dose and method of administration. As 
extensive neurogenesis and cell death take place during development it is possible that 
alterations in GC levels during brain development may interfere with this delicate 
balance. Indeed, GCs are known to impact upon both neurogenesis and apoptosis 
(Sapolsky, 1996). However, further studies are required to determine how these 
processes are affected by GCs in the developing midbrain DA systems. In addition to 
their effects on cell survival, it is possible that GCs could affect other factors such as the 
nuclear orphan receptor nurr1. Nurr1 is present in 95% of TH-IR neurons within the 
VTA (Backman et al., 1999) and is essential for the development and survival of 
midbrain DA neurons (Vitalis et al., 2005). Intriguingly it has recently been determined 
that GR is a transcriptional regulator of nurr1 (Carpentier et al., 2008), thus activation of 
GR by the GR agonist DEX may modify the activity of nurr1 influencing the 
development and survival of DA neurons. DEX treatment not only affected neurons 
within the VTA but it also modified astrocyte and microglial populations. Within the 
adult male VTA the astrocyte population was reduced but the microglial population 
increased. These changes may alter the integrity of the MLDA and MCDA systems.  
 
In addition to alterations at the level of the VTA, levels of DA within the adult NAcc 
were increased in males that had received DEX prenatally. Although studies have not 
previously reported elevated basal levels of NAcc DA, there is compelling evidence to 
suggest that early life exposure to stressors is associated with an increase in activity 
within the MLDA. For example anoxia (Boksa and El-Khodor, 2003), maternal 
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separation (Meaney et al., 2002) and prenatal exposure to LPS (Fortier et al., 2004) all 
lead to increased DA release in response to stress or amphetamine. The fact that 
prenatal exposure to GCs also modifies the MLDA and MCDA systems implies that 
they may underlie the effects of stress early in life. Early life stress has been shown to 
alter DA receptor expression and decrease DAT availability later in life (Berger et al., 
2002) (Diaz et al., 1998) (Meaney et al., 2002). Reduced DAT expression may result in 
enhanced post-synaptic DA activity as less DA is cleared from the synapse.  
 
4.4.3 Prenatal DEX in combination with adult treatments: Curiously, 
preceding perinatal GC exposure attenuated DA levels in both stressed and GC treated 
adult male rats. This novel finding suggests that the male MLDA is susceptible to early 
life programming where it results in an altered response to an adult challenge in male 
animals. Early life exposure to stress and GCs results in an increased HPA response to 
stress (Plotsky and Meaney, 1993; Liu et al., 1998) and reduced negative feedback 
sensitivity (Ladd et al., 2000), thus one would expect prolonged elevation of GC levels 
in GC or stress treated rats that received DEX prenatally. As TH-IR was not altered in 
these animals it is possible that increases in DA release, possibly by excessive DA 
action on autoreceptors or increases in uptake, by alterations in DAT expression or 
function may underlie these changes. As there was no change in DA turnover and there 
is no evidence to suggest metabolising enzymes are under GC control (Lindley et al., 
2005) it is unlikely that the effects seen are due to altered metabolism of DA. Further 
studies are required to determine the mechanism behind this interactive effect. 
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4.4.4 Effect of stress and GC treatments on the MCDA 
 
The HPLC data presented within this chapter for PFC DA levels show some important 
inconsistencies which make it difficult to interpret the data unless these experiments are 
repeated. In particular female DA levels in study 2 look extremely high (Table 4.2 and 
4.5). Although we didn’t find a consistent effect on DA levels in the PFC, it has 
previously been shown that prenatal and postnatal stress result in decreased 
dopaminergic drive to the PFC (Brake et al., 2000). The PFC is dependent upon 
environmental experiences for maturation (Zhang et al., 2005b) thus is particularly 
susceptible to the effects of GCs. Previous studies have shown that early life stress 
results in increased synaptic densities within the PFC and altered densities of DA and 5-
HT terminals (Braun et al., 2000). In human studies child maltreatment as well as 
causing neuroendocrine changes also results in alterations in the size and volume of the 
PFC that correlate with the initiation of addictive behaviour (De Bellis et al., 2002).  
 
Chronic GCs exposure has been shown to cause structural changes within the PFC 
(Wellman, 2001) (Brown et al., 2005; Cerqueira et al., 2005) and it has been established 
that there is an increase in DA activity in the PFC in response to a variety of stressors 
(Gresch et al., 1994; Finlay et al., 1995; Cuadra et al., 1999; Cabib et al., 2002; Dalla et 
al., 2008). It has been proposed that this is an adaptive mechanism that results in 
inhibitory control of the NAcc. Our data did not show any effect of adult stress or GC 
treatment on PFC DA in naïve animals with the exception of increased DA turnover in 
DEX treated males.  
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4.4.5 Inflammation and neuropsychiatric disorders 
 
The HPA axis and immune axes are inextricably linked and there is bi-directional 
crosstalk between the two systems. Indeed, in depressed patients there is activation of 
the innate immune system as well as the presence of elevated GC levels (Herbert and 
Cohen, 1993; Maes, 1999). Immunologic alterations in depression occur as a result of 
an impaired balance of Th1 and Th2 inflammatory mediators both of which can be 
increased by circulating GC levels. Potentially activation of microglia may increase 
glutamate levels resulting in neurotoxicty. Importantly evidence of neurotoxicity has not 
yet been confirmed in depression. The present data show that both prenatal DEX 
treatment and adult stress result in an elevated number of microglial cells within the 
VTA of adult animals. This increased population of microglia may increase 
vulnerability to this proposed neurotoxic pathway. Additionally in DEX treated animals 
we consistently found a reduced population of astrocytes in adulthood. As astrocytes are 
responsible for mopping up excess glutamate (Danbolt, 2001) and promote neuronal 
survival via the release of growth factors, this reduction in astrocyte population may 
further endanger DA systems. Schizophrenia may also have an inflammatory 
component. It has been shown that there is a decreased production of Th1 cytokines 
such as IFN-gamma (Wilke et al., 1996; Muller et al., 2000). There is a 
neurodevelopmental risk for schizophrenia associated with obstetric complications and 
pre and post natal infections that has been suggested to be associated with glutamate 
excitotoxic damage within the fetal brain (Fearon 200; Farker 1995). Type-1 cytokines 
can result in stimulation of NMDA receptors through the accumulation of kynurenic 
acid that has been reported to be elevated in the PFC of patients with schizophrenia. 
Thus, a deficit in glutamate transmission may result in DA dysfunction and an 
uncontrolled flow of sensory information to the PFC resulting in psychotic problems 
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(Muller 2008). Alterations in HPA function as well as the altered populations of 
astrocytes and microglia that were seen in response to treatment could well contribute to 
immune dysfunction that in turn may contribute to the onset of disorders such as 
schizophrenia and depression. 
4.4.6 Sex differences 
 
Here we confirm previous reports of innate sex differences in the MLDA system where 
females have a higher number of dopaminergic neurons in the VTA and greater NAcc 
DA content. It is known that males and females have different susceptibilities to 
addictive behaviour and mood disorders (Simon and Volicer, 1976). They also differ in 
GC secretory profiles and in GC responses to stress (Patchev et al., 1997) as well as in 
hormonal and behavioural responses to prenatal stress (Bowman et al., 2004). It is 
perhaps therefore unsurprising that the effects of stress and GC treatments result in 
significantly different effects within the female rat MLDA and MCDA systems. Unlike 
McArthur et al., 2005, 2007a) we did not see an increase in adult TH-IR in the VTA of 
females exposed to prenatal DEX.  Interestingly in contrast to the elevated DA levels in 
the NAcc of male animals treated with prenatal DEX, levels of DA within the adult 
female NAcc were reduced in prenatally DEX treated animals. This reduction in DA 
was independent of changes in TH-IR in the VTA 
 
Human studies show that women are more vulnerable to addiction (for review see 
(Lynch et al., 2002). Furthermore animal studies show that female rats are more 
sensitive to the psychomotor activating effects of psychostimulants than males and 
show greater psychomotor sensitisation (Hu et al., 2003) . Evidence that estrogen is 
involved in this sex difference comes from studies demonstrating that ovariectomy 
attenuates amphetamine induced DA release and that estrogen agonists augment DA 
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release (Robinson et al., 1981; Xiao and Becker, 1998). The MLDA is also influenced 
by the stage of estrus. Becker and Cha (1989) showed that amphetamine induced DA 
release was higher during estrus than at any other stage of the cycle. Our finding of 
attenuated DA levels in response to stress or GC treatments contrasts significantly with 
their effect in males and appears to contradict these findings. However, DA activity as 
measured by DA turnover was increased in our female treatment groups. This increased 
DA activity in females and subsequent depletion of dopamine may result in an increased 
propensity to addictive behaviour, although this remains to be tested. 
 
The ability of prior DEX treatment to eliminate the effects of adult stress in males was 
not seen in females. This adds to the literature supporting the idea that programming 
effects are sexually dimorphic (Bale, 2009). If correct these effects may contribute to 
sex differences in prevalence of neurodevelopmental disorders. This is further supported 
by evidence in the MCDA system. Although data from the PFC is inconsistent there 
was decreased DA turnover within the PFC of DEX treated females that were subjected 
to stress in adulthood. This provides evidence that prenatal exposure to GCs endangers 
the female MCDA rendering it susceptible to adult stress, thus corroborates the idea that 
early life stress may predispose to depressive behaviour in adult females. It is possible 
that interactions between GC and sex hormone signalling may underlie this 
vulnerability, indeed estrogen has been shown to amplify stress induced PFC 
dysfunction in female rats (Shansky et al., 2004). Additionally, recent reports suggest 
that the male and female MCDA pathway have different proportions of DA neurons 
(Kritzer and Creutz, 2008). Again, it is possible that interplay between organisational 
hormones such as GCs and gonadal hormones may impact upon this during 
development resulting in a vulnerable phenotype. (Dalla et al., 2008) compared the 
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effects of two types of stress in males and females. They reported either a lack of, or 
reduced PFC DA activity in females compared to males. This would reduce inhibitory 
control of the NAcc thus resulting in a failure to cope that may be related to the higher 
prevalence of depression in females.  
4.4.7 6-OHDA model 
 
6-OHDA administered to the MFB resulted in a loss of TH-IR and depleted NAcc and 
PFC DA but to a lesser magnitude to that seen in the NSDA. Previous studies show that 
the VTA is less susceptible to degeneration than the SNpc (Matzuk and Saper, 1985; 
Sullivan and Szechtman, 1995) The lesion and subsequent DA loss in the female 
MLDA was greater than that in the male for both TH-IR cells and NAcc DA levels 
suggesting that the female MLDA is more susceptible to 6-OHDA neurotoxicity. 
Although prenatal DEX had no effect in males it was shown to be neuroprotective in the 
female MLDA in 6-OHDA treated rats. Similarly adult stress or GC treatment had little 
effect on DA or TH loss in males but attenuated them in females again suggesting that 
stress and GCs are neuroprotective in females. Interestingly DEX treatment exacerbated 
TH-IR loss in GC treated and DA loss in both stress and GC treated males. Within the 
contralateral hemisphere effects on TH-IR that were seen in naïve animals were lost 
whereas effects on NAcc DA levels were maintained in female but not male animals. 
This provides further evidence that effects on DA levels are independent of changes in 
neuronal numbers. Within the male contralateral NAcc, prenatal DEX treatment in 
combination with either adult treatment resulted in reduced DA content. This correlates 
with increased DA loss in these animals suggesting that prenatal DEX treatment can 
render the male MLDA susceptible to future insults. The effects of stress and GCs on 
the MLDA are largely comparable with the effects seen within the NSDA where stress 
and GCs are detrimental in males but protective in females. Furthermore sex differences 
 207
in susceptibility to 6-OHDA are unlikely due to changes in glial populations as stress 
and GC treatments produce similar effects on glia in males and females and these 
changes differ to those seen within the NSDA. 
 
4.4.8 Conclusions 
 
The data presented within this chapter adds to a wider body of evidence supporting 
crosstalk between steroids and neurotransmitter systems. Dopamine and stress related 
disorders are not always easy to study as they are multifactorial, involve complex 
pathways and often have both genetic and environmental components. Our data  support 
growing evidence that females display a differential response and adaptation to stress. 
Stressful experiences early in life predispose individuals to neuropsychaitric disorders 
such as addiction, schizophrenia and major depression. Here it is reported that the 
MLDA and MCDA systems are susceptible to sex-specific programming effects of 
GCs.  These alterations in the MLDA and MCDA systems that we report as a result of 
elevations of prenatal GC levels, improve our understanding of the effects of early life 
stress and GC exposure on the developing brain. Furthermore the data presented here 
along with earlier studies also provide evidence that adult stress and GC treatment can 
modify the MLDA and MCDA systems in a highly sexually dimorphic manner and that 
these modifications may result in sex differences in susceptibility to neuropsychiatric 
disorders such as depression and addiction later in life. In addition, as degeneration of 
these pathways occurs in PD they may well contribute to the development and the 
subsequent progression of a variety of neuropsychiatric disturbances that are present in 
PD patients.  
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CHAPTER 5 
The sex dependent effects of stress and 
glucocorticoids on non-dopaminergic pathways 
affected in Parkinson’s disease. 
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5.1 INTRODUCTION 
 
In addition to the degeneration of DA systems, other ascending neurotransmitter 
systems are affected in PD. The noradrenergic (LC), serotonergic (dorsal raphe nucleus; 
DRN) and cholinergic (NBM) systems are all affected to a varying degree in PD 
(Jellinger, 1999). Disturbances in cognition and mood that are present in PD patients 
may be a result of complex interactions of these neurotransmitter pathways. This 
chapter therefore aims to determine the effects of stress and GCs on these transmitter 
pathways with a view to their involvement in PD.  
 
5.1.1 Noradrenergic system 
The locus coeruleus (LC), is located on the dorsal wall of the rostral pons and is the 
principal site of NA synthesis in the brain, with extensive projections throughout the 
entire CNS. NA shares the same biosynthetic pathway as DA with DA being converted 
to NA by DβH. The LC mediates arousal and is highly sensitive to alerting or stressfull 
stimuli. Many brain regions involved in the stress response are innervated by the LC 
and mediate alertness, focus and cognition (Foote 1995). There are complex interactions 
between the CRH neurons of the PVN and the neurons of the LC. CRH acts as a 
neurotransmitter within the LC, which receives projections from the PVN (Rassnick et 
al., 1998). Conversely central NA stimulates CRH neurons within the PVN (Sawchenko 
and Swanson, 1982) and lesions of the LC decrease stress induced ACTH and CORT 
release (Maccari et al., 1990; Ziegler et al., 1999).  Thus it is thought that there is a 
positive feedback loop between the PVN and LC (Dunn et al., 2004). The LC also 
mediates autonomic effects during stress to increase sympathetic and decrease 
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parasympathetic outflow.  Disruptions in the LC have been associated with clinical 
depression, panic disorder and anxiety, where there is evidence for excessive NA 
activity (Young et al., 2005). 
 
The LC nearly always shows cell loss or lewy body inclusions (most often both) in PD 
patients (Forno et al., 1993) and there is evidence to suggest that neuronal loss in the LC 
may precede SN degeneration and even surpass it (German et al., 1992; Del Tredici et 
al., 2002; Braak et al., 2003; Zarow et al., 2003). The loss of NA innervation is also 
thought to facilitate the onset of dyskinesias in PD patients during DA replacement 
therapy (Fornai et al., 2007). Interestingly, PD patients with depression show more 
pronounced PD symptoms that can be alleviated by use of the NET (norepinephrine 
transporter) blocker reboxetine (Papapetropoulos et al., 2006; Pintor et al., 2006) again 
suggesting an involvement of NA in PD. Furthermore, α2 antagonists provide relief 
from L-dopa induced dyskinesias(Grondin et al., 2000; Archer and Fredriksson, 2003). 
NA neurons directly innervate both midbrain DA neurons and the striatum with 
stimulation of LC NA neurons facilitating the burst firing of SNpc neurons (Grenhoff et 
al., 1993). 
 
5.1.2 The Cholinergic system 
 
There are four groups of cholinergic neurons within the basal forebrain consisting of the 
medial septum, nucleus basalis of meynert (NBM), the vertical diagonal band and the 
horizontal diagonal band. The medial septum and vertical diagonal band form the 
medial pathway that innervates the hippocampus. The lateral pathway is composed of 
the horizontal diagonal band that innervates the olfactory bulb and the nucleus basalsis 
of meynert that innervates the neocortex and amygdale (Rye et al., 1984; Saper, 1984). 
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Cortical cholinergic transmission is involved in the mediation of arousal, attention and 
memory. Neurodegenerative diseases and age-related cognitive decline have partly been 
attributed to defects in cholinergic transmission (Bartus et al., 1982; Coyle et al., 1983; 
Kasa et al., 1997). For example during aging there is a loss of basal forebrain cells and 
cholinergic markers (Baxter et al., 1999). Cholinergic neurons have a large impact on 
cognitive processes (Myhrer, 2003) and a decreased activity of the cholinergic system 
can affect attention, learning, memory and contributes to the cognitive deficits observed 
in AD (McGaughy et al., 2000). 
 
Cholinergic degeneration and the presence of Lewy bodies in the NBM has also been 
identified in PD patients (Perry et al., 1985; Tiraboschi et al., 2000). Subsequently, a 
cholinergic deficit has been hypothesised to play a role in the development of dementia 
and psychosis in PD that occurs in 20-39% of patients. Indeed, the degree of cholinergic 
deficit is related to the severity of cognitive impairment in PD patients (Mattila et al., 
2001). 
 
5.1.3 Serotonergic system 
 
5-HT is synthesised by a small group of nuclei in the brain stem known as the raphe 
nuclei (Dahlstrom and Fuxe, 1964). These can be split into two groups: the inferior 
group that mainly project to the grey matter of the spinal cord and a superior group 
composed of the dorsal raphe nucleus (DRN) and medial raphe neucleus (MRN) which 
together provide about 80% of the 5-HT input to the forebrain. Although there is 
considerable overlap between the projection fields of these two nuclei the MRN 
preferentially innervates the hippocampus, preoptic area, suprachiasmatic nucleus, 
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olfactory bulb and medial septum with the DRN preferentially innervating the basal 
ganglia circuitry including the corpus striatum, globus pallidus, STN, SN, PPN, VTA, 
NAcc and most innervation to the PFC. Despite this discrete population of serotonergic 
nuclei there is an almost ubiquitous distribution of 5-HT containing terminals. There are 
7 classes of 5-HT receptor with 15 subtypes (Hoyer et al., 2002) leading to diverse 
effects of 5-HT signalling. 5-HT is known to play a role in the control of mood, 
emotion, sleep and appetite. 
 
Biochemical evidence suggests 5-HT transmission is abnormal in the basal ganglia of 
PD patients (Hornykiewicz, 1998) and is involved in the resting tremor (Doder et al., 
2003) and L-Dopa induced dyskinesias (Bezard et al., 2001; Carta et al., 2007). A loss 
of 5-HT cell bodies in the DRN of PD patients has been reported (find ref). Post-
mortem studies show that there is decreased 5-HT in the cortex and striatum (Scatton et 
al., 1983) (Birkmayer and Birkmayer, 1987) and a reduction in all 5-HT  markers in the 
caudate (Kish et al., 2008). In-vivo studies show that there is reduced 5-HIAA in csf 
and reduced 5-HT activity in the caudate, putamen, thalamus and mPFC of PD patients 
(Haapaniemi et al., 2001; Kim et al., 2003). 
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5.2 EXPERIMENTAL DESIGN 
In order to investigate the effects of stress and GCs on non dopaminergic 
neurotransmitter systems affected in PD we assessed the morphology of the LC and 
NBM using immunohistochemical markers for NA and ACh neurons. NA cell number 
within the LC was assessed using immunohistochemistry for DβH and NeuN along with 
stereological quantification techniques. The number of neurons within the NBM was 
similarly assessed by stereological quantification of cells immunoreactive for choline-
acetyl-transferase (ChAT) and NeuN. Furthermore the glial populations within these 
two regions were quantified by immunohistochemical identification of GFAP and OX-
42. 3-NT immunoreactivity was also assessed within both the LC and NBM. The effects 
of stress and GCs on neurotransmitter levels were also investigated. HPLC was used to 
determine the concentration of DA, 5-HT and the 5-HT metabolite 5-HIAA within the 
PFC, NAcc and striatum. Study 1 investigated the effects of prenatal treatment with 
DEX and/or adult repeated restraint stress and study 2 the effects of prenatal DEX 
and/or adult chronic GC treatment. For more detailed methodology see chapter 2.  
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5.3 RESULTS 
5.3.1 Noradrenergic system 
 
Innate sex differences: Female controls had a significantly greater number of DβH-
IR cells in the LC than male controls (487.7 ± 32.49 in males vs 641 ± 32.97 in females; 
p<0.01; Figure 5.1). The same was true for NeuN-IR cells where males had 1532 ± 66 
and females 1744 ± 61.4 (p<0.05) NeuN-IR cells within the LC (Figure 5.2). There was 
no significant effect of sex on GFAP, OX-42 or 3-NT immunoreactivities within the LC 
(Figures 5.3-5.5). Within the striatum and PFC levels of NA were higher in females 
than males (p<0.01 and p<0.001 respectively; Table 5.1, 5.3). There was no sex 
difference in NAcc NA levels (Table 5.2) 
 
Adult treatments: Adult repeated stress or adult chronic GC treatment had no effect 
on the NA system at the time point examined with the exception of a doubling of striatal 
NA in female rats subjected to adult GC treatment (p<0.05; Table 5.1), which was 
further increased 4-fold compared with controls after Dex (p<0.001; Table 5.1). 
 
Prenatal DEX treatment: Adult male and female rats that had received DEX 
treatment prenatally exhibited fewer DβH-IR cells than controls (Figure 5.1). In study 1 
the number of DβH cells was reduced by ~34% from 454.5 ± 48.2 to 298.8 ± 41.9 in 
males (p<0.05) and by 25% from 642.8 ± 47.9 to 480.0 ± 46.9 in females (p<0.05). 
Similarly in study 2 the number of cells in prenatally DEX treated rats compared to 
controls fell by ~35% in males (p<0.05) and ~22% in females (p<0.05) (Figure 5.2). 
DEX treated males also exhibited fewer NeuN-IR cells in the LC (-19%) in both study 1 
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and 2 (p<0.05). In the female, NeuN-IR cell number was reduced by 16% in the 
prenatal DEX group in study 1 (p<0.05) but this was not significant in study 2 (p=0.07). 
Prenatal DEX treatment reduced the number of GFAP-IR cells by ~26% in adult males 
and females (although this did not reach significance in study 1 males where p=0.09; 
Figure 5.3). However, prenatal DEX treatment had no effect on adult numbers of OX-
42-IR or 3-NT-IR cells within the LC and had no influence on NA levels in the 
projection areas studied. 
 
Prenatal DEX treatment in combination with adult treatments: Animals that 
were subjected to stress in adulthood and had received prenatal DEX treatment had a 
significantly lower number of DβH-IR LC cells compared to stressed or control groups 
in both males and females (p<0.05; Figure 5.1). In these animals the number of NeuN-
IR cells within the LC was no longer significant but in females was significantly lower 
than the group that received adult stress only (p<0.05; Figure 5.2). Males subjected to 
both prenatal DEX and adult GC treatment had a DβH-IR cell number not significantly 
different to controls but significantly lower than the GC treated group (p<0.05) whereas 
females had fewer DβH-IR cells compared to controls and the GC treated group 
(p<0.05). Both male and females subjected to prenatal DEX and adult GC treatment had 
fewer NeuN-IR cells in the LC (Figure 5.2). Interestingly, females exposed to the 
combination of prenatal DEX and adult GC treatment had greater levels of striatal NA 
when compared to controls or the GC treated group (P<0.001/p<0.05; Table 5.1).   
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Figure 5.1. Effect of prenatal dexamethasone and/or adult stress or GC treatment on 
DβH-IR cells within the LC. Stereological estimates of total DβH-IR cells within the LC 
in adult (5.5 month) male (A,C,) and female (B,D,) animals as assessed by DβH 
immunohistochemistry. A and B indicate the effect of prenatal (GD16-19) DEX 
treatment and/or adult (3.5 month) stress (repeated restraint for 1 hour every other day 
for 6 weeks). C and D depict the effects of prenatal DEX treatment and or adult GC 
treatment (hydrocortisone via the drinking water for 6 weeks) Data are expressed as 
means ± SEM. Statistical significance was assessed by two way ANOVA with tukeys 
post hoc comparison tests. *p<0.05, **p<0.01, ***p<0.001 vs controls, # vs DEX, + vs 
adult treatment. A: n=6 (control), 7 (DEX), 8(stress), 7 (DEX + stress). B: n= 7 (control), 8 
(DEX), 7 (stress), 8 (DEX + stress). C: n = 7 (control), 6 (DEX), 5 (CORT), 5 (DEX + CORT). 
D: n=7 (control), 6 (DEX), 6 (CORT), 7 (DEX + CORT). 
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Figure 5.2. Effect of prenatal dexamethasone and/or adult stress or GC treatment on 
NeuN-IR cells within the LC. Stereological estimates of total NeuN-IR cells within the 
LC in adult (5.5 month) male (A,C,) and female (B,D,) animals as assessed by NeuN 
immunohistochemistry. A and B indicate the effect of prenatal (GD16-19) DEX 
treatment and/or adult (3.5 month) stress (repeated restraint for 1 hour every other day 
for 6 weeks). C and D depict the effects of prenatal DEX treatment and or adult GC 
treatment (hydrocortisone via the drinking water for 6 weeks) Data are expressed as 
means ± SEM. Statistical significance was assessed by two way ANOVA with tukeys 
post hoc comparison tests. *p<0.05, **p<0.01, ***p<0.001 vs controls # vs DEX, + vs 
adult treatment. A: n=6 (control), 7 (DEX), 8(stress), 7 (DEX + stress). B: n= 7 (control), 8 
(DEX), 7 (stress), 8 (DEX + stress). C: n = 7 (control), 6 (DEX), 5 (CORT), 5 (DEX + CORT). 
D: n=7 (control), 6 (DEX), 6 (CORT), 7 (DEX + CORT). 
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Figure 5.3. Effect of prenatal dexamethasone and/or adult stress or GC treatment on 
GFAP-IR cells within the LC. Stereological estimates of total GFAP-IR cells within the 
LC in adult (5.5 month) male (A,C,) and female (B,D,) animals as assessed by GFAP 
immunohistochemistry. A and B indicate the effect of prenatal (GD16-19) DEX 
treatment and/or adult (3.5 month) stress (repeated restraint for 1 hour every other day 
for 6 weeks). C and D depict the effects of prenatal DEX treatment and or adult GC 
treatment (hydrocortisone via the drinking water for 6 weeks). Data are expressed as 
means ± SEM. Statistical significance was assessed by two way ANOVA with tukeys 
post hoc comparison tests. *p<0.05, **p<0.01, ***p<0.001 vs controls, # vs DEX, + vs 
adult treatment. A: n=6 (control), 7 (DEX), 8(stress), 7 (DEX + stress). B: n= 7 (control), 8 
(DEX), 7 (stress), 8 (DEX + stress). C: n = 7 (control), 6 (DEX), 5 (CORT), 5 (DEX + CORT). 
D: n=7 (control), 6 (DEX), 6 (CORT), 7 (DEX + CORT). 
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Figure 5.4. Effect of prenatal dexamethasone and/or adult stress or GC treatment on 
OX-42-IR cells within the LC. Stereological estimates of total OX-42-IR cells within the 
LC in adult (5.5 month) male (A,C,) and female (B,D,) animals as assessed by OX-42 
immunohistochemistry. A and B indicate the effect of prenatal (GD16-19) DEX 
treatment and/or adult (3.5 month) stress (repeated restraint for 1 hour every other day 
for 6 weeks). C and D depict the effects of prenatal DEX treatment and or adult GC 
treatment (hydrocortisone via the drinking water for 6 weeks). Data are expressed as 
means ± SEM. Statistical significance was assessed by two way ANOVA with tukeys 
post hoc comparison tests. *p<0.05, **p<0.01, ***p<0.001 vs controls, # vs DEX, + vs 
adult treatment. A: n=6 (control), 7 (DEX), 8(stress), 7 (DEX + stress). B: n= 7 (control), 8 
(DEX), 7 (stress), 8 (DEX + stress). C: n = 7 (control), 6 (DEX), 5 (CORT), 5 (DEX + CORT). 
D: n=7 (control), 6 (DEX), 6 (CORT), 7 (DEX + CORT). 
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Figure 5.5. Effect of prenatal dexamethasone and or adult stress or GC treatment on 3-
NT-IR cells within the LC. Stereological estimates of total DβH-IR cells within the LC in 
adult (5.5 month) male (A,C,) and female (B,D,) animals as assessed by DβH 
immunohistochemistry. A and B indicate the effect of prenatal (GD16-19) DEX 
treatment and / or adult (3.5 month) stress (repeated restraint for 1 hour every other 
day for 6 weeks). C and D depict the effects of prenatal DEX treatment and or adult GC 
treatment (hydrocortisone via the drinking water for 6 weeks) Data are expressed as 
means ± SEM. Statistical significance was assessed by two way ANOVA with tukeys 
post hoc comparison tests. *p<0.05, **p<0.01, ***p<0.001 vs controls #p<0.05 vs adult 
treatment.. A: n=6 (control), 7 (DEX), 8(stress), 7 (DEX + stress). B: n= 7 (control), 8 (DEX), 
7 (stress), 8 (DEX + stress). C: n = 7 (control), 6 (DEX), 5 (CORT), 5 (DEX + CORT). D: n=7 
(control), 6 (DEX), 6 (CORT), 7 (DEX + CORT). 
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Figure 5.6. Representative photomic rographs of immunohistochemical  
staining within the LC.  DβH in male control(A) and DEX treated(B) rats. GFAP in 
male control(C) and DEX treated(D) rats. OX-42(E) and 3-NT(F) in male controls. 
Images taken at x200 magnification.  
 
 
A 
E 
DC 
B
F
 222
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1 Effect of prenatal DEX an d/or adult repeated stress or GC 
treatment on NA levels within the striatum. Striatal NA was assesed by HPLC at 
5.5 months of age. Male and female rats were treated prenatally with DEX via the 
maternal drinking water and were subjected to adult (3.5month) repeated restraint stress 
or chronic GC treatment. Data are means ± SEM in ng/mg. Statistical significance was 
assessed by two way anova with tukeys post hoc multiple comparison tests. *p<0.05, 
**p<0.01, ***p<0.001 vs controls, # vs DEX, + vs adult treatment. Study 1 male: n=8 
(control), 9 (DEX), 8(stress), 8 (DEX + stress). Female:: n= 10 (control), 8 (DEX), 10 
(stress), 10 (DEX + stress). Study 2: male:: n = 7 (control), 6 (DEX), 7 (CORT), 5 
(DEX + CORT). Female: n=7 (control), 6 (DEX), 7 (CORT), 7 (DEX + CORT). 
 
 
0.18 ± 0.04 0.14 ± 0.03 0.26 ± 0.05 0.19 ± 0.02 NA 
Female 
0.12 ± 0.01 0.09 ± 0.007 0.11 ± 0.005 0.12 ± 0.01 NA 
Male 
DEX + 
STRESS 
STRESS DEXCON STUDY 1 
Adult striatal NA levels 
0.69 ± 0.12*** 0.36 ± 0.08 * 0.32 ± 0.04 0.17 ± 0.03 NA 
Female 
0.07 ± 0.01 0.08 ± 0.007 0.06 ± 0.009 0.09 ± 0.01  NA 
Male 
DEX + CORTCORTDEXCON STUDY 2 
Adult striatal NA levels 
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Table 5.2 Effect of prenatal DEX an d/or adult repeated stress or GC 
treatment on NA levels w ithin the NAcc. NAcc NA was assesed by HPLC at 5.5 
months of age. Male and female rats were treated prenatally with DEX via the maternal 
drinking water and were subjected to adult (3.5month) repeated restraint stress or 
chronic GC treatment. Data are means ± SEM in ng/mg. Statistical significance was 
assessed by two way anova with tukeys post hoc multiple comparison tests. *p<0.05, 
**p<0.01, ***p<0.001 vs controls, # vs DEX, + vs adult treatment. Study 1: male: n=8 
(control), 9 (DEX), 8(stress), 8 (DEX + stress). Female:: n= 10 (control), 8 (DEX), 10 
(stress), 10 (DEX + stress). Study 2: male:: n = 7 (control), 6 (DEX), 7 (CORT), 5 
(DEX + CORT). Female: n=7 (control), 6 (DEX), 7 (CORT), 7 (DEX + CORT). 
 
0.18 ± 0.04 0.14 ± 0.03 0.26 ± 0.05 0.17 ± 0.03 NA 
Female 
0.22 ± 0.01 0.22 ± 0.03 0.23 ± 0.02 0.22 ± 0.06 NA 
Male 
DEX + 
STRESS 
STRESS DEXCON STUDY 1 
Adult nucleus accumbens NA levels  
0.27 ± 0.04 0.31 ± 0.06 0.25 ± 0.02 0.21 ± 0.02 NA 
Female 
0.43 ± 0.11 0.19 ± 0.02 0.25 ± 0.06 0.33 ± 0.05 NA 
Male 
DEX + CORTCORTDEXCON STUDY 2 
Adult nucleus accumbens NA levels  
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Table 5.3 Effect of prenatal DEX an d/or adult repeated stress or GC 
treatment on NA levels with in the PFC. PFC NA was assesed by HPLC at 5.5 
months of age. Male and female rats were treated prenatally with DEX via the maternal 
drinking water and were subjected to adult (3.5month) repeated restraint stress or 
chronic GC treatment. Data are means ± SEM in ng/mg. Statistical significance was 
assessed by two way anova with tukeys post hoc multiple comparison tests. *p<0.05, 
**p<0.01, ***p<0.001 vs controls, # vs DEX, + vs adult treatment. Study 1: male: n=8 
(control), 9 (DEX), 8(stress), 8 (DEX + stress). Female:: n= 10 (control), 8 (DEX), 10 
(stress), 10 (DEX + stress). Study 2: male:: n = 7 (control), 6 (DEX), 7 (CORT), 5 
(DEX + CORT). Female: n=7 (control), 6 (DEX), 7 (CORT), 7 (DEX + CORT). 
 
 
0.76 ± 0.04 0.74 ± 0.77 ± 0.03 0.82 ± 0.02 NA 
Female 
0.69 v ± 0.009 0.77 ± 0.06 0.71 ± 0.04 0.61 ± 0.01 NA 
Male 
DEX + 
STRESS 
STRESS DEXCON STUDY 1 
Adult frontal cortex NA levels 
0.99 ± 0.05 0.94 ± 0.03 1.05 ± 0.02 1.10 ± 0.05 NA 
Female 
0.62 ± 0.05 0.70 ± 0.03 0.75 ± 0.11 0.58 ± 0.10 NA 
Male 
DEX + CORTCORTDEXCON STUDY 2 
Adult frontal cortex NA levels 
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5.3.2 Cholinergic system 
 
No sex differences were observed in the number of neurons or glia within the NBM. 
Furthermore, prenatal DEX treatment or adult exposure to repeated stress or chronic GC 
treatment had no effect on the morphology of the NBM in either sex. 
 
5.3.3 Serotinergic system 
 
Innate sex differences:  5-HT levels were significantly higher in control females 
than in males within the striatum (p<0.01/p<0.001; Table 5.4), NAcc (p<0.05/p<0.01; 
Table 5.5) and PFC (p<0.05; Table 5.6) with male 5-HT turnover significantly 
exceeding that of females within the NAcc (p<0.05/p<0.01; Table 5.5) and PFC 
(p<0.001; Table 5.6). 
 
Adult repeated stress: In the male repeated restraint stress in adulthood exerted no 
effect on the serotinergic system in the striatum or NAcc but increased 5-HT levels and 
reduced 5-HT turnover within the PFC (Table 5.6). In the female adult, stress increased 
5-HIAA levels (P<0.01) and 5-HT turnover (p<0.01) in the striatum (Table 5.4) and 
within the NAcc reduced 5-HT levels (p<0.05) and increased 5-HT turnover (p<0.05; 
Table 5.5). In contrast to the male, repeated stress reduced 5-HT (p<0.01) and elevated 
5-HT turnover (p<0.01) in the female PFC (Table 5.6).  
 
Adult chronic GC treatment: Adult treatment with hydrocortisone did not alter 5-
HT parameters in the male striatum or NAcc but reduced 5-HT turnover within the male 
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PFC (p<0.05). In females adult GC treatment increased 5-HIAA (p<0.001) and 5-HT 
turnover (p<0.05) in the striatum, elevated 5-HT turnover (p<0.05) in the NAcc and 
reduced 5-HT (p<0.01), increased 5-HIAA (p<0.01) and increased turnover (p<0.001) 
in the PFC. 
 
Prenatal DEX treatment: Prenatal DEX treatment did not affect 5-HT measures in 
the male striatum or NAcc but did increase 5-HT levels within the male PFC in study 1 
(p<0.05 vs control) which did not reach significance in study 2 (p=0.059; Table 5.6). 
However, prenatal DEX treatment reduced 5-HT turnover in the male PFC in both 
studies (p<0.01/p<0.001 vs control). Conversely, in females prenatal DEX treatment 
increased 5-HIAA levels (p<0.01 vs control – s1 only) and 5-HT (p<0.05/p<0.001) 
turnover within the striatum (Table 5.4). Within the female NAcc, prenatal DEX 
resulted in reduced 5-HT and 5-HIAA levels and increased 5-HT turnover (p<0.001) in 
study 2 (Table 5.5). These parameters were altered in a similar fashion in study 1 but 
did not reach significance. Interestingly and in contrast to the male prenatal DEX 
exerted no effect on 5-HT within the PFC. 
 
Prenatal DEX treatment in combination with adult treatments: Although 
prenatal DEX, adult repeated stress and chronic GC treatment exerted no effect on 
striatal 5-HT on their own, a history of prenatal DEX treatment resulted in increased 5-
HT turnover in male rats exposed to repeated stress (p<0.05) or chronic GCs (p<0.05) 
showing a significant interaction of the two treatments (insert stats). In the female, 
combination of prenatal DEX and adult stress had no interactive effect on 5-HT within 
the striatum. However, in females treated prenatally with DEX and then GCs in 
adulthood 5-HIAA levels (p<0.001) and 5-HT turnover (p<0.05) were significantly 
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attenuated . Within the NAcc and PFC there is no interaction between prenatal DEX and 
adult treatment in either se 
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Table 5.4 Effect of pre natal DEX and/or adult repeated stress or GC treatment on 
5-HT and 5-HIAA level s within the striatum. Striatal 5-HT, 5-HIAA and 5-HT turnover 
were assesed by HPLC at 5.5 months of age. Male and female rats were treated prenatally with 
DEX via the maternal drinking water and were subjected to adult (3.5month) repeaterestraint 
stress. Data are means ± SEM in ng/mg. DA turnover was calculated as the ratio of 5-HIAA to 
5-HT in pmol/mg. Statistical significance was assessed by two way anova with tukeys post hoc 
multiple comparison tests. *p<0.05, **p<0.01, ***p<0.001 vs controls, # vs DEX, + vs adult 
treatment. Study 1 male: n=8 (control), 9 (DEX), 8(stress), 8 (DEX + stress). Female:: n= 10 
(control), 8 (DEX), 10 (stress), 10 (DEX + stress). Study 2: male:: n = 7 (control), 6 (DEX), 7 
(CORT), 5 (DEX + CORT). Female: n=7 (control), 6 (DEX), 7 (CORT), 7 (DEX + CORT). 
 
 
1.63 ± 0.09 *1.82 ± 0.16 **1.56 ± 0.06 *1.27 ± 0.08Turnover
1.37 ± 0.09 *1.51 ± 0.07 **1.50 ± 0.04 **1.17 ± 0.045-HIAA
1.76 0.181.80 ± 0.201.97 ± 0.081.93 ± 0.115-HT
Female
1.98 ± 0.13 *1.61 ± 0.061.59 ± 0.041.58 ± 0.09Turnover
1.24 ± 0.040.99 ± 0.061.11 ± 0.051.08 ± 0.045-HIAA
1.32 ± 0.111.26 ± 0.101.41 ± 0.071.43 ± 0.105-HT
Male
DEX + 
STRESS
STRESS DEXCON STUDY 1 
Adult striatal 5-HT and 5-HIAA levels
1.76 ± 0.17 #2.09 ± 0.10 * 2.65 ± 0.12 1.661 ± 0.08Turnover
0.42 ± 0.02 #0.55 ± 0.01 *** 0.48 ± 0.020.42 ± 0.025-HIAA
0.55 ± 0.190.55 ± 0.10 0.40 ± 0.120.53 ± ± 0.14 5-HT 
Female
3.74 ± 1.72 *3.27 ± 1.21 2.10 ± 1.182.09 ± 0.91Turnover
0.42 ± 0.0390.34 ± 0.02 0.30 ± 0.030.36 ± 0.055-HIAA
0.33 ± 0.100.25 ± 0.04 0.34 ± 0.060.31 ± 0.04 5-HT 
Male
DEX + CORTCORT DEXCON STUDY 2 
Adult striatal 5-HT and 5-HIAA levels  
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Table 5.5 Effect of pre natal DEX and/or adult repeated stress or GC treatment on 
5-HT and 5-HIAA levels  within the NAcc. NAcc 5-HT, 5-HIAA and 5-HT turnover were 
assesed by HPLC at 5.5 months of age. Male and female rats were treated prenatally with DEX 
via the maternal drinking water and were subjected to adult (3.5month) repeaterestraint stress. 
Data are means ± SEM in ng/mg. DA turnover was calculated as the ratio of 5-HIAA to 5-HT in 
pmol/mg. Statistical significance was assessed by two way anova with tukeys post hoc multiple 
comparison tests. *p<0.05, **p<0.01, ***p<0.001 vs controls, # vs DEX, + vs adult treatment. . 
Study 1 male: n=8 (control), 9 (DEX), 8(stress), 8 (DEX + stress). Female:: n= 10 (control), 8 
(DEX), 10 (stress), 10 (DEX + stress). Study 2: male:: n = 7 (control), 6 (DEX), 7 (CORT), 5 
(DEX + CORT). Female: n=7 (control), 6 (DEX), 7 (CORT), 7 (DEX + CORT). 
 
7.15 ± 1.80 *6.01 ± 0.71 * 4.27 ± 0.65 3.40 ± 0.25Turnover
1.84 ± 0.101.74 ± 0.09 1.78 ± 0.041.79 ± 0.155-HIAA
0.74 ± 0.14 *0.64 ± 0.07 * 0.99 ± 0.181.13 ± 0.145-HT 
Female
3.24 ± 0.213.35 ± 0.64 3.54 ± 0.285.36 ± 1.13Turnover
1.35 ± 0.051.04 ± 0.05 1.41 ± 0.061.28 ± 0.245-HIAA
0.89 ± 0.060.85 ± 0.14 0.85 ± 0.080.69 ± 0.165-HT 
Male
DEX + 
STRESS 
STRESS DEXCON STUDY 1 
Adult nucleus accumbens 5-HT and 5-HIAA levels  
2.03 ± 0.10 *2.06 ± 0.11 * 2.37 ± 0.19 1.53 ± 0.08Turnover
0.42 ± 0.03 *0.55 ± 0.02 0.47 ± 0.01 *0.55 ± 0.025-HIAA
0.43 ± 0.02 ***0.56 ± 0.03 0.47 ± 0.08 **0.77 ± 0.065-HT 
Female
4.63 ± 0.354.40 ± 0.36 4.21 ± 0.253.62 ± 0.68Turnover
0.78 ± 0.040.86 ± 0.05 0.76 ± 0.050.67 ± 0.075-HIAA
0.35 ± 0.020.42 ± 0.03 0.38 ± 0.030.47 ± 0.075-HT 
Male
DEX + CORTCORT DEXCON STUDY 2 
Adult nucleus accumbens 5-HT and 5-HIAA levels  
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Table 5.6 Effect of pre natal DEX and/or adult repeated stress or GC treatment on 
5-HT and 5 -HIAA level s w ithin th e prefronta l cortex. PFC 5-HT, 5-HIAA and 5-HT 
turnover were assesed by HPLC at 5.5 months of age. Male and female rats were treated 
prenatally with DEX via the maternal drinking water and were subjected to adult (3.5month) 
repeaterestraint stress. Data are means ± SEM in ng/mg. DA turnover was calculated as the ratio 
of 5-HIAA to 5-HT in pmol/mg. Statistical significance was assessed by two way anova with 
tukeys post hoc multiple comparison tests. *p<0.05, **p<0.01, ***p<0.001 vs controls, # vs 
DEX, + vs adult treatment. Study 1 male: n=8 (control), 9 (DEX), 8(stress), 8 (DEX + stress). 
Female:: n= 10 (control), 8 (DEX), 10 (stress), 10 (DEX + stress). Study 2: male:: n = 7 
(control), 6 (DEX), 7 (CORT), 5 (DEX + CORT). Female: n=7 (control), 6 (DEX), 7 (CORT), 7 
(DEX + CORT). 
 
1.01 ± 0.10 **1.06 ± 0.08 ** 0.81 ± 0.120.60 ± 0.04 Turnover 
0.32 ± 0.010.33 ± 0.010.30 ± 0.02 0.28 ± 0.01 5-HIAA 
0.70 ± 0.05 *0.64 ± 0.05 ** 0.79 ± 0.060.92 ± 0.04 5-HT 
Female
1.15 ± 0.15 **1.03 ± 0.08 ** 0.84 ± 0.09 ***2.91 ± 0.21 Turnover 
0.44 ± 0.020.45 ± 0.020.38 ± 0.030.34 ± 0.04 5-HIAA 
0.85 ± 0.130.89 ± 0.07 * 0.91 ± 0.04 *0.48 ± 0.17 5-HT 
Male
DEX + 
STRESS 
STRESS DEXCON STUDY 1 
Adult frontal cortex 5-HT and 5-HIAA levels  
0.98 ± 0.09 **1.09 ± 0.09 *** 0.76 ± 0.040.62 ± 0.04 Turnover 
0.34 ± 0.02 **0.34 ± 0.01 ** 0.30 ± 0.010.25 ± 0.0095-HIAA 
0.70 ± 0.02 *0.64 ± 0.03 ** 0.81 ± 0.010.82 ± 0.04 5-HT 
Female
1.13 ± 0.15 *1.06 ± 0.08 * 0.85 ± 0.09 **1.58 ± 0.18 Turnover 
0.41 ± 0.030.42 ± 0.020.39 ± 0.050.37 ± 0.05 5-HIAA 
0.78 ± 0.070.81 ± 0.040.98 ± 0.150.47 ± 0.18 5-HT 
Male
DEX + CORTCORTDEXCON STUDY 2 
Adult frontal cortex 5-HT and 5-HIAA levels  
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5.4 DISCUSSION 
 
This chapter reveals some salient effects of stress and GC treatment, at different times 
in life, on non-dopaminergic systems. Notably, although the adult LC was largely 
resistant to adult stress or GC treatment, prenatal DEX treatment resulted in a dimished 
number of noradrenergic cells within both the adult male and female LC. Interestingly 
the adult astrocyte population was similarly reduced in this group of animals. In contrast 
the effects of stress and GCs on 5-HT neurotransmission were found to be sexually 
dimorphic. For example within the PFC, prenatal DEX treatment resulted in reduced 5-
HT activity in males but had no effect on females. Adult treatments also reduced 5-HT 
activity in males but in females 5-HT levels in the PFC were reduced and 5-HT activity 
increased. Serotonergic and noradrenergic pathways are altered in PD thus these data 
may have relevance to the hypothesis that stress and glucocorticoids may be involved in 
the development of PD. 
5.4.1 Noradrenergic system 
The present data are consistent with previous findings of sex differences within the LC 
NA system (Guillamon et al., 1988; Luque et al., 1992). It has been suggested that more 
apoptosis early in life in the male and an extended postpuberal neurogenetic period in 
the female are responsible for the sex difference in neuronal number within the LC 
(Pinos et al., 2001). Sex differences in the NA system have been implicated in the 
higher prevalence of depression in women . One could speculate that increased NA 
input to the NSDA may also contribute to reduced prevalence of PD and the resistance 
to NSDA toxins in females (see section 3.4.4). 
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This chapter presents the novel finding that prenatal DEX treatment in the last week of 
gestation permanently reduces the number of noradrenergic neurons within the LC of 
both male and female rats. The effect of prenatal GCs on LC neuronal number has not 
previously been explored, however studies of prenatal stress have shown that prenatally 
stressed rats have reduced NA content and turnover within the hippocampus and PFC 
(Takahashi et al., 1992; Muneoka et al., 1997) and exhibit increased anxiety and 
depressive behaviour in adulthood (Vallee et al., 1997) (Morley-Fletcher et al., 2003; 
Morley-Fletcher et al., 2004). Interestingly perinatal food restriction has also been 
found to reduce the number of LC neurons (Morgane et al., 1993; Pinos et al., 2004). As 
prenatal malnutrition has been shown to reduce placental 11βHSD2 activity and activate 
the maternal HPA axis, the developing fetus would be exposed to higher levels of 
maternal GCs (Langley-Evans et al., 1996). The present data thus support a role for GCs 
in the effects of prenatal malnutrition on LC neurons. GRs are present within the LC 
from E15 (Cintra et al., 1993) so DEX administered on GD16-19 could have a direct 
effect on developing neurons within the LC. Increased cell death during development 
may underlie the observed reduction in cell number however cell death does not 
underlie the decrease in LC neurons of malnourished rats (Pinos et al., 2004). It remains 
to be determined if apoptosis plays a role in the effect of GCs on the LC neuron 
population. An alternative possibility is that GCs may limit or slow neurogenesis within 
the developing LC. GCs influence both apoptosis and neurogenesis, however most work 
has been carried out on the hippocampus. GCs also have profound effects on sex 
hormone status as well as having a strong influence on the development of the rat LC 
(Guillamon et al., 1988; Pinos et al., 2001) thus GCs may indirectly act on the LC 
through changes in levels of sex hormones. In addition to neuronal loss there was also a 
decrease in the size of the astrocyte population in the LC in both sexes. This may occur 
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through similar mechanisms to those described above and could possibly contribute to 
neuronal loss, due to a lack of neurotrophic support. Prenatal DEX treatment didn’t alter 
NA levels in projection areas therefore one could assume that despite the neuronal 
deficit the adult noradrenergic system is able to function normally. Further studies 
examining the activation and firing of LC neurons and NA turnover would be necessary 
to confirm this.  
 
Adult repeated stress or GC treatment largely did not produce persistent effects on the 
noradrenergic system. However, in females exposed to chronic GCs in adulthood an 
increase in striatal NA was observed. Whereas stress would result in activation of LC 
neurons due to excitatory input from the PVN, chronic GCs would not elicit the same 
effect. Essentially, GCs would decrease PVN activity through GC negative feedback 
leading to reduced activation of LC neurons and reduced NA release in projection areas. 
Since this is in contrast to the rise in striatal NA observed it may be that GCs are having 
a direct effect on noradrenergic transmission. GCs can alter the transcription of TH, 
DβH and the NAtransporter (NET) (references) that might alter levels of NA within the 
striatum. Intriguingly, there is evidence that NA has neuroprotective actions within the 
NSDA (Fornai et al., 2005; Pintor et al., 2006) thus an increase in striatal NA in GC 
treated females may be responsible for the neuroprotection observed in these animals in 
response to 6-OHDA (chapter 3). NA is critical for the firing of NSDA neurons and the 
striatal release of DA (Rousselet et al., 2003). Furthermore NA has anti-inflammatory 
(Feinstein et al., 2002) and anti-oxidant properties (Liu et al., 2003) and NA neurons 
can release neuroprotective modulators such as galanin and BDNF (Xu et al., 1998) 
Conner 1997; Elliott-hunt 2004; sun 2004). Moreover, depression is associated with 
dysregulation of the NA system and elevated levels of NA (Frazer, 2000) thus this data 
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provides further evidence that increased GC levels may be responsible for an increased 
risk of depression in females. The fact that increased striatal NA in GC treated females 
was potentiated if they had been exposed to prenatal DEX suggests that prenatal GCs 
may sensitise the female NA system to the effects of adult GCs. 
 
5.4.2 Cholinergic system 
Although we found no effect of stress or GCs on the NBM, there is evidence to suggest 
that that stress and GCs can alter cholinergic neurotransmission. Repeated restraint 
stress has previously been shown to reduce acetylcholinesterase activity (Kaufer et al., 
1998), presumably increasing levels of ACh within the cortex, which wasn’t measured 
in the present study. Indeed, handling stress increases the extracellular concentration of 
ACh within the PFC which can be reversed by environmental enrichment (Segovia et 
al., 2008). GRs are present within the NBM and PFC (Cintra et al., 1994; Morimoto et 
al., 1996) and GR mediated transactivation can result n the manipulation of signalling 
pathways involved in cholinergic transmission (Maroder et al., 1993) (Nordeen et al., 
1994). This evidence suggests that it is likely that our treatment regimes may have 
altered functioning of the cholinergic system that wasn’t assessed in the present study. 
Interestingly high or low levels of chronic corticosterone administration in 
adrenalectomised rats result in increased susceptibility to NMDA induced 
neurodegeneration within the NBM via a GR mediated mechanism (Abraham et al., 
2000) thus although we didn’t observe an effect on neuron number within the NBM, 
stress or GC treatment may render the NBM more vulnerable to further insults. 
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Prenatal DEX exposure has previously been shown to impair spatial learning and 
memory in rats (Brabham et al., 2000) (Rayburn et al., 1997; Welberg et al., 2001), 
functions that are associated with cortical cholinergic transmission. Moreover, school 
age children that were treated prenatally with DEX have a lower IQ (Yeh et al., 2004). 
Prenatal DEX treatment can render cholinergic neurons vulnerable to challenge with 
prenatally DEX treated animals exhibiting a larger lesion in response to the 
immunotoxin 192IgG-saporin. Postnatal handling also results in a higher loss of ChAT 
neurons in the NBM in response to an NMDA excitotoxic lesion (Horvath 2004). In the 
present study prenatal DEX treatment did not alter the effects of an adult insult 
(repeated stress or chronic GC treatment) on the NBM.  
 
5.4.3 Serotinergic system 
There are numerous reports of sex differences in 5-HT neurotransmission (Cosgrove et 
al., 2007). In general, females have higher levels of 5-HT than men (Ortiz et al., 1988) 
and have higher levels of the 5-HT transporter (SERT) (Staley et al., 2001). On the 
other hand men synthesise 5-HT faster than women (Kessler et al., 1991). In line with 
these findings the present data show females have greater levels of 5-HT in all three of 
the regions examined with males showing greater 5-HT activity in the NAcc and PFC. It 
is thought that sex differences within the brain can be attributed to the effects of sex 
hormones, both during development and in adulthood. Indeed estrogen is known to 
modulate the serotinergic system by increasing the density of 5-HT receptors and SERT 
(Fink et al., 1998).   
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Serotonin in detectable in the rat brain from E13 and plays a trophic role in neuronal 
development (Wallace and Lauder, 1983) thus prenatal exposure to synthetic GCs may 
act upon the developing serotinergic system. Prenatal DEX treatment did not affect 
male striatal or NAcc 5-HT measures but reduced 5-HT activity within the male PFC. 
Reduced 5-HT activity, as indicated by a reduction in 5-HT turnover has previously 
been detected in cortex, hippocampus, hypothalamus and midbrain of neonates exposed 
to DEX during the last week of gestation (Muneoka et al., 1997). This study 
demonstrates that for at least the PFC this effect is maintained into adulthood. 
Furthermore, prenatal GCs can reduce SERT mRNA expression in the postnatal male 
rat brain (Fumagalli et al., 1996) (Slotkin et al., 1996). By contrast prenatal DEX 
increases 5-HT activity in the NAcc and striatum of females but has no effect on the 
PFC. These findings further highlight the sexually dimorphic response of the brain to 
GC programming. Further evidence for sex differences in the GC programming  of the 
5-HT system is provided by evidence that that prenatal GCs exert sexually dimorphic 
effects on SERT expression within the DRN and MRN (Andrews and Matthews, 2004). 
Neonatal handling that permanently reduces the HPA axis response to stress due to 
increased maternal care (Smythe et al., 1994) (Liu et al., 1997) (opposite effect of 
prenatal GCs) has been shown to increase 5-HT and turonover within the hippocampus 
(Smythe et al., 1994) resulting in upregulation of GR within the hippocampus. However 
this increase in 5-HT did not persist into adulthood (Smythe et al., 1994). 
 
Similar to the effects of prenatal DEX, adult stress or GC treatment do not affect 5-HT 
measures within the striatum or NAcc but reduce 5-HT activity in the PFC. Conversely 
in the female adult stress or GC treatment potentiates 5-HT activity in all three regions. 
It is well known that there is significant interplay between the serotinergic system and 
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the HPA axis. For example the loss of 5-HT terminals potentiates stress induced 
elevations of cort (Richardson, 1984), 5-HT agonists elevate ACTH and cort levels 
(Wetzler et al., 1996) (Klaassen et al., 2002) and increased 5-HT activity can result in 
upregulation of GRs within the hippocampus (Smythe et al., 1994). Conversely, in 
response to stress there is an increase in DRN activity as indicated by elevated c-fos 
expression (Greenwood et al., 2003) and an increased release of 5-HT in projection 
areas (Bland et al., 2003; Amat et al., 2005). Corticosterone has a stimulatory effect on 
tryptophan hydroxylase activity (Singh et al., 1990) the rate limiting enzyme in 5-HT 
synthesis. However, chronic stress or GC treatment reduces 5-HT levels as well as 
reducing 5-HT1A receptor expression and binding (Mendelson and McEwen, 1991; 
Crayton et al., 1996) (Luine et al., 1993). Furthermore the transcription of 5-HT1A 
receptors is negatively regulated by glucocorticoids (Meijer et al., 1997; Ou et al., 
2001). The present data suggest that repeated stress produces region and sex specific 
effects on 5-HT neurotransmission that are likely mediated by GCs. 
 
Interestingly several effects of prenatal DEX on adult treatments were seen in the 
striatum whereby prior DEX treatment altered the response to adult insult by increasing 
5-HT turnover in males. Furthermore, in the female prenatal DEX altered the adult 
response to GC treatment, but not stress, by attenuating 5-HT activity. These findings 
suggest a sensitivity of the striatum to the programming effects of DEX and that there is 
an altered 5-HT response to stress and GCs in DEX treated animals. Interestingly these 
effects are strikingly sexually dimorphic and may underlie sex differences in 
susceptibility to disease states associated with the serotinergic system. 
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Reduced 5-HT levels are associated with an increased risk of depression (van Praag and 
de Haan, 1979) which has a 25-40% comorbidity with PD {Leentjens, 2004 #726}. 
Furthermore, altered 5-HT transmission may also influence cognitive symptoms such as 
memory consolidation (Schmitt et al., 2000). Moreover, in addition to its influence on 
the non-motor symptoms of PD, 5-HT can also influence dopaminergic 
neurotransmission within the basal ganglia. It is generally thought that 5-HT has an 
inhibitory effect on striatal DA release, however different receptor subtypes can 
differentially influence DA release (Lucas et al., 2000). Stimulation of 5-HT1A receptors 
increases locomotor activity (Mignon and Wolf, 2002) and has a neuroprotective effect 
in the 6-OHDA rat (Matsubara et al., 2006). Importantly 5-HT may not directly 
influence DA neurons but may modulate glutamate neurons, reducing glutamatergic 
drive to the STN or striatum, ultimately resulting in disinhibition of the 
thalamus(Mignon and Wolf, 2007) or may interact with cholinergic interneurons that 
have inhibitory control over striatal MSN’s (Pakhotin and Bracci, 2007). Indeed 5-HT 
action at 5-HT2c receptors increases activity of cholinergic interneurons (Blomeley and 
Bracci, 2005). 
 
5.4.4 Summary 
The present chapter provides confirmation of previous findings of innate sex differences 
within neurotransmitter systems. Importantly the data present compelling evidence that 
prenatal DEX treatment alters the development of the LC, resulting in a reduced neuron 
and astrocyte population in adulthood that may have important implications for the 
adult stress response. As an adult, chronic GC treatment but not repeated stress resulted 
in elevated levels of NA within the female but not male striatum that was potentiated by 
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prior DEX treatment. Stress and GCs also produced wide ranging effects on 
serotonergic neurotransmission that were region and sex specific. Prenatal DEX reduced 
5-HT activity (turnover) in the adult male PFC but increased activity in the female 
NAcc and striatum. Adult treatments reduced 5-HT activity in the adult male PFC but 
increased 5-HT activity in the female PFC, NAcc and striatum. By contrast the NBM 
was insensitive to stress and GC treatments. Modulation of these neurotransmitter 
systems in response to stress and GCs may affect the development of both motor (via 
interactions with the DA system) and non motor symptoms of PD. 
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CHAPTER 6 
Discussion 
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6.1 Summary of main findings 
 
The data presented within this thesis provides confirmation that stress and GC treatment 
at different times in life are capable of producing persistent changes within brain 
regions that are known to degenerate in PD. Furthermore, novel evidence illustrating 
that stress or GC treatment can sex dependently potentiate neurotoxicty in an animal 
model of PD is presented. The principal findings of this study are as follows: 
 
 Confirmation of previous reports that prenatal DEX treatment exerts long term 
changes in midbrain DA pathways. 
 Prenatal DEX treatment consistently reduces the number of noradrenergic 
neurons within the adult LC.  
 Prenatal DEX treatment results in persistent changes in glial populations largely 
by increasing microglial numbers and reducing astrocyte numbers in DA and 
NA nuclei.  
 Adult stress and chronic GC treatment exert differential sex and region specific 
changes in neuron and glial populations.  
 Adult stress and chronic GC treatment elevate levels of nitrosative stress in the 
male NSDA. 
 The highly novel finding that exposure to prenatal DEX treatment results in an 
altered response to adult challenge within the male midbrain DA pathways, 
whereby the number of SNpc neurons and striatal and NAcc DA levels are 
attenuated. 
 Adult repeated stress or chronic GC treatment exacerbates neuron loss and the 
neurochemical deficit in the 6-OHDA rat model of PD in males but affords 
neuroprotection in females. 
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 Prenatal DEX does not alter susceptibility to 6-OHDA within the NSDA. 
However, in the male MLDA where 6-OHDA did not produce a significant 
lesion in males exposed to a single treatment - males treated prenatally with 
DEX who went on to receive either stress or GC treatment as adults did exhibit a 
significant lesion. This provides further evidence for a programming effect of 
prenatal DEX on the DA midbrain resulting in a vulnerable phenotype.   
 Sex differences in the unchallenged brain as well as in the effects of stress and 
GCs are repeatedly reported highlighting the importance of sex within this area 
of research.  
 
6.2 Methodological considerations 
 
This thesis provides significant evidence that stress and exposure to elevated levels of 
GC hormones have the potential to affect PD pathogenesis. The use of an in-vivo PD 
model is suggestive of significant clinical relevance to the human condition. 
Unfortunately there is currently no animal model of PD that recapitulates all features of 
the human disease. Despite this they do provide us with useful insights into the possible 
pathogenesis of PD (section 1.1.12). In the present study a rat model of PD was created 
by unilateral injection of 6-OHDA to the MFB. This regime was used as preliminary 
data (section 2.1.7) showed that it produced a partial lesion of the NSDA that would 
allow the determination of any detrimental or protective effects of treatment regimes on 
lesion size, as well as providing an internal control. Importantly, the 6-OHDA model 
was chosen as the lesions produced are highly reproducible. Based on the present 
findings and those of others in future studies it may be useful to use a model that is 
firstly more progressive so that the effects of stress and GCs and stress on disease 
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progression can be assessed. For example stress and GCs have recently been shown to 
accelerate neuron loss in a 6-OHDA model (Metz, 2007) and data from PD patients 
report that stress worsens PD symptoms (Macht et al., 2005). Unfortunately the 6-
OHDA model is relatively acute, although there is some evidence to suggest that 
degeneration is progressive (Marinova-Mutafchieva et al., 2009) it is likely maximal at 
the time point used in this study (2 weeks post lesion). Secondly, in light of the findings 
that stress and GCs alter not only DA pathways but also NA and 5-HT pathways, a 
model that recapitulates the multi-system degeneration observed in PD, would be 
especially useful. The proteosome inhibitor model of PD would be a highly attractive 
model for further study of the effects of stress and GCs on brain regions implicated in 
PD as not only does it elicit neurodegeneration in non-dopaminergic pathways but also 
exhibits protein aggregates  - a key feature of the human disease. However there is still 
considerable controversy around the use of this model with some groups reporting that 
there is no lesion at all. As we did not predict that stress or GC exposure would elicit 
such a striking effect on the size of the 6-OHDA lesion behavioural testing was not 
employed. In the future this would enable further characterisation of the effects of stress 
and GC’s on the model.  The large lesion produced in males that had received adult 
restraint stress or adult hydrocortisone treatment may also have prevented any additive 
effects of prenatal DEX treatment from being detected. Indeed an effect of DEX in 
combination with adult stress or GCs did further endanger the MLDA system where 
there was a much smaller lesion size, owing to the MLDA being less susceptible to 6-
OHDA induced neurotoxicity. A lower dose or altered delivery of 6-OHDA may enable 
interactive effects of treatments to be identified more clearly.   
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As discussed in previous chapters one can not conclude that the effects of stress and the 
effects of GC treatments are one and the same as the two paradigms employed involve 
activation of different pathways and have a different severity. Importantly the HPA axis 
is suppressed in GC treated animals therefore CRF or ACTH may be involved in their 
differential effects. Furthermore animals are able to habituate to repeated stress. The 
daily rhythm of CORT secretion is also known to be disrupted in the GC treated group 
(Magarinos et al., 1998). Although many similarities between their effects have been 
identified, presumably due to elevated levels of GCs we have reported important 
differences. Other studies confirm that repeated restraint stress and chronic cort 
treatment do not elicit the same effects. For example chronic cort treatment decreases 
the volume fraction occupied by mitochondria in the CA3 region of the hippocampus 
whereas repeated restraint stress increased mitochondrial profiles in mossy fibre 
terminals (Coburn-Litvak et al., 2004) (Magarinos et al., 1997). Moreover GC treatment 
and restraint stress resulted in CA3 remodelling alone but when given in combination 
abolished the change (Magarinos et al., 1998) which is suggestive of the activation of 
different mechanisms.  
 
 
Despite the fact that estrus cycle is affected by GCs and that it affects 6-OHDA 
lesioning estrus cycle stage was not taken into account in the present studies as although 
smears were taken on the morning of 6-OHDA surgery, grouping animals according to 
estrus cycle stage would have resulted in very small n numbers which would not enable 
the determination of any statistical significance. In order to account for estrus stage it 
would be necessary to have 4 groups of females as well as a group of males which 
would have significant cost implications and would have made organisation of the study 
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very difficult owing to the extremely large number of animals that would be required. 
Additionally, although circadian rhythm may have affected the cort concentration the 
animal was exposed to at the time of surgery, we were unable to fully take this into 
account due to the practicalities of using surgery facilities. These factors may contribute 
to some variability within the data although they are unlikely to produce highly 
significant effects as it has been shown that estrus stage and circadian stage only 
produce small changes in the effects of 6-OHDA (Datla et al., 2003). It is important to 
note that there are some discrepancies between data sets. However, the salient results 
are consistently confirmed across the studies. These discrepancies may have arisen due 
to the highly plastic nature of the pathways that were being studied. Indeed as we have 
shown relatively mild stress to have a significant impact on the pathways, it is possible 
that small differences in environment owing to the fact that studies were carried out 6 
months apart may underlie these differences, despite every effort being made to ensure 
conditions within the animal house were maintained.  Furthermore regarding HPLC 
data, it was impossible to run all samples in the same run thus data from different 
runs/studies can not be directly compared. This is likely to account for some base line 
differences between and within studies. 
 
The experimental design and the model system in which the effects of stress or cort 
exposure are measured, dramatically affect the outcome. For example the effects of 
restraint stress, chronic variable stress, psycho-social stress and novelty stress all differ.  
Therefore it is important for future work and the advancement of the field that the 
effects of different stress paradigms are characterised so that we can gain an 
understanding of how the nature of the stressor also affects outcome. Chronic stress 
procedures are also nearly always different between laboratories. It would be extremely 
 246
useful if standard experimental protocols for chronic stressors were created to enable 
easier and more useful comparison of the literature. There is also a tendency to group 
together early life manipulations when one is talking about programming. However, 
there are very different outcomes in terms of the type of manipulation and especially in 
the timing of the manipulation.  Manipulations carried out prenatally, postnatally and in 
adolescence have very different outcomes as they impact on different stages of brain 
development.  
 
Although many neurochemical and histological changes were identified, the functional 
consequences of these changes were not examined. This makes it difficult to determine 
whether the results presented within this thesis are clinically meaningful or whether the 
changes identified have little impact on overall physiological function. However the 
data presented provides a novel insight into several stress induced changes within the 
brain that may or may not be relevant to pathologies known to have a stress component. 
This is discussed further in section 6.8. 
6.3 Stress as a risk factor for Parkinson’s disease 
 
Stress was first implicated in PD in the 1960’s when Schwab and England reported 
cases of emotional and physical trauma that had directly preceded the onset of 
Parkinsonian symptoms. More recently in light of the discovery that GCs could result in 
the loss of neurons within the hippocampus this hypothesis started to regain attention 
(Smith et al., 2002; Metz, 2007) although very few studies have looked at this in any 
depth. One of the major findings within the present study is that repeated stress or 
chronic treatment with GCs can render adult male rats more susceptible to 6-OHDA 
induced neurodegeneration. GCs have the potential to impact upon most pathological 
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pathways that have been identified as important in PD.  These processes are often 
intricately interlinked which is depicted in figure 6.1, thus elevated or dysregulated GC 
levels may result in the initiation of a deleterious cascade that may promote or 
exacerbate neurodegeneration. This is discussed further below. 
 
 
 
 
Figure 6.1. The complex interactions between GCs and the pathogeneic 
mechanisms involved in PD. 
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Dopamine 
GCs are known to elevate DA levels. This rise in DA has the potential to cause 
neurotoxicity. Auto-oxidation of DA results in the production of superoxide anion as 
well as a highly reactive quinones that can readily modify proteins by covalently 
modifying cysteine residues, and irreversibly alter or inhibit protein function resulting 
in cytotoxicity (Asanuma et al., 2003). The formation of DA-quinones was found to be 
important in methamphetamine induced neurotoxicity (Miyazaki and Asanuma, 2008). 
In addition, DA metabolism itself may have deleterious consequences. Metabolism of 
DA by MAO results in the production of a toxic intermediate 3,4-
dihydroxyphenylacetaldehyde (DOPAL) which is subsequently converted to DOPAC 
by aldehyde dehydrogenase. However, it has been shown that oxidative stress products 
such as 4HNE and MDA inhibit aldehyde dehydrogenase thereby increasing levels of 
the intermediate DOPAL which has been shown to be toxic to DA cells (Burke et al., 
2004) and involved in the cross linking of α-synuclein (Burke et al., 2008). In addition 
DA metabolism by MAO also produces hydrogen peroxide which can be broken down 
by iron, which is abundant within the SN, to hydroxyl free radicals. These pathways 
may be responsible for the greater susceptibility of DA neurons to degeneration in PD.  
 
Mitochondrial dysfunction 
Mitochondrial dysfunction has been identified in PD and both the 6-OHDA and MPTP 
models of PD work to some degree via mitochondrial inhibition. GRs have been shown 
to be able to translocate to mitochondria (Koufali et al., 2003) as well as the nucleus 
where they have an impact on the role of mitochondria in the regulation of intracellular 
calcium levels and neural plasticity. A recent report shows that chronic high doses of 
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GCs attenuate mitochondrial function and result in reduced mitochondrial GR and Bcl-2 
(anti-apoptotic protein) expression levels (Du et al., 2009). This would have detrimental 
consequences for the cell thus may promote degeneration. Du et al., 2009 suggest that 
by enhancing mitochondrial function you may be able to counteract the effects of 
excessive GCs (Du et al., 2009).  
 
Oxidative stress 
There are many reports that stress and GCs elevate levels of oxidative stress within the 
brain  (Madrigal et al., 2006). We confirm this in our male but not female animals 
where stress and GCs result in elevated levels of protein nitration within the NSDA in 
both naïve males and 6-OHDA treated males. Within DA systems oxidative stress could 
exacerbate intrinsic DA toxicity (see above) and contribute to pathology in PD.   
 
Glutamate excitotoxicity 
In response to stress and HPA activation a large amount of glutamate is released into the 
extracellular space (Moghaddam, 1993). Through excessive activation of its receptors, 
most notably the NMDA receptor, glutamate results in elevated intracellular calcium, 
with the subsequent activation of calcium dependent enzymes, the generation of oxygen 
free radicals and protein misfolding. It is also interesting that stress reduces glutamate 
transporter expression and increases NR1 and NR2 subunits of the NMDA receptor 
(ref). Furthermore DA and glutamate act synergistically and can potentiate each others 
neurotoxic effects (Hoyt et al., 1997). As the SNpc receives gluatamatergic input from 
the STN, excessive glutamate signalling could be detrimental to the NSDA. 
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Inflammation 
Although GCs are classically considered the anti-inflammatory drug of choice, there is 
now a wider appreciation of their proinflammatory effects within the CNS. Stress or 
high GC levels has been shown to induce the release and accumulation of inflammatory 
mediators such as TNF-α, IL-1β, IL-6, IFNγ and the activation of NFκB. Furthermore 
stress can induce microglial activation (Sugama et al., 2007; Kwon et al., 2008). Our 
data confirm previous reports that stress and GCs can result in proliferation of 
microglial within the brain (Nair and Bonneau, 2006). It has been proposed that stress 
induced microglial proliferation is due to a GR, glutamate and NMDA mediated 
mechanism. Stress induced microglial activation on the other hand has been shown not 
to be accompanied by neurotoxic factors such as cytokines and NO (Sugama et al., 
2007) therefore it is unlikely that stress directly triggers microglia induced neuron 
degeneration but rather that it is detrimental in situations where there are dying neurons, 
propelling a vicious cycle. This may indeed be the case in the 6-OHDA model where 
stress and GC treatment exacerbate neuronal loss which is accompanied by increased 
microglial activation. The preceding chapters highlight the potential involvement of 
oxidative stress and microglial activation in the involvement of stress and GCs in PD, 
this is summarised in figure 6.2.     
 
Neuroinflammation can also compromise the integrity of the blood brain barrier (BBB) 
thereby facilitating the activation and infiltration of peripheral immune cells into the 
brain. There is evidence of BBB leakage following treatment with DA neurotoxins and 
the vascular changes that have been identified in PD patients are suggestive of BBB 
dysfunction (Monahan et al., 2008). There is now an emerging hypothesis that PD has 
an autoimmune component based on evidence that animals exposed to DA neurotoxins 
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exhibit BBB dysfunction. This may allow peripheral immune cells to enter the brain 
where they may contribute to the progressive nature of the disease (Monahan et al., 
2008). The immune system-brain interface is crucial for communication between the 
brain in health and disease and pathogens and toxins present in the environment. We 
require a better understanding of the routes of communication between the peripheral 
immune system and the brain including the mechanisms by which microglia can switch 
their phenotype.  
 
Cell survival 
Through regulation of transcription GCs can also reduce expression of anti-apoptotic 
proteins (as in mitochondria) and neurotrophic factors and increase pro-apoptotic 
proteins.  
 
Protein deposition 
 
Stress has been shown to increase deposition of amyloid-beta in an AD model (Green et 
al., 2006). Further investigation could establish whether a similar phenomenon occurs 
with α-synuclein in PD. 
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Figure 6.2. Schematic diagram to illustrate the potential involvement of 
oxidative and inflammatory pathways in stress induced 
neurodegeneration. 
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Although the present data doesn’t allow us to infer that stress or GC treatment causes 
NSDA damage on its own, it does show that stress and elevated levels of GCs increase 
susceptibility to a subsequent toxic insult.  An involvement of stress in PD is supported 
by clinical studies showing that acute or chronic stress worsens the symptoms of PD 
and accelerates the progression of the disease (Treves, 1990) (Gage and Storey, 2004) 
(Goetz et al., 1990). In addition acute stress appears to unmask symptoms in the 
preclinical stage of the disease (Schwab and Zieper, 1965; Snyder et al., 1985). I 
propose that although it is unlikely that stress alone can result in PD, it is probable that 
stress accelerates the onset and subsequently the progression of the disease via the 
above mechanisms in predisposed individuals. Alternatively stress may act as a trigger 
in predisposed individuals and may initiate the neurodegenerative cascade of events. PD 
is now appreciated as a multifactorial disease whereby a number of environmental 
insults (such as chronic stress or GC treatment) in combination with genetic factors 
result in precipitation of the disease. Based on the evidence presented in this thesis and 
within the literature the pathway that I believe to be most likely and would like to 
investigate further is depicted in figure 6.3. Here adult stress and subsequent raised GC 
levels result in increased activation of GR. Increased transcriptional activity via GR 
may result in alterations in the expression of TH, DAT, VMAT, uptake 2 or 
metabolising enzymes. Altered uptake, synthesis or metabolism of DA subsequently 
results in increased DA content. Due to its ability to auto-oxidise this would result in 
elevated levels of oxidative stress within the NSDA. Oxidative stress can then trigger 
microglial activation which in turn can further escalate oxidative stress. This mechanism 
would leave the NSDA in a vulnerable oxidative state so that when presented with an 
oxidative challenge such as 6-OHDA, its toxicity is enhanced.     
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Figure 6.3. Potential mechanism for stress-induced enhanced 
neurotoxicity within the NSDA. 
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Age is by far the biggest risk factor for PD and GCs have long been linked to the aging 
process. The HPA axis promotes survival by enabling adaptation to environmental 
stressors. This is known as ‘allostasis’. A severe, prolonged or inadequate stress 
response means that it is more difficult to maintain homeostasis – in this case the 
organism has an increased ‘allostatic load’ (McEwen and Lasley, 2003). During aging, 
coping and adaptation are less efficient and there is an increase in allostatic load that has 
been associated with increased and prolonged CORT secretion. It has been shown that 
Cort levels increase with age and that this correlates with age associated cognitive 
decline. These rises in CORT levels that occur with aging may further accelerate the 
aging process in a self perpetuating cycle - known as the GC cascade hypothesis. The 
GC cascade hypotheses was proposed before the identification of two corticosteroid 
receptors and it is now thought that it is the MR/GR balance that is key to health and 
disease. MR expression is known to decrease with age and alterations in the balance of 
MR and GR due to either genetics or environmental factors, particularly within the 
limbic system, would result in a dysregulated HPA axis that may ultimately increase 
vulnerability to disease. Moreover, gene variants of MR and GR have been identified 
(DeRijk and de Kloet, 2005) which may go some way to explaining individual 
variability to stress related disease and further highlights the importance of genetic as 
well as environmental impact. For example a loss of function MR gene variant has been 
associated with the development of depression (Kuningas et al., 2007). As aging is the 
single most important risk factor for PD, accelerating the aging process, by HPA 
dysregulation may result in an earlier onset of PD. 
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6.4 Developmental programming and its relevance to PD 
 
Animal studies have shown that within the hippocampus prenatal GC’s can delay the 
maturation of neurons, myelination, glia and vasculature in offspring, can alter neuronal 
structure and synaptogenesis and inhibits neurogenesis (Seckl, 2008). Human data has 
also shown that prenatal GC treatment has long term neurodevelopmental effects 
(Kapoor et al., 2008). The underlying mechanisms of the detrimental effects of GCs on 
brain development are still unclear and could be due to direct actions on neurons and 
glia or though dysregulation of the HPA axis. The present studies confirm previous 
reports that prenatal DEX permanently alters midbrain DA pathways. In addition it is 
shown that prenatal DEX also alters the noaradrenergic LC as well as influencing adult 
glia populations. As these changes have been shown to persist into adulthood, it is likely 
that they have long term consequences for brain function and disease.  
 
It perhaps seems unlikely that elevated developmental GC levels would produce 
opposing effects on NA and DA neurons. However they have distinct origins and 
projection fields. Hindbrain NA neurons of the LC have diffuse projections whereas 
midbrain DA neurons have delineated projection fields. Moreover although NA and DA 
share the same biosynthetic pathway the development of hindbrain NA neurons and 
midbrain DA neurons are under different transcriptional control. LC neurons arise in the 
dorsal isthmic region of the hindbrain and are formed early in development (E9-10.5 in 
the mouse)(ref). The transcription factors Mash1, Phox2a, Phox2b and Rnx/Tlx3 are 
required for early LC development. On the other hand, the first midbrain DA neurons 
are detected at E10 and the correct specification and maintenance of midbrain DA 
neurons is dependent on the activity of the transcriptional regulators Nurr1, Lmx1b and 
Pitx3 (ref). Although in adults GCs negatively influence neurogenesis (Gould and 
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Tanapat, 1999) (Karishma and Herbert, 2002), the effects of GCs in the developing 
brain are essentially unknown. However, Sundberg et al., 2006 (Sundberg et al., 2006) 
have shown that dexamethasone inhibits the proliferation of embryonic neural stem 
cells isolated from the striatum on E17. It is yet to be determined whether early life 
programming is controlled by MR and GR although recent evidence suggests that the 
effects of early life programming are partly due to epigenetic changes in the GR 
promoter (Weaver et al., 2004; Seckl and Holmes, 2007; Oberlander et al., 2008; Szyf et 
al., 2008). Interestingly human hippocampal GR expression was found to be decreased 
in suicide victims that had a history of childhood abuse (McGowan et al., 2009) 
suggesting that epigenetic mechanisms may also be relevant to the human scenario. The 
importance of epigenetic changes induced by early life programming is only just 
emerging but it may be of significant relevance to the data presented here. 
 
Oitzl et al. (2009) introduce the idea that it is not simply a case that an adverse event in 
early life results in a vulnerable phenotype, but that it is a case of whether the early 
environment matches the organism’s future environment. This idea is supported by 
findings that although reduced maternal care is typically thought to be detrimental to 
future health, in the case of cognition this was true for the control state but when 
stressed, maternally separated animals performed better in cognitive tests than controls 
(Champagne et al., 2008). A similar phenomenon appears to occur within the NSDA 
where increases in striatal DA and TH-IR neurons in the SNpc that are seen in stressed 
or cort treated males are prevented by prenatal DEX exposure. Depending on the 
environment the animal is in this could be either an adaptive response or a maladaptive 
response. Figure 6.4 illustrates how the early life environment can contribute to adult 
disease. The present data support the hypothesis that early life manipulations produce 
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long term changes in pathways implicated in PD that in combination with other 
environmental, genetic and adult challenges probably contribute to PD pathogenesis.  
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Figure 6.4. Develop mental programming results in adaptive responses to 
promote survival in future environmen t. Mismatching of the earl y life and  
adult environments results in maladaptation and a vulnerable phenotype 
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6.5 Stress, GCs and the non-motor symptoms of PD  
 
Non-motor symptoms are common in PD patients and have important clinical 
consequences for patients, caregivers and society.  Aarsland et al., 2009 (Aarsland et al., 
2009) found that neuropsychiatric symptoms were present in early unmedicated PD 
cases, the most common symptoms being depression, anxiety, sleep disturbances and 
apathy. This study is important as it is the first to look at unmedicated PD patients as 
medication may have confounding effects on many neuropsychiatric symptoms. The 
aetiology of neuropsychiatric symptoms in PD as with motor symptoms is likely 
multifactorial with contributions from psychological stress and brain changes associated 
with PD. Although the diagnosis of a chronic debilitating disease may induce mood 
symptoms it has previously been described that neuropsychiatric symptoms can precede 
motor symptoms (Ishihara and Brayne, 2006) suggesting that these symptoms are 
related to the disease process. There is a consistent relationship between motor severity 
and neuropsychiatric symptoms in PD suggesting that motor and neuropsychiatric 
symptoms develop in parallel and therefore may have similar underlying pathology. 
Stress and GCs have already been heavily implicated in symptoms such as depression 
and anxiety therefore may be a significant contributory factor to pathogenesis.    
 
6.6 The importance of sex differences 
 
Nearly all tissues show sex differences in both health and disease and an increasing 
number of sexual dimorphisms have been identified within the brain. Moreover sex 
differences are found in the prevalence of many neurological disorders including PD, 
AD, PTSD, anxiety, stroke, MS, autism, addiction, ADHD and eating disorders. The 
purpose of studying sex differences is two fold. Firstly to further our knowledge of the 
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underlying biology of the system to be studied and secondly to determine whether the 
observed sex difference may have significant clinical relevance and should therefore be 
considered in development of preventative, therapeutic or diagnostic interventions. The 
sexually dimorphic nature of the data presented within this thesis emphasises the 
importance of studying sex differences within the brain and in particular with reference 
to PD. The innate sex differences in neurotransmitter systems identified by us and 
others as well as the sex differences in neuronal systems in response to stress and 
elevated GCs identified here may underlie the sex differences we see in susceptibility to 
different disease states. Furthermore the finding that stress and GCs produce sexually 
dimorphic responses in pathways affected in PD may suggest a contribution to the sex 
difference in the prevalence of PD.  An understanding of these differences may be 
crucial in developing our knowledge of the disease process as well as in the 
development of appropriate therapeutics. 
 
The assumption that sex differences arise as a consequence of altered exposure to sex 
steroid hormones is probably false as manipulation of the adult sex steroid environment 
has little impact on brain circuitry. It is more likely therefore that innate sex differences 
predominately arise due to organisational effects of sex steroids during development. 
Therefore sex differences in endocrine-neurotransmitter circuitry may underlie the 
altered responses to stress and GCs that was observed in males and females. All 
biological sex differences are encoded by genes encoded on the sex chromosomes. In 
rats the critical period of brain masculinisation and defeminisation occurs from GD18 to 
PND10 (Arnold and Gorski, 1984). Interestingly this coincides with our DEX treatment 
regime which thus has the potential to interfere with the masculinisation/defeminisation 
of the brain produced by testosterone during development. 
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Large sex differences in neuronal number are probably not a result of effects on the 
birth of neurons (Breedlove and Arnold, 1983) (Cooke et al., 1998) although other 
steroids such as GCs have been shown to modify neurogenesis (Zhang et al., 2008) 
(Ahmed et al., 2008; Galea, 2008). Sex steroids can however influence the outgrowth of 
axons and dendrites, the amount of cell death and can regulate synapse formation 
(Forger, 2006; McCarthy et al., 2008). There is also a recent interest in their epigenetic 
effects whereby steroids can alter the chromatin in the region of specific genes, 
permanently altering transcription. For example histone acetylation has been shown to 
be sexually dimorphic within the hypothalamus (Tsai et al., 2009). The potential of GCs 
to alter sex steroid levels during this critical period of development may have long term 
implications for the individual either making future responses more masculine or 
feminine in their nature. For example it could be hypothesised that the changes in 
neurotransmitter systems that occur as a result of prenatal DEX treatment may be due to 
enhanced masculinisation of the brain.  
 
In adults both animal and human studies indicate that gonadal steroid hormone secretion 
is markedly altered by stress and glucocorticoids (See chapter 1). Conversely sex steroid 
hormones can differentially affect stress responsiveness. Figure 6.5 illustrates the 
interactions between the HPA and HPG axes. Stress and GCs have largely been shown 
to suppress the HPG axis. Acute stress inhibits GnRH and LH secretion presumably via 
direct actions of CRH on GnRH neurons (Gambacciani et al., 1986). Whilst chronic 
stress reduces the release of GnRH , decreases pituitary sensitivity to GnRH and 
interferes with LH stimulation of sex steroid hormones (Rivier and Rivest, 1991). Stress 
inhibition of the HPG axis occurs both in males and females. Furthermore physical 
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stressors (e.g. infection) also suppress HPG axis via a GC mediated mechanism (Debus 
et al., 2002). As is seen in the present work stress can have opposite effects in males and 
females in some systems. These differences may be due to sex differences in the stress 
response rather than the parameter being measured. Both basal and stress-induced 
corticosterone secretion is more pronounced in females than in males (Carey et al., 
1995). Incidental data and data from Cushings patients and long term prednisolone 
treatment also show that stress inhibits the HPG axis in humans. (Sakakura et al., 1975; 
Reame et al., 1985). Furthermore, stress also results in inhibition of testosterone 
secretion in men, secondary to inhibition of the central HPG axis (Morgan et al., 2000). 
 
As previously discussed estrogen has neuroprotective properties. Estrogen regulates 
growth factor supply (Cardona-Gomez et al., 2001; Ivanova et al., 2002), attenuates 
inflammation (Kipp et al., 2007; Vegeto et al., 2008); promotes anti-apoptotic signalling 
(Nilsen and Brinton, 2004); facilitates neuronal activity (Woolley, 2007); can act as a 
free radical scavenger (Behl, 2002b); influences mitochondrial function (Arnold 2009) 
and may even maintain the integrity of the BBB (Sohrabji, 2007). Furthermore estrogen 
can downregulate DAT (McArthur et al., 2007b). These potentially neuroprotective 
effects of estrogen may account for the reduced susceptibility to 6-OHDA in females 
and their lack of stress or GC enhancement of neurodegeneration. 
 
Current literature suggests that some aspects of brain organisation are very similar in 
males in females and in other aspects are remarkably different. This may have an 
evolutionary origin and be explained by the fact that males and females are subjected to 
both similar and markedly different selective pressures. The present work highlights the 
significant importance of sex differences in the field as often opposing effects were 
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observed suggesting that the neuroendocrine-neurotransmitter circuitry is completely 
different in males and females. This implies that it can not be assumed that similar 
processes occur in men and women and therefore that therapeutics will not necessarily 
produce the same effect. Parallel research in males and females is required to further our 
understanding of the implications of sex differences within the brain and may lead to 
tailored therapeutic strategies that are dependent on sex.  
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Figure 6.5. Summary of the interactions between the HPA and HPG axes. 
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6.7 Potential therapeutic and clinical applications 
 
Although it is impossible to eliminate stress from our daily lives, effective stress 
management may be of significant benefit in the preclinical stage of the disease. This 
would only be possible with the development of a reliable biomarker for PD but would 
have the potential to extend the preclinical stage of the disease, delaying the onset of 
symptoms. Stress management may also be important in slowing the progression of the 
disease. The development of social policies and environmental enrichment may aid this. 
A positive outlook on life and good-self esteem have been shown to have long lasting 
health consequences (Pressman and Cohen, 2005). Furthermore good social support and 
having 3 or more regular social contacts has a positive effect on allostatic load (Seeman 
et al., 2002) whereas poor self esteem can result in a reduced ability to habituate and 
elicits greater cortisol responses to stress (Kirschbaum et al., 1995; Pruessner et al., 
2005). In cases of early life abuse or stress, intervention performed early on may 
prevent the deleterious effects of chronic stress or abuse on the developing brain and 
could also help protect the brain against effects of chronic stress on the brain in 
adulthood/aging.  
 
GCs are commonly used to treat a variety of inflammatory diseases. It may be sensible 
to limit their use in PD patients (no epidemiological evidence for this is currently 
available) due to their potential to accelerate disease progression. It is thought that 
transrepression of transcription factors such as AP-1 and NF-κB by GR is responsible 
for reducing the expression of pro-inflammatory genes. Therefore GC receptor ligands 
that could dissociate tranactiavtion from transrepression may confer less deleterious side 
effects. Several agonists and ligands have been developed that bind to GR cause a 
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conformational change favoring receptor- protein interaction rather than receptor DNA 
interaction, these ligands have been shown to have fewer side effects (Catley, 2007; 
McMaster and Ray, 2007).  
 
The use of GCs in perinatal medicine should only be used where there is a significant 
risk of pre-term labour. A recent review advises against repeat doses of corticosteroids 
as there is no evidence to suggest any further beneficial effect (Newnham and Jobe, 
2009). Improved methods of predicting pre-term birth would limit unnecessary 
treatment and research into the prevention of pre-term birth should be made a priority. 
 
Further understanding of the detrimental effects of stress and GCs within the brain may 
highlight potential avenues for therapeutic intervention in the treatment of stress related 
diseases. The current research suggests that anti-inflammatory and anti-oxidative 
strategies may be beneficial in combating the deleterious effects of stress and GCs in 
PD. Furthermore future investigation into the mechanism behind glucocorticoid and 
stress induced neuroprotection in females may reveal novel potential therapeutic targets. 
Due to the multi-factorial nature of the disease, with stress and GCs possibly 
constituting one factor, logical thought suggests that a combination of therapeutic 
strategies are likely to be the most successful approach to disease management. One 
such strategy could involve stress management and the prevention of glucocorticoids 
excess. 
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6.8 Future work 
 
There are many potential avenues for future research stemming from the present work 
and it would be impossible to highlight them all. Below I have detailed some areas for 
future work that I feel would be most interesting and beneficial to the field. 
 
Firstly it is of paramount importance that we follow up children who are enrolled in 
randomized controlled trials of antenatal steroid use. This will provide us with vital 
information as to the long term consequences of their use and determine whether the 
large amount of literature based on animal models is relevant to humans. 
 
In regard to the effect of stress and GCs and their relevance to PD, once the 
reproducibility problems associated with the proteosome inhibitor models are ironed 
out, it would be an ideal model for further study of the effects of stress and GCs on PD. 
Repeating the current studies in this model may provide further confirmation or could 
disprove the relevance of the present data to PD. As the model is progressive it would 
enable us to gain information on the effects of stress and GCs on both the onset and 
progression of degeneration as well providing further information on extra-nigral areas 
of degeneration and the presence of lewy-bodies. It would be especially interesting to 
look at whether stress or GC treatments have an effect on alpha-synuclein deposition as 
there is evidence to suggest that stress can result in increased amyloid-beta in an AD 
model. To further elucidate the role of stress in PD a similar study to the present one 
could be carried out in which the adult manipulation consists of chronic variable stress 
for a period of 6 weeks. This is a more chronic stress model than repeated restraint and 
would allow us to determine whether habituation of the stress response is important in 
the effects of stress on pathways implicated in PD and would indicate whether the 
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involvement of other stress related symptoms such as the autonomic nervous system are 
involved in the effects of stress on these regions. Moreover the effects of chronic 
variable stress may be more applicable to the human population. It would also be 
important to add in functional behavioural testing to any future experiments to 
determine the functional consequences of any neurochemical or histological changes 
that were identified. Furthermore alterations in motor function have been observed in 
the absence of any changes in NSDA measures (Metz, 2007).  
 
It would be very interesting to look at changes in GR (and MR) expression both within 
the limbic system and within our brain regions of interest in response to our treatment 
regimes. This could be investigated using in-situ hybridization on sections containing 
the regions of interest. This would enable us to establish any changes in mRNA 
expression that may contribute to the effects of stress and GCs on these systems. Taking 
this further a very recent study has shown that selective ablation of the GR gene in 
dopaminoceptive neurons of the MLDA facilitated cocaine seeking behavior (Ambroggi 
et al., 2009). This approach could be utilized within the NSDA to determine the 
function of GR and whether the effects of stress are due to HPA axis regulation 
(circulating GC levels) or are GR mediated as I have suggested in figure 6.3. In figure 
6.3 I also indicate that GR activation may initiate changes in gene transcription that 
ultimately result in elevated DA levels. To investigate what these underlying changes 
might be I would look at the effect of our treatment regimes on the expression of TH, 
DAT, VMAT, COMT and MAO. 
 
 We identified sex differences but this doesn’t tell us what hormones, if any underlie 
these differences. This could be achieved by repeating the experiments in 
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gonadectomised animals to determine whether the gonads are important in the sex 
difference and then hormone replacement to see whether this returns the difference to 
control. If this is not the case i.e. gonadectomy does not eliminate the sex difference, it 
may be that the sex difference arose due to the action of testosoterone during 
development that caused permanent alterations. This could then be investigated by 
manipulating hormone levels during development. For example the administration of 
physiological levels of testosterone during fetal and early post-natal life and then 
measuring whether the female is more masculine in terms of the sex difference 
identified. Alternatively administration of an androgen blocker in males could 
determine whether this blocks normal masculinisation. If the sex difference could not be 
explained by the activational effects of gonadal hormones in adulthood or by 
organisational effects during pre and postnatal development another potential 
explanation may be that genes encoded on the sex chromosomes act within cells to 
sexually differentiate XX and XY cells.  
 
6.9 Conclusions 
 
Glucocorticoids have the potential to impact upon virtually all systems thus are able to 
exert wide ranging effects. Although these effects normally exert a protective function 
allowing us to cope with and adapt to changing environments, severe, prolonged or 
dysregulated exposure to GCs can be detrimental. This was initially shown within the 
hippocampus and there is now a wider appreciation for the detrimental effects of GCs in 
other brain regions as well as systemic systems. The work presented within this thesis 
along with the work of others suggests that stress and GCs have extremely wide ranging 
effects on the structure and function of the brain and that these effects vary significantly 
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in a region, dose, and sex-specific manner. The current data along with the work of 
others suggest that stress and GC exposure at different times in life do indeed have the 
potential to interfere with pathways involved in PD and affect the outcome of a PD 
animal model, suggesting that stress may be a significant risk factor for the disease. 
This is extremely timely research as our increasingly stressful life styles combined with 
our aging population mean that the health and economic burden of PD is likely to 
increase over the coming years. Thus the management of stress and GC levels may be 
important in the prevention and management of PD as well as many other stress-related 
and age-related disorders. 
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Figure 6.6. Simplified diagram to show proposed involvement of stress 
and GCs in the development and progression of PD show ing potential 
direct and indirect e ffects of stress/GCs. PD is widely accepted to be a 
multifactorial disease whereby a combination of genetic and environmental insults 
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result in disease onset and progression. Exposure to stress or elevated GCs during early 
life can result in altered neuronal pathways and altered HPA function that may have 
persistent effects on adult physiology that contribute to disease onset. Similarily adult 
stress and GC exposure can alter the functioning of neuronal pathways and alter HPA 
function, elliciting inflammatory and oxidative responses that could contribute to 
neurodegeneration. Additionally our data show that early life experience may alter the 
response to adult challenge which may represent another contributory factor to disease 
progression. Although not included in this diagram for simplicity the HPG axis may 
also have a significant impact on neurodegeneration. 
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APPENDIX 1: Summary of statistical analyses  
 
Two-way ANOVAs 
STUDY 1 DEX STRESS INTERACTION 
 F p F p F p 
Males SNpc       
TH 5.782 0.023 0.246 0.234 14.431 0.012 
NeuN 6.272 0.032 0.376 0.496 16.254 0.002 
OX-42 1.103 0.432 7.907 0.036 0.834 0.876 
GFAP 1.023 0.562 0.768 0.765 0.987 0.865 
3-NT 1.346 0.765 3.268 0.049 0.876 0.235 
Female SNpc       
TH 6.862 0.010 14.109 0.000 0.872 0.352 
NeuN 7.100 0.009 6.95 0.010 1.396 0.240 
OX-42 0.966 0.547 0.002 0.968 0.178 0.444 
GFAP 4.002 0.036 0.214 0.765 0.198 0.322 
3-NT 0.988 0.775 1.134 0.432 0.122 0.988 
Male Striatum       
DA 0.622 0.278 0.982 0.568 17.812 0.000 
DOPAC 1.123 0.110 0.976 0.577 1.432 0.102 
HVA 1.028 0.714 0.725 0.868 5.640 0.032 
Female Striatum       
DA 1.838 0.180 52.456 0.000 8.173 0.006 
DOPAC 0.527 0.471 0.482 0.491 23.43 0.000 
HVA 0.835 0.365 0.342 0.561 6.426 0.014 
Male VTA       
TH 4.332 0.032 3.022 0.044 0.332 0.865 
NeuN 0.136 0.714 15.203 0.000 15.270 0.000 
OX-42 21.210 0.000 15.786 0.000 0.654 0.785 
GFAP 9.243 0.002 1.245 0.436 1.436 0.243 
3-NT 0.988 0.666 1.130 0.543 1.670 0.123 
Female VTA       
TH 0.151 0.699 7.288 0.010 4.405 0.041 
NeuN 1.234 0.788 2.034 0.102 0.236 0.563 
OX-42 19.662 0.000 7.250 0.001 0.025 0.985 
GFAP 8.674 0.000 0.326 0.788 0.024 0.927 
3-NT 0.927 0.340 0.149 0.702 1.120 0.660 
Male NAcc       
DA 3.358 0.079 2.345 0.569 12.023 0.000 
DOPAC 1.002 0.236 0.567 0.543 1.027 0.320 
HVA 0.615 0.331 1.110 0.678 0.245 0.898 
Female NAcc       
DA 6.078 0.032 12.320 0.003 0.206 0.603 
DOPAC 0.604 0.890 1.245 0.320 1.203 0.220 
HVA 0.998 0.335 0.276 0.333 0.778 0.453 
Male LC       
 346
DβH 7.632 0.001 1.345 0.120 1.003 0.520 
NeuN 5.980 0.020 0.276 0.633 0.678 0.953 
OX-42 0.902 0.892 0.668 0.725 0.984 0.764 
GFAP 0.304 0.990 1.246 0.371 1.223 0.320 
3-NT 0.234 0.677 0.311 0.471 1.242 0.481 
Female LC       
DβH 6.459 0.033 0.768 0.825 0.954 0.664 
NeuN 4.896 0.043 0.166 0.686 0.544 0.525 
OX-42 1.675 0.218 1.34 0.721 0.721 0.411 
GFAP 0.232 0.798 0.461 0.653 0.205 0.949 
3-NT 0.140 0.843 0.565 0.782 0.313 0.771 
Male PFC       
NA 0.166 0.851 0.556 0.462 1.560 0.222 
Female PFC       
NA 0.123 0.728 2.141 0.154 0.081 0.778 
 
 
STUDY 2 DEX CORT INTERACTION 
 F p F p F p 
Males SNpc       
TH 0.040 0.843 0.505 0.482 13.3 0.001 
NeuN 0.136 0.714 15.203 0.000 15.270 0.000 
OX-42 0.866 0.537 0.102 0.996 0.278 0.431 
GFAP 0.345 0.444 11.022 0.000 1.325 0.443 
3-NT 0.031 0.861 6.307 0.016 0.071 0.791 
Female SNpc       
TH 0.002 0.968 0.166 0.686 5.544 0.025 
NeuN 7.140 0.009 6.95 0.010 1.396 0.240 
OX-42 0.863 0.682 0.856 0.678 1.431 0.262 
GFAP 0.124 0.782 0.120 0.531 1.063 0.103 
3-NT 0.001 0.977 2.359 0.055 0.055 0.816 
Male Striatum       
DA 1.688 0.143 20.622 0.000 8.108 0.032 
DOPAC 2.083 0.112 5.664 0.003 1.235 0.930 
HVA 0.898 0.476 1.123 0.768 8.765 0.009 
Female Striatum       
DA 0.133 0.678 0.210 0.371 1.342 0.471 
DOPAC 0.923 0.782 0.756 0.778 1.233 0.162 
HVA 1.345 0.215 4.089 0.056 1.402 0.092 
Male VTA       
TH 2.815 0.114 1.560 0.231 0.010 0.920 
NeuN 0.104 0.749 0.120 0.731 10.063 0.003 
OX-42 26.330 0.000 16.291 0.000 0.876 0.100 
GFAP 8.768 0.001 1.430 0.102 0.991 0.231 
3-NT 1.436 0.457 0.777 0.336 1.432 0.118 
Female VTA       
TH 1.675 0.218 1.34 0.721 0.721 0.411 
NeuN 0.132 0.718 0.361 0.553 4.205 0.049 
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OX-42 25.701 0.000 20.021 0.000 0.987 0.765 
GFAP 7.451 0.024 1.672 0.099 1.267 0.789 
3-NT 1.123 0.110 0.976 0.577 1.432 0.102 
Male NAcc       
DA 0.177 0.676 0.279 0.60 13.452 0.001 
DOPAC 0.863 0.582 0.956 0.378 1.231 04262 
HVA 0.797 0.324 0.122 0.453 0.602 0.960 
Female NAcc       
DA 4.056 0.039 3.087 0.051 0.021 0.977 
DOPAC 1.223 0.170 0.774 0.476 1.232 0.107 
HVA 4.745 0.487 6.012 0.044 0.034 0.125 
Male LC       
DβH 3.900 0.043 0.874 0.775 1.331 0.707 
NeuN 3.372 0.050 0.656 0.461 1.660 0.254 
OX-42 0.978 0.428 0.123 0.983 0.802 0.460 
GFAP 4.273 0.046 0.156 0.542 0.893 0.342 
3-NT 0.140 0.843 0.975 0.682 1.023 0.801 
Female LC       
DβH 6.235 0.034 1.775 0.118 1.640 0.721 
NeuN 3.675 0.059 0.677 0.728 0.023 0.983 
OX-42 4.823 0.039 1.167 0.564 1.230 0.432 
GFAP 1.476 0.428 1.630 0.721 0.221 0.314 
3-NT 0.232 0.798 0.461 0.653 0.205 0.949 
Male PFC       
NA 0.240 0.643 0.765 0.882 0.363 0.972 
Female PFC       
NA 1.785 0.209 0.998 0.786 6.983 0.028 
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Three way ANOVAs 
 
STUDY 1 DEX x Lesion Stress x Lesion DEX x Stress x 
Lesion 
 F p F p F p 
Males SNpc       
TH 4.166 0.051 0.556 0.462 1.560 0.222 
NeuN 0.123 0.728 2.141 0.154 0.081 0.778 
Female SNpc       
TH 4.674 0.044 2.173 0.049 0.586 0.345 
NeuN 0.245 0.765 1.256 0.267 1.132 0.432 
Male Striatum       
DA 1.301 0.444 7.510 0.018 0.876 0.635 
DOPAC 1.123 0.110 0.976 0.577 1.432 0.102 
HVA 0.797 0.324 0.122 0.453 0.602 0.960 
Female 
Striatum 
      
DA 0.978 0.328 0.022 0.883 0.002 0.960 
DOPAC 0.174 0.483 0.120 0.431 1.063 0.103 
HVA 0.301 0.777 1.359 0.555 1.055 0.416 
Male VTA       
TH 0.745 0.728 1.630 0.221 0.210 0.714 
NeuN 1.232 0.298 0.562 0.453 1.205 0.243 
Female VTA       
TH 1.675 0.218 1.34 0.721 0.721 0.411 
NeuN 1.132 0.180 0.761 0.537 0.205 0.949 
Male Striatum       
DA 0.233 0.478 1.210 0.771 0.442 0.471 
DOPAC 0.923 0.782 0.756 0.778 1.233 0.162 
HVA 0.345 0.825 1.088 0.156 1.002 0.192 
Female 
Striatum 
      
DA 1.648 0.180 1.654 0.230 1.173 0.606 
DOPAC 0.528 0.471 0.472 0.491 1.334 0.850 
HVA 0.835 0.365 0.342 0.561 6.426 0.014 
 
 
STUDY 2 DEX x Lesion CORT x Lesion DEX x CORT x 
Lesion 
 F p F p F p 
Males SNpc       
TH 1.797 0.424 2.142 0.098 0.502 0.760 
NeuN 0.360 0.552 3.725 0.061 1.164 0.287 
Female SNpc       
TH 2.648 0.064 1.554 0.130 1.174 0.406 
NeuN 0.217 0.644 0.027 0.870 0.984 0.327 
Male Striatum       
DA 1.325 0.043 3.244 0.039 0.987 0.675 
DOPAC 0.832 0.765 0.220 0.978 2.668 0.062 
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HVA 0.898 0.476 1.123 0.768 8.765 0.009 
Female 
Striatum 
      
DA 1.702 0.190 1.246 0.220 1.603 0.219 
DOPAC 0.798 0.635 0.236 0.433 0.788 0.753 
HVA 0.002 0.968 0.166 0.686 1.544 0.625 
Male VTA       
TH 1.123 0.110 0.976 0.577 1.432 0.102 
NeuN 0.797 0.324 0.122 0.453 0.602 0.960 
Female VTA       
TH 0.978 0.428 0.123 0.983 0.802 0.460 
NeuN 0.217 0.644 1.844 0.182 71.890 0.000 
Male NAcc       
DA 1.675 0.218 1.34 0.721 0.721 0.411 
DOPAC 0.232 0.998 0.461 0.653 0.205 0.949 
HVA 1.576 0.326 1.620 0.821 0.421 0.714 
Female NAcc       
DA 0.628 0.471 0.472 0.491 1.334 0.850 
DOPAC 0.835 0.765 0.242 0.561 1.426 0.214 
HVA 0.223 0.728 0.141 0.754 0.181 0.978 
 
 
 
